DolceraWiki - User contributions [en]

File:Cholinebitartrate.jpg

2009-08-19T04:10:49Z

Naveen:

Choline Bitartarate

2009-08-19T04:10:32Z

Naveen: /* '''STN Search Strategy''' */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

'''L1'''

[[Image:Cholinebitartrate.jpg|thumb|center|750px|'''Cholinebitartrate''']]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

'''L2'''

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

'''L3'''

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

'''L4'''

=<nowiki>></nowiki> S L3 NOT PATENT/DT

'''L5'''

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> '''LOGOFF Y'''

----

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T15:09:43Z

Naveen: /* '''STN Search Strategy''' */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

'''L1'''

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

'''L2'''

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

'''L3'''

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

'''L4'''

=<nowiki>></nowiki> S L3 NOT PATENT/DT

'''L5'''

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> '''LOGOFF Y'''

----

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T15:01:26Z

Naveen: /* Analysis Taxonomy */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

'''L1'''

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

'''L2'''

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

'''L3'''

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

'''L4'''

=<nowiki>></nowiki> S L3 NOT PATENT/DT

'''L5'''

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> '''LOGOFF Y'''

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T15:01:04Z

Naveen: /* '''STN Search Strategy''' */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

'''L1'''

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

'''L2'''

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

'''L3'''

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

'''L4'''

=<nowiki>></nowiki> S L3 NOT PATENT/DT

'''L5'''

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> '''LOGOFF Y'''

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:56:52Z

Naveen: /* '''STN Search Strategy''' */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

L3

|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:56:20Z

Naveen: /* '''STN Search Strategy''' */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:55:46Z

Naveen: /* '''STN Search Strategy''' */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
|L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:51:50Z

Naveen: /* STN Search Strategy */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

===='''STN Search Strategy'''====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
| L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:51:28Z

Naveen: /* Analysis Taxonomy */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

====STN Search Strategy====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
| L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:50:59Z

Naveen: /* STN Search Strategy */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

====STN Search Strategy====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|750px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
| L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

File:Document1 01.jpg

2009-08-18T14:50:35Z

Naveen:

Choline Bitartarate

2009-08-18T14:50:21Z

Naveen: /* STN Search Strategy */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

====STN Search Strategy====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.jpg|thumb|center|450px|Cholinebitartrate]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
| L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet - Total count: 444]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet ON Target count: 22]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

Choline Bitartarate

2009-08-18T14:48:39Z

Naveen: /* Search Strategy */

==Overview==
*Choline is an organic compound, usually grouped within the Vitamin B complex. There are eight B vitamins in the Vitamin B complex family. Although each performs a different function in the body, they all work together to maintain good health.
[[Image:CBT Image.jpg|Right|250px|thumb|'''Structure of Choline bitartrate''' [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6900#Synonyms Source]]]
*Choline is available in various forms namely, choline bitartrate, choline citrate,choline chloride and others.
* '''Choline Bitartrate''' (L(+) choline bitartrate) is a colorless or white crystal powder, which is a water-soluble part of the B Vitamin family. Its IUPAC Name: 2-hydroxyethyl(trimethyl)azanium; (2R,3R)-2,3,4-trihydroxy-4-oxobutanoate and CAS Registry Number is : 87-67-2. [http://www.chemicalregister.com/D_-_Choline_Bitartrate/Suppliers/pid56388.htm Source]
*The body needs B vitamins to manufacture neurotransmitters, chemicals that control alertness and mood by speeding nerve signals through the brain.
* As B vitamins are water soluble, they are excreted in the urine and can be quickly depleted from the body. Only a small amount is stored in the body. Because of this, it is important that we take supplements to replenish these important vitamins in our body. [http://www.add-adhd-help-center.com/Ingredients/choline_bitartrate.htm Source]

* Choline bitartrate is an essential nutrient needed by the nervous system to produce acetylcholine. Acetylcholine is a neurotransmitter that facilitates the transmission of impulses between neurons. [http://www.ncbi.nlm.nih.gov/pubmed/14972364 Source]

'''Natural Source of Choline bitartrate''': Egg yolk, peanuts, wheat germ, organ meats and legumes.

'''Health Benefits of Choline Bitartrate''':
* Being a product of vitamin, it can be applied to medicine, healthcare product and food.
* It is a nutritious additive and fat remover, enhance fatty metabolism and eliminate the accumulation of fat in liver.
* Influence muscle contractions, movement, coordination and enhance memory.
* Involved in higher level brain functions like memory, thought and intellect.
* Is vital to the structural integrity of cell walls, the production of amino acids and proteins and the metabolism of fats.
* Aid in the treatment of Alzheimer’s Disease, manic depression and improve the symptoms of Parkinson’s Disease.

'''Deficiencies in B vitamins causes''':
* Depression or signs of decreased mental functioning.
* Decrease cognitive function.

==Intellectual Property==
===Search Strategy===
* Databases: USG USA EPA EPB WO JP DEG DEA DET DEU GBA FRA

* Years: From 1836 - To April 18, 2009.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''S.No'''
|align = "center" bgcolor = "#99CCFF"|'''Concept'''
|align = "center" bgcolor = "#99CCFF"|'''Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search Query'''
|align = "center" bgcolor = "#99CCFF"|'''Hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''1'''
|bgcolor = "#99CCFF"|'''Choline bitartarate'''
|Full Spec.
|align = "center"|((choline ADJ1 bitartarate<nowiki>*</nowiki>) OR (choline ADJ1 bitartrate<nowiki>*</nowiki>) OR (choline ADJ1 bi ADJ1 tartrate<nowiki>*</nowiki>) OR (2-Hydroxyethyl ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl) ADJ1 trimethyl ADJ1 ammonium ADJ1 bitartrate) OR ((2-Hydroxyethyl)trimethylammonium ADJ1 bitartrate))
|align = "center"|'''1016 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''2'''
|bgcolor = "#99CCFF"|'''Food & beverage'''
|Claims, Title or Abstract
|align = "center"|(beverage<nowiki>*</nowiki> OR drink<nowiki>*</nowiki> OR juice<nowiki>*</nowiki> OR potion OR tonic OR spirit<nowiki>*</nowiki> OR (liquid ADJ1 refreshment) OR Tea OR milk OR coffee OR cocoa OR (liquid ADJ (formulation<nowiki>*</nowiki>1 OR preparation<nowiki>*</nowiki>1)) OR capsule<nowiki>*</nowiki> OR caplet<nowiki>*</nowiki> OR tablet<nowiki>*</nowiki> OR powder<nowiki>*</nowiki>2 OR (Nutri<nowiki>*</nowiki> ADJ supplement<nowiki>*</nowiki>) OR Food<nowiki>*</nowiki> OR Meal<nowiki>*</nowiki> OR composition OR (Nutrition<nowiki>*</nowiki> NEAR3 adjuvant<nowiki>*</nowiki> ) OR (food NEAR3 supplement<nowiki>*</nowiki>) OR formula OR formulation<nowiki>*</nowiki>)
|align = "center"|''' 3677912 hits'''
|-
|align = "center" bgcolor = "#99CCFF"|'''3'''
|bgcolor = "#99CCFF"|
|Combine
|align = "center"|'''1AND 2'''
|align = "center"|''' 881 hits (Unique Records 444)'''
|-
|}

====STN Search Strategy====
=<nowiki>></nowiki> FILE REGISTRY

=<nowiki>></nowiki> UPLOAD STRUCTURE

L1

[[Image:Document1_01.png]]

=<nowiki>></nowiki> D L1

=<nowiki>></nowiki> S L1 EXACT SAM

L2

=<nowiki>></nowiki> D SCAN

=<nowiki>></nowiki> S L1 EXACT FULL

{|border="0" cellspacing="2" width="100%"
| 
| L3
|-
|}

SET PLURAL ON PERM

SET ABBREVIATION ON PERM

SET SPELLINGS ON PERM

=<nowiki>></nowiki> S L3 AND PATENT/DT

L4

=<nowiki>></nowiki> S L3 NOT PATENT/DT

L5

=<nowiki>></nowiki> D L4 IALL 1-

=<nowiki>></nowiki> D L5 IALL 1-

=<nowiki>></nowiki> LOGOFF Y

===Analysis Taxonomy===
[[image:Choline bitartarate updated.jpeg|center|750 px|thumb|]]

====IP activity over the years====

* Maximum number of patents have been filed in the year 2004.
* Patents are published 18 months after application.

[[Image: CBT IP Trend.jpg|center|700 px|thumb|Graph showing IP Activity Over Years (Assignee versus earliest priority year)]]

====Top Assignees====
*Council of Scientific & Industrial Research found to be the Top assignees with 3 patents.
* For 2 patent / publications Assignee name is not available.
[[Image:CBT TOP assignee.jpg|center|600 px|thumb|Graph showing Top assignee names]]

====Patent Focus====
* Patents focusing on Composition.
* Patents focusing on Methods.
* Patents focusing on Composition and Methods.
* Patents focusing on process of prepration.

[[Image:CBT pie chart.jpg|center|600 px|thumb|Graph showing patents focusing on composition / methods or Both]]

====Action of Choline bitartrate containing Compositions====

<mm>[[Choline_bitartrate.mm]]</mm>

====Choline Bitartarate Patents categorised as per formulation====
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FF9900"|'''Product form'''
|align = "center" bgcolor = "#FF9900"|'''Patent/publication'''
|align = "center" bgcolor = "#FF9900"|'''Patent focus'''
|align = "center" bgcolor = "#FF9900"|'''Ingredients other than Choline Bitartarate'''
|align = "center" bgcolor = "#FF9900"|'''Application'''
|-
|align = "center" rowspan = "16"|'''Beverage / liquid / Drink'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
|align = "center"|Composition and Method
|1. At least one substance that enhance oxygen uptake such as Gingko A, Caffeine, Green Tea, L-pyroglutamate, Xanthinol nicotinate. 2. A protein supplement.
|Used for weight loss.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
|align = "center"|Composition, Method, Process of prepration
|1. one or more omega 3 fatty acids. 2. milk or milk-based products .
|lowers levels of cholesterol and triglycerides.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
|align = "center"|Composition
|1. A first ingredient comprising at least one of a polyol, a fiber or a combination thereof. 2. Second ingredient comprising calcium. 3. Third ingredient comprising at least one of flavanol, stimulant and antioxidant.
| Used for weight management.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
|align = "center"|Composition and Method
|An essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, inositol, antioxidants and herbs.
|A dietary supplement to help facilitate weight loss
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
|align = "center"|Composition and Process of prepration
|An protein component and a carbohydrate component.
|Nutritional Supplement
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|align = "center"|Composition and Process of prepration
|Sugar including the carbohydrates, fructose and maltodextrin, and electrolytes chromium, copper, potassium, magnesium, sodium, and citric acid.
|Restoring human growth hormone.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|align = "center"|Composition and Method
|Betaine, pyridoxal-5-phosphate, and N-acetyl-cysteine.
|Promotes decrease of homocysteine levels in humans.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
|align = "center"|Composition and Method
|A uridine, an acyl derivative thereof, a uridine phosphate, uracil, or a salt thereof;
|Ameliorating or inhibiting decline in memory or intelligence.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
|align = "center"|Composition
|Wasabia japonica, Silybum marianum, Cynara scolymus.
|Nutritional supplement for a human diet.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
|align = "center"|Composition and Method
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, decaffeinated green tea extract, vitamin B1,B5, B6, B12,folic acid, Dimethylglycine, huperzine A, Griffonia simplicifolia extract and 1-phenylalanine.
|Improves neuromuscular facilitation and enhances cognitive functions, such as memory and mental focus.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
|align = "center"|Composition
|An energy content, a protein fraction, a lipids fraction, a nucleotide fraction and a mineral fraction.
|An anti-allergic infant formulation.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
|align = "center"|Composition
|A protein equivalent, a suitable lipid, a carbohydrate component , essential vitamins , minerals and an emulsion stabilizer.
|Providing nourishment for a human patient in need of such nourishment .
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|align = "center"|Composition
|Essential amino acids, carbohydrates, fats, vitamins namely vitamin A, B1, B6, B12, C, D2, E, K1, calcium pantothenate, nicotinic acid amide, biotin, folic acid or choline bitartrate and minerals.
|New elemental diets for liver diseases.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|align = "center"|Composition, Method, Process of prepration
|L-Tyrosine, L-Phenylalanime, L-Leucine, Zinc (from Zinc Gluconate) and Copper (from Copper Gluconate).
|A medication for Alzheimer<nowiki>’</nowiki>s disease.
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
|align = "center"|Composition
|Digestible saccharide and a carotenoid.
|A health drink
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
|align = "center"|Composition
|Carbohydrate, electrolyte, ammonia neutralizer, energy enhancer namely choline Bitartrate and others , antioxidant, neuromuscular function enhancer.
|
|-
|align = "center" rowspan = "2"|'''Foodstuff'''
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
|align = "center"|Composition and Process of prepration
|Whole wheat, Roasted (defatted) soy Peanut paste, Sesame seed paste Sesame seed , Wheat germ (roasted), Non fat dry milk, Sugar Powder, Liquid, Lecithin, Sodium Chloride, mmonium bicarbonate, vitamins and others.
|Nutritious baked snack food with high protein content
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
|align = "center"|Composition and Process of prepration
|vegetable sources as wheat flout, roasted peanut paste, sesame seed, soybean flour and well balanced mixture of vitamins, minerals and others.
|Food stuff for children and adult supplementing their nutritional requirement.
|-
|}

====Choline Bitartarate containing compositions====
*Composition components matrix showing all the ingredients used along with Choline Bitartarate.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Beverage / liquid / Drink'''
|-
|align = "center" bgcolor = "#CCFFCC"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#CCFFCC"|'''Amino acids'''
|align = "center" bgcolor = "#CCFFCC"|'''Antioxidant'''
|align = "center" bgcolor = "#CCFFCC"|'''Carbohydrates / Sugars'''
|align = "center" bgcolor = "#CCFFCC"|'''Energy Source / Enhancer'''
|align = "center" bgcolor = "#CCFFCC"|'''Fatty Acids / A lipid Source'''
|align = "center" bgcolor = "#CCFFCC"|'''Herbal Extracts'''
|align = "center" bgcolor = "#CCFFCC"|'''Minerals'''
|align = "center" bgcolor = "#CCFFCC"|'''Proteins'''
|align = "center" bgcolor = "#CCFFCC"|'''Stimulant'''
|align = "center" bgcolor = "#CCFFCC"|'''Vitamins'''
|align = "center" bgcolor = "#CCFFCC"|'''Vegetable Sources'''
|align = "center" bgcolor = "#CCFFCC"|'''Others'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040005368%22.PGNR.&OS=DN/20040005368&RS=DN/20040005368 US20040005368A1]
| 
| 
| 
| 
| 
| 
| 
|align = "center"|x
|Caffeine, Green Tea
| 
| 
|Oxygen uptake enhancing substance.
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040191294%22.PGNR.&OS=DN/20040191294&RS=DN/20040191294 US20040191294A1]
| 
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
| 
|Milk or milk-based products
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060121158%22.PGNR.&OS=DN/20060121158&RS=DN/20060121158 US20060121158A1]
| 
|align = "center"|x
| 
| 
| 
| 
|align = "center"|x
|align = "center"|x
|align = "center"|x
|align = "center"|x
| 
|Flavanol
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5626849.PN.&OS=PN/5626849&RS=PN/5626849 US5626849A]
| 
|align = "center"|x
| 
| 
|gamma-linolenic acid
|align = "center"|x
| 
| 
| 
| 
| 
|L-carnitine
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5904948.PN.&OS=PN/5904948&RS=PN/5904948 US5904948A]
| 
| 
|Maltodextrin
| 
| 
|align = "center"| 
|align = "center"|x
|Whey , milk or vegetable
| 
|align = "center"|x
| 
| 
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006052231&F=0 WO2006052231A1]
|leucine, isoleucine, valine and arginine.
| 
|align = "center"|x
| 
| 
| 
|align = "center"|x
| 
| 
| 
| 
| 
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050171034%22.PGNR.&OS=DN/20050171034&RS=DN/20050171034 US20050171034A1]
|N-acetyl-cysteine
|Alpha-lipoic acid
| 
| 
| 
| 
|Zn
| 
| 
|A, B, C, E
| 
|Betaine
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060241077%22.PGNR.&OS=DN/20060241077&RS=DN/20060241077 US20060241077A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|Uridine or its derivative
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070065456%22.PGNR.&OS=DN/20070065456&RS=DN/20070065456 US20070065456A1]
| 
|Green tea extract
| 
|Taurine
| 
|Wasabia japonica, Silybum marianum and Cynara scolymus.
|Mn, Se Zn
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070248696%22.PGNR.&OS=DN/20070248696&RS=DN/20070248696 US20070248696A1]
| 
| 
| 
| 
| 
| 
| 
| 
| 
|B1,B5, B6, B12,folic acid
| 
|Dimethylaminoethanol, cytidine 5<nowiki>’</nowiki>-diphosphocholine, turmeric extract, Green tea extract
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220080317868%22.PGNR.&OS=DN/20080317868&RS=DN/20080317868 US20080317868A1]
| 
| 
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
| 
| 
|Nucleotide fraction
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4497800.PN.&OS=PN/4497800&RS=PN/4497800 US4497800A]
| 
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4499076.PN.&OS=PN/4499076&RS=PN/4499076 US4499076A]
|Essential AA<nowiki>’</nowiki>S
| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"|x
|align = "center"| 
|align = "center"| 
|Calcium pantothenate, nicotinic acid amide, biotin, folic acid
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4837219.PN.&OS=PN/4837219&RS=PN/4837219 US4837219A]
|L-Tyrosine, L-Phenylalanime, L-Leucine
| 
| 
| 
| 
| 
|Zn and Cu
| 
| 
| 
| 
|align = "center"|x
|-
|[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5437880.PN.&OS=PN/5437880&RS=PN/5437880 US5437880A]
| 
|align = "center"|x
|Digestible saccharide
| 
| 
| 
| 
| 
| 
|A B, C, D, E and K .
| 
|Carotenoids
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO9415488&F=0 WO1994015488A2]
| 
|align = "center"|x
|align = "center"|x
|choline Bitartrate
| 
| 
| 
| 
| 
| 
| 
|Neuromuscular function enhancer
|-
|align = "center" bgcolor = "#FFCC99" colspan = "13"|'''Foodstuff'''
|-
|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050208191%22.PGNR.&OS=DN/20050208191&RS=DN/20050208191 US20050208191A1]
| 
| 
|x
| 
| 
| 
|Fe, Zn, Cu, I ,
| 
| 
|x
|Sesame seed paste Sesame seed
|Whole wheat, Roasted (defatted) soy Peanut paste, Wheat germ (roasted), Non fat dry milk
|-
|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005087018&F=0 WO2005087018A1]
| 
| 
| 
| 
| 
| 
|x
| 
| 
|x
|Wheat flour, roasted peanut paste, sesame seed, soybean flour
|x
|-
|}

*'''[[Media:cbt composition matrix.xls|Click here]]''' for Composition matrix showing all the ingredients used along with Choline Bitartarate.

===Patent Analysis Sheets===

*'''[[Media:All Patent Analysis sheet.xls|Click here for all Patents spread sheet-444 ON Targets]]'''

*'''[[Media:cbt Patent Analysis sheet.xls|Click here for the complete Analysis spread sheet-22 ON Targets]]'''

* '''[[Media:Other than cbt ingredients.xls|Click here]]''' for list of ingredients that are in combination with Choline Bitartarate, obtained from Patents.

===Scientific Literature Analysis===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFCC99"|'''S.No.'''
|align = "center" bgcolor = "#FFCC99"|'''Title'''
|align = "center" bgcolor = "#FFCC99"|'''Citations'''
|align = "center" bgcolor = "#CCFFCC"|'''Publication Date'''
|align = "center" bgcolor = "#CCFFCC"|'''Results / Statastical data'''
|align = "center" bgcolor = "#CCFFCC"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#FFCC99"|'''1'''
|Effect of choline supplementation on fatigue in trained cyclists.
|[http://www.ncbi.nlm.nih.gov/pubmed/7674870 Med Sci Sports Exerc. 1995 May;27(5):668-73.]
|align = "center"|1995-05-01
|1. Twenty male cyclists (ages 23-29) with maximal aerobic power (VO2max) between 58 and 81 ml.min-1.kg-1 were randomly divided into BRIEF (N = 10) and PROLONGED (N = 10) groups. 2. One hour after drinking a beverage with or without choline bitartrate (2.43 g), cyclists began riding at a power output equivalent to approximately 150% (BRIEF) and 70% (PROLONGED) of VO2max at a cadence of 80-90 rpm. 3.Time to exhaustion, indirect calorimetry and serum choline, lactate, and glucose were measured.
|Trained cyclists do not deplete choline during supramaximal brief or prolonged submaximal exercise, nor do they benefit from choline supplementation to delay fatigue under given conditions.
|-
|}

*'''[[Media:cbt Non_Patent Analysis sheet.xls|Click here for Scientific Literature Analysis spread sheet]]'''

==Dashboard==
* Click at this link for '''[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=554 Dashboard]'''

File:Statistical information of Bilski citations.xls

2009-05-05T13:32:46Z

Naveen:

Bilski 35 USC § 101 Rejections Patent Application List

2009-05-05T13:32:07Z

Naveen:

* [[Bilski Medtech Sample]]
* [[Bilski Pharma Sample]]
* [[Bilski Diagnostic Sample]]
* [[SAP Software Patents Sample]]
* [[Bilski Diagnostic Methods Big Sample Sheet]]
* [[SAP Software Patents Sample(6 months before and after October 2008)]]
* [[Software Patents Sample(6 months before and after October 2008)]]
* [[101 rejections of Software Patents(Date of Rejections After October-30-2008)]]
* [[101 rejections of Diagnostic Patents(Date of Rejections After October-30-2008)]]
* [[Media:Bilski 1.xls|Bilski]]
* [[Media:Statistical information of Bilski citations.xls|Statistical information of Bilski]]

File:Statistical information of Bilski.xls

2009-04-30T05:52:07Z

Naveen:

Bilski 35 USC § 101 Rejections Patent Application List

2009-04-30T05:51:52Z

Naveen:

File:Bilski 1.xls

2009-04-30T05:12:22Z

Naveen:

Bilski 35 USC § 101 Rejections Patent Application List

2009-04-30T05:11:40Z

Naveen:

101 rejections of Diagnostic Patents(Date of Rejections After October-30-2008)

2009-04-30T04:14:23Z

Naveen:

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''Sl.No.'''
|align = "center" bgcolor = "#808080"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Publication'''
|align = "center" bgcolor = "#808080"|'''Application Date'''
|align = "center" bgcolor = "#808080"|'''Date of rejection'''
|align = "center" bgcolor = "#808080"|'''FR or N/FR'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|align = "center" bgcolor = "#808080"|'''Other than Bilski citations in 101 rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|bgcolor = "#CCFFFF"|US20070060798A1
|align = "right"|3/15/2007
|align = "right"|9/15/2005
|2/25/2009
|N/FR
|101 and 103 rejections
|Claims 1-9 and 17-22 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claims 1-9 and 17-22 are directed to a method that does not pass the machine or- transformation test and are therefore non-statutory (In re Bilski, 545 F.3d 943, 88 USPQ2d 1385 (Fed. Cir. 2008).)
|N/A
|Claims 1-3, 5-12, and 14-22 rejected under 35 U.S.C. 103(a) as being unpatentable over Oya (U.S. Publication 2005/0046699) in view of Glukhovsky (U.S. Publication 2003/0174208).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|bgcolor = "#CCFFFF"|US20060270950A1
|align = "right"|11/30/2006
|align = "right"|4/11/2006
|2/18/2009
|N/FR
|101 and 103 rejections
|In re Bilski, 545 F.3d 943 (Fed. Cir. 2008) (en bane). Claims 7-14 and 21-23 are process claims in which data is merely gathered or outputted (1) without being tied to a particular machine or apparatus, and (2) without having a transformative effect
|N/A
|Claims 7-17 and 19-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Herr et al. (US Pub No. 2005/0070834) in view of Dariush (US Patent No. 7,135,003).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''3'''
|bgcolor = "#CCFFFF"|US20060253302A1
|align = "right"|11/9/2006
|align = "right"|5/3/2006
|3/18/2009
|N/FR
|101 and 103 rejections
|Claims 1-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008).
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Loeb Pre-Grant Pub. No. 2002/0178030 in view of Henley Pre-Grant Pub No. 2005/0182660.
|N/A
|Diamond v. Diehr, 450 U.S. 175, 184 (1981); Parkerv. Flook, 437 U.S. 584, 588 n.9 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972); Cochrane v. Deener, 94 U.S. 780, 787-88 (1876)
|-
|align = "center" bgcolor = "#808080"|'''4'''
|bgcolor = "#CCFFFF"|US20060247510A1
|align = "right"|11/2/2006
|align = "right"|9/29/2005
|2/25/2009
|N/FR
|101 and 103 rejections
|Claim(s) 1-5 is/are rejected under 35 U.S.c. 101 as not falling within one of the four statutory categories of invention. Federal Circuit precedent requires that a statutory "process" under 35 U.S.c. 101 must "(1) be tied to a particular machine or apparatus, or (2) transform a particular article into a different state or thing." (In re Bilski, 88 USPQ2d 1385, 1391 (Fed. Cir. 2008).)
|N/A
|Claims 1,5,6,9, 10 are rejected under 35 U.S.c. 103(a) as being unpatentable over the combination of the article entitled "Automatic segmentation of the colon for virtual colonoscopy" by Wyatt et ai. (hereinafter "Wyatt") and Vining et aI., U.S. Patent No. 6,366,800 (hereinafter "Vining").
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|bgcolor = "#CCFFFF"|US20060241409A1
|align = "right"|10/26/2006
|align = "right"|2/11/2005
|3/18/2009
|N/FR
|101, 103 and 112 rejections
|Claims 15 and 16 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claims 15 and 16 are directed towards methods of estimating electromagnetic material parameters, the steps of which comprise the mere manipulation of electromagnetic signals without transforming a particular article to a different state or thing. Methods which do not meet the machine or transformation requirements have previously been held as non-statutory (In re Bilski, F.3d, 2008 WL 4757110,88 U.S.P.Q.2d (BNA) 1385 (Fed. Cir. Oct. 30,2008)).
|N/A
|Claims 1-6, 13-21,28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van Veen et al (US PO Pubs. No. 2003/0088180 AI), hereinafter Van Veen (<nowiki>’</nowiki>180), of record, in view of Kang et al (A New 2-D Image Reconstruction Algorithm Based on FDTD and Design Sensitivity Analysis. IEEE Transactions on Microwave Theory and Techniques.
|Claims 4,9-12 and 24-27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|bgcolor = "#CCFFFF"|US20060231108A1
|align = "right"|10/19/2006
|align = "right"|4/18/2005
|3/13/2009
|FR
|101 and 103 rejections
|In re Bilski and the machine-or-transformation test. The physical article does not necessarily appear in the body as an element that is necessarily present to satisfy the claim. Therefore claims 13-17 stand rejected.
|N/A
|Claims 1-10, 12-20 are rejected under 35 U.S.C. 103(a) as being obvious over Vara et aI, (US 6,063,030), hereinafter Vara in view of Shostack et aI., (US 2004/0249811 AI), Shostack
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|bgcolor = "#CCFFFF"|US20060064396A1
|align = "right"|3/23/2006
|align = "right"|4/14/2005
|11/24/2008
|N/FR
|101 and 112 rejections
|Claims 1-5, 7, 8, and 89-91 are rejected under 35 U.S.C. 101 because these claims are drawn to non-statutory subject matter. These claims are rejected for the following reasons. For a process that comprises an abstract idea to be statutory, it must compnse a practical application of the abstract idea. Claimed subject matter may require a practical application by claiming, or requiring use of, a machine, or by requiring a physical transfonnation of an article to a different state or thing <nowiki>[</nowiki>In Re Bilski (88 USPQ2d 1385 Fed. Cir. 2008)<nowiki>]</nowiki>.
|N/A
|N/A
|Claims 1-46 and 89-91 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|bgcolor = "#CCFFFF"|US20060064020A1
|align = "right"|3/23/2006
|align = "right"|9/20/2004
|4/15/2009
|N/FR
|101, 102, 103 and 112 rejections
|Claims 8-20 are rejected under 35 U.S.C §1 01 because the claimed invention is directed to a non-statutory subject matter. In order for a method to be considered a "process" under § 101, a claimed process must either: (1) be tied to a particular machine or apparatus or (2) transforms a particular article to a different state or thing. In re Bilski, 545 F.3d 943,88 USPQ2d 1385 (Fed. Cir. 2008).
|Claim 1 is rejected under 35 U.S.C 102(e) as being anticipated by Jones et al. (U.S.Pub 2005/0192838)
|1. Claims 2, 5-8,11,17-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jones et al. (U.S. Pub 2005/0192838) in view of Evans (Patent 5924074). 2. Claim 3-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jones et al. (U.S. Pub 2005/0192838) in view of Haller (U.S. Pub 2002/0013613).
|Claims 21 is rejected under 35 U.S.c. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|Diamond v. Diehr, 450 U.S. 175, 184 (1981); Parkerv. Flook, 437 U.S. 584,588 n.9 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972);
|-
|align = "center" bgcolor = "#808080"|'''9'''
|bgcolor = "#CCFFFF"|US20060058618A1
|align = "right"|3/16/2006
|align = "right"|8/15/2005
|12/31/2008
|FR
|101 and 103 rejections
|1. Claims 6 and 10- 14 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claim(s) 20 - 25 are rejected under 35 U.S.C. 101 as not falling within one of the four statutory categories of invention (In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008)
|N/A
|Claims 6, 10-14 and 20 - 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsujino et ai., U.S. Patent Application Publication No. 2003/0171668 published on Sep. 11, 2003 ("Tsujino").
|N/A
|Diamond v. Diehr, 450 u.s. 175, 184 (1981); Parker v. Flook, 437 U.S. 584, 588 n.9 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972); Cochrane v. Deener, 94 U.S. 780, 787-88 (1876)) and recent Federal Circuit decisions (In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008)
|-
|align = "center" bgcolor = "#808080"|'''10'''
|US20070066889A1
|align = "right"|3/22/2007
|align = "right"|9/21/2006
|4/15/2009
|N/FR
|101, 103 and 112 rejections
|Claims 16-35 are rejected under 35 U.S.C. 101 because the disclosed invention is inoperative and therefore lacks utility
|N/A
|Claims 16-30 and 33-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,944,022 to Nardella et a1 in view of U.S. Patent No. 6,594,521 to Tucker in further view of U.S. Patent No. 6,298,261 to Rex
|Claims 16-35 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''11'''
|US20070055142A1
|align = "right"|3/8/2007
|align = "right"|3/14/2003
|1/7/2009
|FR
|101, 103 and 112 rejections
|Claims 1-8, 10-1 1, 13-1 6, 31 -38, 40-41, 43-46, 67, 69-70, and 72 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|Claims 1-8, 10-1 1, 13-25, 31 -38, 40-41, 43-54, 60-67, 69-70, 72-83, 89, 91 -94 and 99-100 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rasche (US 6,473,635).
|Claims 8, 10-1 1, 13-1 6, 38, 40-41, 43-46, 67, 69-70, 72-75, 89, and 91 -94 are rejected under 35 U.S.C. 11 2, first paragraph, as failing to comply with the written description requirement.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|US20060281997A1
|align = "right"|12/14/2006
|align = "right"|6/6/2006
|3/6/2009
|FR
|103 and 112 rejections
|N/A
|N/A
|Claim(s) 1 - 12, 14, 17 - 20, 22 - 25, 28 - 52, and 54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Boileau et al. (US 200410267321, herein Boileau).
|Claim(s) 1, 18, 22, 29, 31, 38, 41, 48 - 55, 60, and 62 rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|US20060264740A1
|align = "right"|11/23/2006
|align = "right"|2/3/2006
|11/14/2008
|N/FR
|101 and 103 rejections
|Claims 15-1 8 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|Claims 1-1 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kendrick et al. (US PG Pub 200310206614 Al) in view of Blumhofer et al. (US Patent 6,865,253).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|US20060253015A1
|align = "right"|11/9/2006
|align = "right"|6/6/2005
|3/19/2009
|FR
|101 and 102 rejections
|Claims 1-9, 18-28 and 30-33 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to nonstatutory subject matter
|Claims 33 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Speier et al (US 2003/0020473)
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|US20060240393A1
|align = "right"|10/26/2006
|align = "right"|12/19/2005
|1/26/2009
|N/FR
|101, 102 and 103 rejections
|Claims 6- 18 are rejected under USC 10 1, the claimed invention is directed to non-statutory subject matter.
|Claims 1-3 and 5 are rejected under 35 U.S.C. 102(e) as being anticipated by Calhoun et al. (US 6,280,198 Bl)
|Claims 4, 6-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Calhoun et al. (US 6,280,198 B1) in view of Borsuk (US 5,475,399).Re claim 4, Calhoun does not explicitly teach of said output device includes a display that displays textual information and each program module includes computer readable instructions for adjusting font of textual information.
|N/A
|In re Hirao, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and Kropa v. Robie, 187 F.2d 150, 152, 88 USPQ 478,481 (CCPA 195 1).
|-
|align = "center" bgcolor = "#808080"|'''16'''
|US20060235280A1
|align = "right"|10/19/2006
|align = "right"|11/19/2004
|3/2/2009
|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-31 are rejected under 35 U.S.C. 101 because the claimed invention is directed to nonstatutory subject matter.
|Claims 16-18 and 20-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Lavin et al. (US 5,772,585).
|Claim I , 4-7 and 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent 5,772,585 to Lavin et al. in view of US Patent 6,108,635 to Herren et al.
|Claims 1-15 and 31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|US20060217623A1
|align = "right"|9/28/2006
|align = "right"|6/9/2006
|11/25/2008
|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-1 7 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter
|Claims 1-4, 12-1 4, and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Morganroth et al. ("How to obtain and Analyze Electrocardiograms in Clinical Trials" hereinafter referred to as the Morganroth publication).
|Claims 5-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Morganroth publication.
|Claims 14 and 16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|US20060069321A1
|align = "right"|3/30/2006
|align = "right"|9/30/2004
|12/15/2008
|N/FR
|101 and 112 rejections
|Claims 1-5, 8-1 7, 19-21, 31 -34, 36-45,47-50, 59-64, 66-74, 76-78 and 90-1 03 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.
|N/A
|N/A
|Claims 1-5, 8-1 7, 19-21, 31 -34, 36-45,47-50, 59-64, 66-74, 76-78 and 90-1 03 are also rejected under 35 U.S.C. 11 2, first paragraph.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''19'''
|US20060069317A1
|align = "right"|3/30/2006
|align = "right"|9/27/2005
|2/25/2009
|FR
|102 and 103 rejections
|N/A
|Claims 1-4, 6-14, 16-25 and 27 are rejected under 35 U.S.C. 102(e) as being anticipated by Chen et al. ("Chen") P S 7,319,781 B2<nowiki>]</nowiki>.
|Claims 5,15 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen et al. ("Chen") P S 7,319,781 B2<nowiki>]</nowiki> in view of Medscape Gastroenterology <nowiki>[</nowiki>NPL document titled, "A Mosaic Pattern of the Descending Duodenum"<nowiki>]</nowiki>.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''20'''
|US20060063987A1
|align = "right"|3/23/2006
|align = "right"|8/25/2005
|12/24/2008
|N/FR
|101 and 103 rejections
|Claims 1-1 0 are rejected under 35 U.S.C. 101 since the claimed invention is directed to non-statutory subject matter; listed method claims do not transform subject matter to a different state. The methods are also not tied to another statutory class.
|N/A
|Claims I, 2, 3, 5, 7, 10, and I I are rejected under 35 U.S.C. 103(a) as being unpatentable over Robinson et al. (US 6,622,032) in view of Shaw et. al article (Infrared Spectroscopy . . . . . . . . . . . . , 1996 The American Physiological society).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''21'''
|US20060058629A1
|align = "right"|3/16/2006
|align = "right"|5/25/2005
|2/3/2009
|N/FR
|101 rejection
|Claim 5 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter as follows. Claim 5 defines a computer usable medium embodying functional descriptive material (i.e., a computer program or computer executable code)
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|US20060058622A1
|align = "right"|3/16/2006
|align = "right"|8/24/2005
|2/17/2009
|N/FR
|101, 102 and 103 rejections
|Claim 63 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. A "software arrangement" is not considered statutory subject matter. Appropriate correction is required
|Claims I , 2, 4, 7, 9-12, 27-34, 36, 38, 39, 54-57, and 64-68 are rejected under 35 U.S.C. 102(b) as being anticipated by Chin et al. (U.S. 4,998,972).
|Claims 8 and 63 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chin et al. Claims 3,23, 37 and 53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chin et al. in view of Tashiro (U.S. 4,827,907).
|N/A
|N/A
|-
|}

101 rejections of Diagnostic Patents(Date of Rejections After October-30-2008)

2009-04-30T04:12:49Z

Naveen:

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''Sl.No.'''
|align = "center" bgcolor = "#808080"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Publication'''
|align = "center" bgcolor = "#808080"|'''Application Date'''
|align = "center" bgcolor = "#808080"|'''Date of rejection'''
|align = "center" bgcolor = "#808080"|'''FR or N/FR'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|align = "center" bgcolor = "#808080"|'''Other than Bilski citations in 101 rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|bgcolor = "#CCFFFF"|US20070060798A1
|align = "right" bgcolor = "#FFFF99"|3/15/2007
|align = "right" bgcolor = "#FFFF99"|9/15/2005
|2/25/2009
|N/FR
|101 and 103 rejections
|Claims 1-9 and 17-22 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claims 1-9 and 17-22 are directed to a method that does not pass the machine or- transformation test and are therefore non-statutory (In re Bilski, 545 F.3d 943, 88 USPQ2d 1385 (Fed. Cir. 2008).)
|N/A
|Claims 1-3, 5-12, and 14-22 rejected under 35 U.S.C. 103(a) as being unpatentable over Oya (U.S. Publication 2005/0046699) in view of Glukhovsky (U.S. Publication 2003/0174208).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|bgcolor = "#CCFFFF"|US20060270950A1
|align = "right" bgcolor = "#FFFF99"|11/30/2006
|align = "right" bgcolor = "#FFFF99"|4/11/2006
|2/18/2009
|N/FR
|101 and 103 rejections
|In re Bilski, 545 F.3d 943 (Fed. Cir. 2008) (en bane). Claims 7-14 and 21-23 are process claims in which data is merely gathered or outputted (1) without being tied to a particular machine or apparatus, and (2) without having a transformative effect
|N/A
|Claims 7-17 and 19-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Herr et al. (US Pub No. 2005/0070834) in view of Dariush (US Patent No. 7,135,003).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''3'''
|bgcolor = "#CCFFFF"|US20060253302A1
|align = "right" bgcolor = "#FFFF99"|11/9/2006
|align = "right" bgcolor = "#FFFF99"|5/3/2006
|3/18/2009
|N/FR
|101 and 103 rejections
|Claims 1-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008).
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Loeb Pre-Grant Pub. No. 2002/0178030 in view of Henley Pre-Grant Pub No. 2005/0182660.
|N/A
|Diamond v. Diehr, 450 U.S. 175, 184 (1981); Parkerv. Flook, 437 U.S. 584, 588 n.9 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972); Cochrane v. Deener, 94 U.S. 780, 787-88 (1876)
|-
|align = "center" bgcolor = "#808080"|'''4'''
|bgcolor = "#CCFFFF"|US20060247510A1
|align = "right" bgcolor = "#FFFF99"|11/2/2006
|align = "right" bgcolor = "#FFFF99"|9/29/2005
|2/25/2009
|N/FR
|101 and 103 rejections
|Claim(s) 1-5 is/are rejected under 35 U.S.c. 101 as not falling within one of the four statutory categories of invention. Federal Circuit precedent requires that a statutory "process" under 35 U.S.c. 101 must "(1) be tied to a particular machine or apparatus, or (2) transform a particular article into a different state or thing." (In re Bilski, 88 USPQ2d 1385, 1391 (Fed. Cir. 2008).)
|N/A
|Claims 1,5,6,9, 10 are rejected under 35 U.S.c. 103(a) as being unpatentable over the combination of the article entitled "Automatic segmentation of the colon for virtual colonoscopy" by Wyatt et ai. (hereinafter "Wyatt") and Vining et aI., U.S. Patent No. 6,366,800 (hereinafter "Vining").
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|bgcolor = "#CCFFFF"|US20060241409A1
|align = "right" bgcolor = "#FFFF99"|10/26/2006
|align = "right" bgcolor = "#FFFF99"|2/11/2005
|3/18/2009
|N/FR
|101, 103 and 112 rejections
|Claims 15 and 16 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claims 15 and 16 are directed towards methods of estimating electromagnetic material parameters, the steps of which comprise the mere manipulation of electromagnetic signals without transforming a particular article to a different state or thing. Methods which do not meet the machine or transformation requirements have previously been held as non-statutory (In re Bilski, F.3d, 2008 WL 4757110,88 U.S.P.Q.2d (BNA) 1385 (Fed. Cir. Oct. 30,2008)).
|N/A
|Claims 1-6, 13-21,28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van Veen et al (US PO Pubs. No. 2003/0088180 AI), hereinafter Van Veen (<nowiki>’</nowiki>180), of record, in view of Kang et al (A New 2-D Image Reconstruction Algorithm Based on FDTD and Design Sensitivity Analysis. IEEE Transactions on Microwave Theory and Techniques.
|Claims 4,9-12 and 24-27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|bgcolor = "#CCFFFF"|US20060231108A1
|align = "right" bgcolor = "#FFFF99"|10/19/2006
|align = "right" bgcolor = "#FFFF99"|4/18/2005
|3/13/2009
|FR
|101 and 103 rejections
|In re Bilski and the machine-or-transformation test. The physical article does not necessarily appear in the body as an element that is necessarily present to satisfy the claim. Therefore claims 13-17 stand rejected.
|N/A
|Claims 1-10, 12-20 are rejected under 35 U.S.C. 103(a) as being obvious over Vara et aI, (US 6,063,030), hereinafter Vara in view of Shostack et aI., (US 2004/0249811 AI), Shostack
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|bgcolor = "#CCFFFF"|US20060064396A1
|align = "right" bgcolor = "#FFFF99"|3/23/2006
|align = "right" bgcolor = "#FFFF99"|4/14/2005
|11/24/2008
|N/FR
|101 and 112 rejections
|Claims 1-5, 7, 8, and 89-91 are rejected under 35 U.S.C. 101 because these claims are drawn to non-statutory subject matter. These claims are rejected for the following reasons. For a process that comprises an abstract idea to be statutory, it must compnse a practical application of the abstract idea. Claimed subject matter may require a practical application by claiming, or requiring use of, a machine, or by requiring a physical transfonnation of an article to a different state or thing <nowiki>[</nowiki>In Re Bilski (88 USPQ2d 1385 Fed. Cir. 2008)<nowiki>]</nowiki>.
|N/A
|N/A
|Claims 1-46 and 89-91 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|bgcolor = "#CCFFFF"|US20060064020A1
|align = "right" bgcolor = "#FFFF99"|3/23/2006
|align = "right" bgcolor = "#FFFF99"|9/20/2004
|4/15/2009
|N/FR
|101, 102, 103 and 112 rejections
|Claims 8-20 are rejected under 35 U.S.C §1 01 because the claimed invention is directed to a non-statutory subject matter. In order for a method to be considered a "process" under § 101, a claimed process must either: (1) be tied to a particular machine or apparatus or (2) transforms a particular article to a different state or thing. In re Bilski, 545 F.3d 943,88 USPQ2d 1385 (Fed. Cir. 2008).
|Claim 1 is rejected under 35 U.S.C 102(e) as being anticipated by Jones et al. (U.S.Pub 2005/0192838)
|1. Claims 2, 5-8,11,17-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jones et al. (U.S. Pub 2005/0192838) in view of Evans (Patent 5924074). 2. Claim 3-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jones et al. (U.S. Pub 2005/0192838) in view of Haller (U.S. Pub 2002/0013613).
|Claims 21 is rejected under 35 U.S.c. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|Diamond v. Diehr, 450 U.S. 175, 184 (1981); Parkerv. Flook, 437 U.S. 584,588 n.9 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972);
|-
|align = "center" bgcolor = "#808080"|'''9'''
|bgcolor = "#CCFFFF"|US20060058618A1
|align = "right" bgcolor = "#FFFF99"|3/16/2006
|align = "right" bgcolor = "#FFFF99"|8/15/2005
|12/31/2008
|FR
|101 and 103 rejections
|1. Claims 6 and 10- 14 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claim(s) 20 - 25 are rejected under 35 U.S.C. 101 as not falling within one of the four statutory categories of invention (In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008)
|N/A
|Claims 6, 10-14 and 20 - 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsujino et ai., U.S. Patent Application Publication No. 2003/0171668 published on Sep. 11, 2003 ("Tsujino").
|N/A
|Diamond v. Diehr, 450 u.s. 175, 184 (1981); Parker v. Flook, 437 U.S. 584, 588 n.9 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972); Cochrane v. Deener, 94 U.S. 780, 787-88 (1876)) and recent Federal Circuit decisions (In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008)
|-
|align = "center" bgcolor = "#808080"|'''10'''
|bgcolor = "#FFFF99"|US20070066889A1
|align = "right" bgcolor = "#FFFF99"|3/22/2007
|align = "right" bgcolor = "#FFFF99"|9/21/2006
|4/15/2009
|N/FR
|101, 103 and 112 rejections
|Claims 16-35 are rejected under 35 U.S.C. 101 because the disclosed invention is inoperative and therefore lacks utility
|N/A
|Claims 16-30 and 33-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,944,022 to Nardella et a1 in view of U.S. Patent No. 6,594,521 to Tucker in further view of U.S. Patent No. 6,298,261 to Rex
|Claims 16-35 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''11'''
|bgcolor = "#FFFF99"|US20070055142A1
|align = "right" bgcolor = "#FFFF99"|3/8/2007
|align = "right" bgcolor = "#FFFF99"|3/14/2003
|1/7/2009
|FR
|101, 103 and 112 rejections
|Claims 1-8, 10-1 1, 13-1 6, 31 -38, 40-41, 43-46, 67, 69-70, and 72 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|Claims 1-8, 10-1 1, 13-25, 31 -38, 40-41, 43-54, 60-67, 69-70, 72-83, 89, 91 -94 and 99-100 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rasche (US 6,473,635).
|Claims 8, 10-1 1, 13-1 6, 38, 40-41, 43-46, 67, 69-70, 72-75, 89, and 91 -94 are rejected under 35 U.S.C. 11 2, first paragraph, as failing to comply with the written description requirement.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|bgcolor = "#FFFF99"|US20060281997A1
|align = "right" bgcolor = "#FFFF99"|12/14/2006
|align = "right" bgcolor = "#FFFF99"|6/6/2006
|3/6/2009
|FR
|103 and 112 rejections
|N/A
|N/A
|Claim(s) 1 - 12, 14, 17 - 20, 22 - 25, 28 - 52, and 54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Boileau et al. (US 200410267321, herein Boileau).
|Claim(s) 1, 18, 22, 29, 31, 38, 41, 48 - 55, 60, and 62 rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|bgcolor = "#FFFF99"|US20060264740A1
|align = "right" bgcolor = "#FFFF99"|11/23/2006
|align = "right" bgcolor = "#FFFF99"|2/3/2006
|11/14/2008
|N/FR
|101 and 103 rejections
|Claims 15-1 8 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|Claims 1-1 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kendrick et al. (US PG Pub 200310206614 Al) in view of Blumhofer et al. (US Patent 6,865,253).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|bgcolor = "#FFFF99"|US20060253015A1
|align = "right" bgcolor = "#FFFF99"|11/9/2006
|align = "right" bgcolor = "#FFFF99"|6/6/2005
|3/19/2009
|FR
|101 and 102 rejections
|Claims 1-9, 18-28 and 30-33 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to nonstatutory subject matter
|Claims 33 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Speier et al (US 2003/0020473)
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|bgcolor = "#FFFF99"|US20060240393A1
|align = "right" bgcolor = "#FFFF99"|10/26/2006
|align = "right" bgcolor = "#FFFF99"|12/19/2005
|1/26/2009
|N/FR
|101, 102 and 103 rejections
|Claims 6- 18 are rejected under USC 10 1, the claimed invention is directed to non-statutory subject matter.
|Claims 1-3 and 5 are rejected under 35 U.S.C. 102(e) as being anticipated by Calhoun et al. (US 6,280,198 Bl)
|Claims 4, 6-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Calhoun et al. (US 6,280,198 B1) in view of Borsuk (US 5,475,399).Re claim 4, Calhoun does not explicitly teach of said output device includes a display that displays textual information and each program module includes computer readable instructions for adjusting font of textual information.
|N/A
|In re Hirao, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and Kropa v. Robie, 187 F.2d 150, 152, 88 USPQ 478,481 (CCPA 195 1).
|-
|align = "center" bgcolor = "#808080"|'''16'''
|bgcolor = "#FFFF99"|US20060235280A1
|align = "right" bgcolor = "#FFFF99"|10/19/2006
|align = "right" bgcolor = "#FFFF99"|11/19/2004
|3/2/2009
|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-31 are rejected under 35 U.S.C. 101 because the claimed invention is directed to nonstatutory subject matter.
|Claims 16-18 and 20-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Lavin et al. (US 5,772,585).
|Claim I , 4-7 and 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent 5,772,585 to Lavin et al. in view of US Patent 6,108,635 to Herren et al.
|Claims 1-15 and 31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|bgcolor = "#FFFF99"|US20060217623A1
|align = "right" bgcolor = "#FFFF99"|9/28/2006
|align = "right" bgcolor = "#FFFF99"|6/9/2006
|11/25/2008
|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-1 7 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter
|Claims 1-4, 12-1 4, and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Morganroth et al. ("How to obtain and Analyze Electrocardiograms in Clinical Trials" hereinafter referred to as the Morganroth publication).
|Claims 5-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Morganroth publication.
|Claims 14 and 16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|bgcolor = "#FFFF99"|US20060069321A1
|align = "right" bgcolor = "#FFFF99"|3/30/2006
|align = "right" bgcolor = "#FFFF99"|9/30/2004
|12/15/2008
|N/FR
|101 and 112 rejections
|Claims 1-5, 8-1 7, 19-21, 31 -34, 36-45,47-50, 59-64, 66-74, 76-78 and 90-1 03 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.
|N/A
|N/A
|Claims 1-5, 8-1 7, 19-21, 31 -34, 36-45,47-50, 59-64, 66-74, 76-78 and 90-1 03 are also rejected under 35 U.S.C. 11 2, first paragraph.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''19'''
|bgcolor = "#FFFF99"|US20060069317A1
|align = "right" bgcolor = "#FFFF99"|3/30/2006
|align = "right" bgcolor = "#FFFF99"|9/27/2005
|2/25/2009
|FR
|102 and 103 rejections
|N/A
|Claims 1-4, 6-14, 16-25 and 27 are rejected under 35 U.S.C. 102(e) as being anticipated by Chen et al. ("Chen") P S 7,319,781 B2<nowiki>]</nowiki>.
|Claims 5,15 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen et al. ("Chen") P S 7,319,781 B2<nowiki>]</nowiki> in view of Medscape Gastroenterology <nowiki>[</nowiki>NPL document titled, "A Mosaic Pattern of the Descending Duodenum"<nowiki>]</nowiki>.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''20'''
|bgcolor = "#FFFF99"|US20060063987A1
|align = "right" bgcolor = "#FFFF99"|3/23/2006
|align = "right" bgcolor = "#FFFF99"|8/25/2005
|12/24/2008
|N/FR
|101 and 103 rejections
|Claims 1-1 0 are rejected under 35 U.S.C. 101 since the claimed invention is directed to non-statutory subject matter; listed method claims do not transform subject matter to a different state. The methods are also not tied to another statutory class.
|N/A
|Claims I, 2, 3, 5, 7, 10, and I I are rejected under 35 U.S.C. 103(a) as being unpatentable over Robinson et al. (US 6,622,032) in view of Shaw et. al article (Infrared Spectroscopy . . . . . . . . . . . . , 1996 The American Physiological society).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''21'''
|bgcolor = "#FFFF99"|US20060058629A1
|align = "right" bgcolor = "#FFFF99"|3/16/2006
|align = "right" bgcolor = "#FFFF99"|5/25/2005
|2/3/2009
|N/FR
|101 rejection
|Claim 5 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter as follows. Claim 5 defines a computer usable medium embodying functional descriptive material (i.e., a computer program or computer executable code)
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|bgcolor = "#FFFF99"|US20060058622A1
|align = "right" bgcolor = "#FFFF99"|3/16/2006
|align = "right" bgcolor = "#FFFF99"|8/24/2005
|2/17/2009
|N/FR
|101, 102 and 103 rejections
|Claim 63 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. A "software arrangement" is not considered statutory subject matter. Appropriate correction is required
|Claims I , 2, 4, 7, 9-12, 27-34, 36, 38, 39, 54-57, and 64-68 are rejected under 35 U.S.C. 102(b) as being anticipated by Chin et al. (U.S. 4,998,972).
|Claims 8 and 63 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chin et al. Claims 3,23, 37 and 53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chin et al. in view of Tashiro (U.S. 4,827,907).
|N/A
|N/A
|-
|}

Bilski 35 USC § 101 Rejections Patent Application List

2009-04-30T04:11:21Z

Naveen:

File:Bilski.xls

2009-04-18T13:09:06Z

Naveen:

Bilski 35 USC § 101 Rejections Patent Application List

2009-04-18T13:08:24Z

Naveen:

SAP Software Patents Sample

2009-04-18T13:01:02Z

Naveen: /* Examination Information Not Available */

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''S.No.'''
|align = "center" bgcolor = "#808080"|'''Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Publication'''
|align = "center" bgcolor = "#808080"|'''Application date'''
|align = "center" bgcolor = "#808080"|'''Date of rejection'''
|align = "center" bgcolor = "#808080"|'''FR or N/FR'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|align = "center" bgcolor = "#CCFFFF"|US20080120265A1
|align = "right"|5/22/2008
|align = "right"|11/17/2006
|align = "center"|1/29/2009
|align = "center"|N/FR
|101 rejection
|The invention as disclosed in claims 1-20 are rejected under 35 U.S.C. § 101 as being non-statutory subject matter.
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|align = "center" bgcolor = "#CCFFFF"|US20080243564A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|3/6/2009
|align = "center"|N/FR
|101, 102 and 103 rejections
|Claims 1-11 and 23 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1, 3-12, and 14-23 are rejected under 35 U.S.C. 102(e) as being anticipated by Sladky et al. (US 2006/0173617).
|Claims 2 and 13 rejected under 35 U.S.C. 103(a) as being unpatentable over Sladky et al. in view of Examiner<nowiki>’</nowiki>s Official Notice.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''3'''
|align = "center"|US20080127101A1
|align = "right"|5/29/2008
|align = "right"|8/7/2006
|align = "center"|12/17/2008
|align = "center"|N/FR
|101 and 102 rejections
|Claim 4 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 5. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain g patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See Miller v.Eagle Mfg. Co., 151 U.S. 186 (1894); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and In re Vogel, 422 F.2d 438,164 USPQ 619 (CCPA 1970).
|Claims 8, 10-13 are rejected under 35 U.S.C. 102(e) as being anticipated by Barnes et al., (U.S. Patent number 733743 1).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''4'''
|align = "center"|US20080133478A1
|align = "right"|6/5/2008
|align = "right"|11/30/2006
|align = "center"|10/6/2008
|align = "center"|N/FR
|101, 103 and 112 rejections
|Claims 1-9 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sklarz et al. (US 200210087389).
|Claims 1-20 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement.
|-
|align = "center" bgcolor = "#808080"|'''5'''
|align = "center"|US20080134059A1
|align = "right"|6/5/2008
|align = "right"|12/4/2006
|align = "center"|2/13/2009
|align = "center"|N/FR
|101, 102 and 103 rejections
|Claims 8-1 6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-1 5, 17-1 8 rejected under 35 U.S.C. 102(b) as being anticipated by Watts, US 6,614,433 (Hereinafter, Watts).
|Claims 16 rejected under 35 U.S.C. 103(a) as being unpatentable over Watts, US 6,614,433 (Hereinafter, Watts) in view of Jiang, US 200710250764 (Hereinafter, Jiang).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|align = "center"|US20080141237A1
|align = "right"|6/12/2008
|align = "right"|12/7/2006
|align = "center"|10/29/2008
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|Claims 1 - 27 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1 - 3, 10 - 14, 16 - 17, 19 - 20, 22 - 23, and 25 - 27 are rejected under 35 U.S.C. 102(b) as being anticipated by Bharati et al. (Bharati hereinafter) (US 2004/0040021)
|Claims 4, 6, 15, 18, 21, and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bharati et al. (Bharati hereinafter) (US 200410040021) in view of Hayton et al. (Hayton hereinafter) (US 2002101 20679).
|Claims 1 - 9, 14 - 19, and 26 - 27 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''7'''
|align = "center"|US20080155038A1
|align = "right"|6/26/2008
|align = "right"|12/20/2006
|align = "center"|11/24/2008
|align = "center"|N/FR
|101, 102 and 103 rejections
|1. Claims 1-7 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 8-1 2 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-4 and 6 are rejected under 35 U.S.C. 102(b) as being anticipated by Shah et al., U.S. PGPub 200310208572 (hereinafter "Shah").
|Claims 5, 7-10 and 12-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shah et al., U.S. PGPub 200310208572 (hereinafter "Shah") in view of Sugihara et al., U.S. PGPub 200510038771 (hereinafter "Sugihara").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|align = "center"|US20080154948A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|10/9/2008
|align = "center"|N/FR
|101 and 102 rejections
|Claims 11 -21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Spence et al. (Patent No. 6,591,277 B2 filed December 27, 2000, hereinafter Spence).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''9'''
|align = "center"|US20080154854A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|12/31/2008
|align = "center"|N/FR
|101, 102 and 103 rejections
|Claims 10-1 9 and 21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-3, 5, 8, 10-1 2, 14, 17 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Grimes et al (U.S. Patent Application 200510144895 A1 hereinafter, "Grimes").
|Claims 4, 6-7, 20, 12, 15-1 6 and 21 are rejected under 35 U.S.C. 103(a) as being obvious by Grimes et al as applied to claims 1-3, 5, 8, 10-1 2, 14, 17 and 19, and in view of Friend et al (U.S. Patent Application 2006101 07224 A1 hereinafter, "Friend").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''10'''
|align = "center"|US20080149712A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|1/28/2009
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-3 and 24-25 are rejected under 35 U.S.C. 101 as being directed to nonstatutory subject matter.
|Claims 1-3, 18-21, and 24-25 are rejected under U.S.C. 102(e) as being anticipated by Quinn et al. (Quinn hereinafter) (U.S. PG Pub No. 200610026197).
|Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Quinn et al. (U.S. PG Pub No. 200610026197) as applied to claims 1-3, 18-21, and 24-25 in view of Falls et al. (Falls hereinafter) (U.S. Patent No 7,287,001).
|Claim 25 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''11'''
|align = "center"|US20080154994A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|1/8/2009
|align = "center"|N/FR
|101, 102 and 103 rejections
|Claims 1-1 3 and 19-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-8, and 11 -24 are rejected under 35 U.S.C. 102 (b) as being anticipated by Stata et al. (US 200610036580)
|Claims 9 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stata et al. (US 200610036580) and OFFICIAL NOTICE.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|align = "center"|US20080162458A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|3/5/2009
|align = "center"|N/FR
|101 and 103 rejections
|Claims 1-18 are rejected under 35 U.S.C. § 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|1. Claims 1-4, 6, 8, 9, 15 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shurtleff et al. (U.S. Pub. No.: U.S. 200610282427, hereinafter, Shurtleff), in view of Steinmaier et al. (U.S. Pub. No.: U.S. 200510198052, hereinafter, Steinmaier). 2. Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shurtleff et al. (U.S. Pub. No.: U.S. 200610282427, hereinafter, Shurtleff), in view of Steinmaier et al. (U.S. Pub. No.: U.S. 200510198052, hereinafter, Steinmaier), and further in view of Owens et al. (U.S. Pub. No.: U.S. 200610265518, hereinafter, Owens). 3. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shurtleff et al. (U.S. Pub. No.: U.S. 200610282427, hereinafter, Shurtleff), in view of Steinmaier et al. (U.S. Pub. No.: U.S. 200510198052, hereinafter, Steinmaier), and further in view of Annau et al. (U.S. Patent No.: U.S. 6,804,662, hereinafter, Annau). 4. Claims 10 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shurtleff et al. (U.S. Pub. No.: U.S. 200610282427, hereinafter, Shurtleff), in view of Steinmaier et al. (U.S. Pub. No.: U.S. 200510198052, hereinafter, Steinmaier), and further in view of Boyle et al. (U.S. Patent No.: U.S. 7,451,103, hereinafter, Boyle). 5. Claims 12, 13, 16 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shurtleff et al. (U.S. Pub. No.: U.S. 200610282427, hereinafter, Shurtleff), in view of Steinmaier et al. (U.S. Pub. No.: U.S. 200510198052, hereinafter, Steinmaier), and further in view of Davis et al. (U.S. Patent No.: U.S.2002101 3351 6 A1, hereinafter, Davis). 6. Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shurtleff et al. (U.S. Pub. No.: U.S. 200610282427, hereinafter, Shurtleff), in view of Steinmaier et al. (U.S. Pub. No.: U.S. 200510198052, hereinafter, Steinmaier), and further in view of Hanson et al. (U.S. Patent No.: U.S. 5,956,736 Al, hereinafter, Hanson).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|align = "center"|US20080162457A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|11/14/2008
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|1. Claims 1-24 are rejected under 35 U.S.C. 101 because invention is directed to non-statutory subject matter. 2. Claim 1 ,I 6,24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1,8,14 of co-pending application 11/647,768.
|1. Claims 1-7, are rejected under 35 U.S.C. 102(b) as being anticipated by Berner et a1 <nowiki>[</nowiki>hereafter Berner<nowiki>]</nowiki>, US Patent No. 5907846 published on May 25, 1999. 2. Claims 8-12, 15-20,23-24 are rejected under 35 U.S.C. 102(b) as being anticipated by Cazemier et a1 <nowiki>[</nowiki>hereafter Cazemier<nowiki>]</nowiki>, US Patent No. 6609123 published on Aug 19,2003
|Claims 13-14,21-22 are rejected under 35 U.S. C. 103(a) as being unpatentable over Cazemier et a1 <nowiki>[</nowiki>hereafter Cazemier<nowiki>]</nowiki>, US Patent No. 6609123 published on Aug 19,2003 as applied to claim8,16, above, and further in view of Berner et a1 <nowiki>[</nowiki>hereafter Berner<nowiki>]</nowiki>, US Patent No. 5907846 published on May 25, 1999.
|In claim 24, applicant appear to be invoking 112, sixth paragraph "means for" type language, but it is unclear what "structures" are being used to perform the functions.
|-
|align = "center" bgcolor = "#808080"|'''14'''
|align = "center"|US20080162426A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|10/1/2008
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|1. Claims I, 2, 6-10, and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Brown (US 6,334,122). 2. Claims 11 -1 5 are rejected under 35 U.S.C. 102(b) as being anticipated by Raciborski (US 2005101 77562).
|Claims 3-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brown as applied to claim 1 above, and further in view of Raciborski (US 2005/0177562)
|Claims 11 -1 5 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''15'''
|align = "center"|US20080162415A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|11/24/2008
|align = "center"|N/FR
|101, 102 and 103 rejections
|Claims 1-1 8 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-3, 8-1 0 and 15-1 7 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 6,356,901 B1 (MacLeod et al., hereinafter as MacLeod).
|1. Claims 4-5, 1 1-1 2 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 6,356,901 B1 (MacLeod et al., hereinafter as MacLeod) in view of US Patent No. 6,460,052 B1 (Thomas et al., hereinafter as Thomas). 2. Claims 6 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 6,356,901 B1 (MacLeod et al., hereinafter as MacLeod) in view of Pub. No.: US 200610288036 A1 (Sadovski et al., hereinafter as Sadovski).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''16'''
|align = "center"|US20080162563A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|11/7/2008
|align = "center"|N/FR
|101, 102 and 103 rejections
|1. Claims 1-5 are rejected under 35 U.S.C. § 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 6-10 are rejected under 35 U.S.C. § 101 because the claimed invention is directed to non-statutory subject matter. 3. Claims 11 and 12 are rejected under 35 U.S.C. § 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1, 6 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Aubel et al. (U.S. Patent No.: US 5,696,693, hereinafter, Aubel).
|Claims 1-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wesemann (U.S. Pub. No.: US 200410186842 Al), in view of Cook et al. (U.S. Pub. No.: US 200610150169 A1, hereinafter, Cook).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|align = "center"|US20080162279A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|2/20/2009
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|Claims 14-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-2, 4-9, 11-12, 14, 16-23 and 25-26 are rejected under 35 U.S.C. 102(b) as being anticipated by Katz et al. (US 2002/0138316 A1) (hereinafter Katz)
|1. Claims 3, 10 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Katz et al. (US 2002/0138316 Al) (hereinafter Katz) 2. Claims 13 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Katz et al. (US 2002/0138316 Al) (hereinafter Katz) in view of Irby et al. (US 2005/0209934 Al) (hereinafter Irby) .
|Claims 7-9 and 12-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''18'''
|align = "center"|US20080163126A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|12/24/2008
|align = "center"|N/FR
|101 and 103 rejections
|1. Claims 1 - 19 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claim 20 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter
|N/A
|1. Claims 1 - 11, and 13 - 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Guido et al. (US PGPub 2005/0149873), hereinafter <nowiki>’</nowiki>Guido<nowiki>’</nowiki>, in view of Glatfelter et al. (US PGPub 2008/0091942), hereinafter <nowiki>’</nowiki>Glatfelter<nowiki>’</nowiki>. 2. Claims 12, and 15 - 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Guido et al. (US PGPub 200510149873), hereinafter <nowiki>’</nowiki>Guido<nowiki>’</nowiki>, in view of Glatfelter et al. (US PGPub 200810091942), hereinafter <nowiki>’</nowiki>Glatfelter<nowiki>’</nowiki>, in further view of Lunawat (US PGPub 200710168940).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''19'''
|align = "center"|US20080162558A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|12/23/2008
|align = "center"|N/FR
|101 and 102 rejections
|Claims 16-20 rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Hughes et al. (PGPub. No. 200610136906; Filing date: Dec. 20, 2004) (hereinafter Hughes).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''20'''
|align = "center"|US20080195586A1
|align = "right"|8/14/2008
|align = "right"|2/9/2007
|align = "center"|12/22/2008
|align = "center"|N/FR
|101 and 102 rejections
|Claim 15 is rejected under 35 USC 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-20 are rejected under 35 U.S.C. 102 (e) as being anticipated by Budzik et al. (US Publication No. 2007101 85847), herein referred to as "Budzik".
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''21'''
|align = "center"|US20080243781A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|2/6/2009
|align = "center"|N/FR
|101 and 103 rejections
|Claims 1 - 25 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|N/A
|1. Claims 1 - 4, 6, 8 - 10, 13 - 15, 18, 19 and 21 - 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 6,178,418 issued to Richard E. Singer (hereinafter "Singer") in view of US Patent Number 5,960,194 issued to David Mun-Hien Choy et al. (hereinafter "Choy"). 2. Claims 5, 7, 12, 16, 17 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Singer and Choy as applied to claims 4, 1, 15 and 24 above respectfully, and further in view of US Patent Number 7,451,148 issued to Allen B. C h ildress et al. (hereinafter "Childress"). 3. Claims 11 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Singer and Choy as applied to claims 10 and 19 above respectfully, and further in view of US Patent Number 6,901,418 issued to Dan G. Gonos (hereinafter "Gonos").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|align = "center"|US20080255968A1
|align = "right"|10/16/2008
|align = "right"|4/12/2007
|align = "center"|10/6/2008
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|1. Claims 1-10 are rejected under 35 U.S.C. 101 because the claimed invention is directed to nonstatutory subject matter 2. Claims 1 1-20 are rejected under 35 U.S.C. 101 based on Supreme Court precedent, and recent Federal Circuit decisions, the Office<nowiki>’</nowiki>s guidance to examiners is that a 5 101 process must (1) be tied to another statutory class (such as a particular apparatus) or (2) transform underlying subject matter (such as an article or materials) to a different state or thing.
|Claims 1, 9, 11, and 19 are rejected under 35 U.S.C. 102 (b) as being anticipated by Lenk et al. (US 2004/006845 1).
|Claims 2- 18, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lenk et al. (US 20041006845 1) in view of LeMasters ET a1 (US 200810027835" .
|Claims 1-10 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''23'''
|align = "center"|US20080163063A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|2/19/2009
|align = "center"|N/FR
|101, 102 and 103 rejections
|Claims 15-21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-4, 6-1 1, 13-18 and 20-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Ho et al ("Ho" US 200710261 043).
|Claims 5, 12 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ho in view of Wen et al ("Wen" US 20061023581 0).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''24'''
|align = "center"|US20080162552A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|2/27/2009
|align = "center"|N/FR
|101, 102 and 103 rejections
|1. Claims 15-21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 1-21 of this application conflict with claims 1-21 of Application No. 111647,979. 37 CFR 1.78(b) provides that when two or more applications filed by the same applicant contain conflicting claims, elimination of such claims from all but one application may be required in the absence of good and sufficient reason for their retention during pendency in more than one application.
|Claims 1-4, 6-1 1, 13-18 and 20-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Ho et al ("Ho" US 200710261 043).
|Claims 5, 12 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ho in view of Wen et al ("Wen" US 20061023581 0).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''25'''
|align = "center"|US20080162547A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|2/11/2009
|align = "center"|N/FR
|101, 102, 103 and 112 rejections
|Claims 1-7 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to nonstatutory subject matter.
|Claims 1, 5-8, 12-15, and 19-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Ho et a1 (US 20070261043), hereafter known as Ho.
|Claims 2, 9, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ho in view of Stoodley et a1 (US 20070226683), hereafter known as Stoodley.
|Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''26'''
|align = "center"|US20080071589A1
|align = "right"|3/20/2008
|align = "right"|8/14/2006
|align = "center"|11/13/2008
|align = "center"|N/FR
|102 and 103 rejections
|N/A
|Claims 1-3 and 5-22 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 7,031,901 to Abu El Ata (hereafter "Abu El Ata").
|Claims 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abu El Ata as applied to claims 1-3 and 5-22 above, and further in view of US Patent Application Publication No. 20041004461 7 to Lu (hereafter "Lu").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''27'''
|align = "center"|US20080077549A1
|align = "right"|3/27/2008
|align = "right"|8/31/2006
|align = "center"|3/18/2009
|align = "center"|FR
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-20 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over NPL Java and SOAP by Englander, in view of US PGPUB 200510080661 by Casati et al. (hereinafter "Casati"), and in further view of US PGPUB 200610242489 by Brockway et al. (hereinafter "Brockway"). 2. Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over NPL Java and SOAP by Englander, in view of US PGPUB 200510080661 by Casati et al. (hereinafter "Casati"), and in further view of US PGPUB 200610242489 by Brockway et al. (hereinafter "Brockway"), as applied to claim 1 above, and further in view of US PGPUB 200410267834 by Sasaki et al. (hereinafter "Sasaki").
|1. Claim 3 is objected to because of the following informalities: claim 1 recites "a message including data copied from a first data set" and claim 2 recites "the first data set is a business object". 2. Claim 13, a system claim, contains subject matter similar to claim 1 and is objected on the same ground. 3. New claim 21 is rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''28'''
|align = "center"|US20080075246A1
|align = "right"|3/27/2008
|align = "right"|8/31/2006
|align = "center"|3/18/2009
|align = "center"|FR
|103 rejection
|N/A
|N/A
|1. Claims 1-6, 9-14, and 17-19, and 21-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over NPL Java and SOAP by Englander, in view of USPGPUB 200410267834 by Sasaki et al. (hereinafter "Sasaki") 2. Claims 8, 16, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over NPL Java and SOAP by Englander, in view of US PGPUB 200410267834 by Sasaki et al. (hereinafter "Sasaki"), as applied to claims I, 9, and 17 above, and further in view of Patent 6898618 by Slaughter et al. (hereinafter "Slaughter").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''29'''
|align = "center"|US20080065262A1
|align = "right"|3/13/2008
|align = "right"|8/31/2006
|align = "center"|12/29/2008
|align = "center"|N/FR
|102 and 103 rejections
|N/A
|Claims 1-2, 4, 7, 11 -15, 17-1 8, 20 and 23-29 are rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent to Hunt et al. (5,835,716).
|1. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hunt et al. 2. Claims 5-6, 8-10, 16, 19 and 21-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hunt et al. in view of the U.S. Patent to Ross et al. (6,332,098 B2).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''30'''
|align = "center"|US20080188955A1
|align = "right"|8/7/2008
|align = "right"|9/29/2006
|align = "center"|3/12/2009
|align = "center"|FR
|112 rejection
|N/A
|N/A
|N/A
|Claims 1-1 7 and 19 are rejected under 35 U.S.C. 11 2, first paragraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''31'''
|align = "center"|US20080082679A1
|align = "right"|4/3/2008
|align = "right"|9/29/2006
|align = "center"|2/23/2009
|align = "center"|FR
|103 rejection
|N/A
|N/A
|1. Claims 1-2, and 6 are rejected under 35 U.S.C. 103 (a) as being unpatentable over Lindholm et al., U.S. Patent Application Publication No. 200410019801 <nowiki>[</nowiki>hereinafter Lindholm <nowiki>]</nowiki> in view of Brauneis et al. U.S. Patent Application Publication 200810140832<nowiki>[</nowiki>hereinafter Brauneis<nowiki>]</nowiki>. 2. Claim 3 is rejected under 35 U.S.C. 103 (a) as being unpatentable over Lindholm et al., U.S. Patent Application Publication No. 200410019801 <nowiki>[</nowiki>hereinafter Lindholm <nowiki>]</nowiki>in view of Brauneis et al. U.S. Patent Application Publication 2008101 40832<nowiki>[</nowiki>hereinafter Brauneis<nowiki>]</nowiki>.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''32'''
|align = "center"|US20080109436A1
|align = "right"|5/8/2008
|align = "right"|11/6/2006
|align = "center"|3/10/2009
|align = "center"|FR
|103 rejection
|N/A
|N/A
|Claims 1-2, 4-10 and 12-20 are rejected under 35 USC 103 as obvious over Jeffrey David Calusinski (U.S. Pub. No. 200510071342) in view of Gorur et al (U.S. Pub. No. 200810065443).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''33'''
|align = "center"|US20080109732A1
|align = "right"|5/8/2008
|align = "right"|11/7/2006
|align = "center"|12/22/2008
|align = "center"|N/FR
|102 and 103 rejections
|N/A
|Claims 1-1 4 are rejected under 35 U.S.C. 102(e) as being anticipated by Li, US Patent 7089500.
|Claims 15 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pullara et al (hereinafter Pullara) US 20030014526.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''34'''
|align = "center"|US20080082691A1
|align = "right"|4/3/2008
|align = "right"|11/9/2006
|align = "center"|2/4/2009
|align = "center"|N/FR
|102, 103 and 112 rejection
|N/A
|Claims 1-3 and 5-23 are rejected under 35 U.S.C. 102(b) as being anticipated by Diesel et al. (2004001401 3: hereinafter Diesel)
|Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Diesel, in view of Beigel (200401 50662: hereinafter Beigel).
|Claims I, 10 and 17 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''35'''
|align = "center"|US20080120279A1
|align = "right"|5/22/2008
|align = "right"|11/22/2006
|align = "center"|2/27/2009
|align = "center"|FR
|103 rejection
|N/A
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liang (US Pub. 200510160107 Al) in view of Omoigui (US 200410230572 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''36'''
|align = "center"|US20080155431A1
|align = "right"|6/26/2008
|align = "right"|12/20/2006
|align = "center"|12/11/2008
|align = "center"|N/FR
|102 rejection
|N/A
|Claims 1-1 3 are rejected under 35 U.S.C. 102(b) as being anticipated by Barton (US 6031 535).
|
|N/A
|-
|align = "center" bgcolor = "#808080"|'''37'''
|align = "center"|US20080154937A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|12/2/2008
|align = "center"|N/FR
|102 rejection
|N/A
|Claims 1-1 3 rejected under 35 U.S.C. 102(a) as being anticipated by Paoli (US 7,275,216)
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''38'''
|align = "center"|US20080154753A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|12/26/2008
|align = "center"|FR
|102 and 103 rejections
|N/A
|Claims 1, 3-10 and 21 -29 are rejected under 35 U.S.C. 102(e) as being anticipated by Lo et al. (US 2006/0095374 Al, hereinafter "Lo").
|Claims 11 -20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lo in view of Argenbright (US 7,454,376 Bl).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''39'''
|align = "center"|US20080154688A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|12/29/2008
|align = "center"|N/FR
|102 and 103 rejections
|N/A
|Claims 1, 8 and 15 are rejected under 35 U.S.C. 102(e) as being anticipated by Oral et al. (US 2008101 40488 A1 ).
|1. Claims 2, 3, 9, 10, 13, 16 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Oral et al. (US 200810140488 Al) in view of Kaufman et al. (US2007/0072156 A1) 2. Claims 4-6, 11 -1 3, 18-20 and 22-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Oral et al. (US 200810140488 Al) in view of Brush et al. ("Brush", US 200810082925 A1 ). 3. Claims 7 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Oral et al. (US 2008101 40488 Al) in view of Forth (US 200710282660).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''40'''
|align = "center"|US20080162344A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|10/9/2008
|align = "center"|FR
|103 rejection
|N/A
|N/A
|1. Claim 1-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over McKenney et al. (US 200610004670), in view of Der Emde et al. (US 200710233598). 2. Claim 18 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over McKenney et al. (US 200610004670), in view of Der Emde et al. (US 200710233598) and further in view of Matena et al.(US 2004101 58549).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''41'''
|align = "center"|US20080162610A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|11/28/2008
|align = "center"|N/FR
|103 rejection
|N/A
|N/A
|Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wiser et al. (US 200510149526) in view of Roy et al. (US 6363403).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''42'''
|align = "center"|US20080148161A1
|align = "right"|6/19/2008
|align = "right"|8/31/2005
|align = "center"|10/15/2008
|align = "center"|N/FR
|102 and 112 rejections
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Diorio et al. (US7,028,264)
|N/A
|Claims 1 - 12 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to non-statutory subject matter.
|-
|align = "center" bgcolor = "#808080"|'''43'''
|align = "center"|US20080005623A1
|align = "right"|1/3/2008
|align = "right"|6/30/2006
|align = "center"|9/18/2008
|align = "center"|N/FR
|101 and 102 rejections
|Claims 15-22 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Przinzing, US 6,496,202 (Hereinafter, Prinzing).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''44'''
|align = "center"|US20080028328A1
|align = "right"|1/31/2008
|align = "right"|7/31/2006
|align = "center"|9/30/2008
|align = "center"|N/FR
|101, 102 and 112 rejections
|Claims 12-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-27 are rejected under 35 U.S.C. 102(b) as being anticipated by Arend et al, US PG PUB<nowiki> </nowiki> 200410230914 A1 (hereinafter Arend).
|N/A
|Claim 6 contains the trademarkltrade name SAP Netweaver Visual Composer. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product.
|-
|align = "center" bgcolor = "#808080"|'''45'''
|align = "center"|US20080059517A1
|align = "right"|3/6/2008
|align = "right"|8/31/2006
|align = "center"|6/27/2008
|align = "center"|N/FR
|101 and 102 rejections
|Claims 16-21, 22 are rejected as being directed to non-statuatory subject matter
|Claims 1-22 are rejected under 35 U.S.C. 102(e) as being anticipated: by US 2010180075 issued to Doug Chasman et al ("Chasman").
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''46'''
|align = "center"|US20090037305A1
|align = "right"|2/5/2009
|align = "right"|8/2/2007
|align = "center"|9/26/2008
|align = "center"|N/FR
|102, 103 and 112 rejection
|N/A
|Claims 1-2, 4, 6-8,lO-14,16,18-20, and 22-23 are rejected under 35 U.S.C. 102(e) as being anticipated by Regan (US 7,234,103).
|Claims 3, 5, 9,15,17,21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Regan (US 7,234,103).
|Claims 12 and 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''47'''
|align = "center"|US20080004939A1
|align = "right"|1/3/2008
|align = "right"|6/29/2006
|align = "center"|9/5/2008
|align = "center"|FR
|102 rejection
|N/A
|Claims 1-28 are rejected under 35 U.S.C. 102(b) as being anticipated by Santos et al. (US 2002101 43665 A1 ).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''48'''
|align = "center"|US20080155105A1
|align = "right"|6/26/2008
|align = "right"|12/21/2006
|align = "center"|7/9/2008
|align = "center"|FR
|102 and 103 rejections
|N/A
|Claims 1-8, 11 -1 8 and 21 are rejected under 35 U.S.C. 102(e) as being anticipated by Moore et al (Hereafter, Moore), U.S. Pat. Application Pub. No. US 2006/0171402 A1
|Claims 9-1 0 and 19-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Moore et al (Hereafter, Moore), U.S. Pat. Application Pub. No. US 2006101 71 402 A1 .
|N/A
|-
|}

=Examination Information Not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''S.No.'''
|align = "center" bgcolor = "#808080"|'''Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Publication'''
|align = "center" bgcolor = "#808080"|'''Application date'''
|align = "center" bgcolor = "#808080"|'''Date of rejection'''
|align = "center" bgcolor = "#808080"|'''FR or N/FR'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|align = "center"|US20090006539A1
|align = "right"|1/1/2009
|align = "right"|6/26/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|align = "center"|US20090007056A1
|align = "right"|1/1/2009
|align = "right"|6/29/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''3'''
|align = "center"|US20090006150A1
|align = "right"|1/1/2009
|align = "right"|6/29/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''4'''
|align = "center"|US20090019424A1
|align = "right"|1/15/2009
|align = "right"|7/12/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|align = "center"|US20090024558A1
|align = "right"|1/22/2009
|align = "right"|7/16/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|align = "center"|US20090024552A1
|align = "right"|1/22/2009
|align = "right"|7/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|align = "center"|US20090030929A1
|align = "right"|1/29/2009
|align = "right"|7/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|align = "center"|US20090031004A1
|align = "right"|1/29/2009
|align = "right"|7/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''9'''
|align = "center"|US20090030928A1
|align = "right"|1/29/2009
|align = "right"|7/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''10'''
|align = "center"|US20090030871A1
|align = "right"|1/29/2009
|align = "right"|7/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''11'''
|align = "center"|US20090030938A1
|align = "right"|1/29/2009
|align = "right"|7/27/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|align = "center"|US20090030934A1
|align = "right"|1/29/2009
|align = "right"|7/27/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|align = "center"|US20090031112A1
|align = "right"|1/29/2009
|align = "right"|7/27/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|align = "center"|US20090037237A1
|align = "right"|2/5/2009
|align = "right"|7/31/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|align = "center"|US20090037453A1
|align = "right"|2/5/2009
|align = "right"|7/31/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''16'''
|align = "center"|US20090037535A1
|align = "right"|2/5/2009
|align = "right"|8/3/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|align = "center"|US20090043592A1
|align = "right"|2/12/2009
|align = "right"|8/6/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|align = "center"|US20090043738A1
|align = "right"|2/12/2009
|align = "right"|8/10/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''19'''
|align = "center"|US20090049539A1
|align = "right"|2/19/2009
|align = "right"|8/13/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''20'''
|align = "center"|US20090049378A1
|align = "right"|2/19/2009
|align = "right"|8/13/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''21'''
|align = "center"|US20090055382A1
|align = "right"|2/26/2009
|align = "right"|8/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|align = "center"|US20090064096A1
|align = "right"|3/5/2009
|align = "right"|8/29/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''23'''
|align = "center"|US20090063988A1
|align = "right"|3/5/2009
|align = "right"|8/31/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''24'''
|align = "center"|US20090063370A1
|align = "right"|3/5/2009
|align = "right"|8/31/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''25'''
|align = "center"|US20090063217A1
|align = "right"|3/5/2009
|align = "right"|8/31/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''26'''
|align = "center"|US20090070336A1
|align = "right"|3/12/2009
|align = "right"|9/7/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''27'''
|align = "center"|US20090070712A1
|align = "right"|3/12/2009
|align = "right"|9/11/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''28'''
|align = "center"|US20090070165A1
|align = "right"|3/12/2009
|align = "right"|9/12/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''29'''
|align = "center"|US20090070300A1
|align = "right"|3/12/2009
|align = "right"|9/5/2008
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''30'''
|align = "center"|US20080126409A1
|align = "right"|5/29/2008
|align = "right"|6/26/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''31'''
|align = "center"|US20080010239A1
|align = "right"|1/10/2008
|align = "right"|7/10/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''32'''
|align = "center"|US20080015919A1
|align = "right"|1/17/2008
|align = "right"|7/14/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''33'''
|align = "center"|US20080027972A1
|align = "right"|1/31/2008
|align = "right"|7/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''34'''
|align = "center"|US20080027778A1
|align = "right"|1/31/2008
|align = "right"|7/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''35'''
|align = "center"|US20080033997A1
|align = "right"|2/7/2008
|align = "right"|8/4/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''36'''
|align = "center"|US20080065463A1
|align = "right"|3/13/2008
|align = "right"|8/24/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''37'''
|align = "center"|US20080126227A1
|align = "right"|5/29/2008
|align = "right"|8/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''38'''
|align = "center"|US20080055313A1
|align = "right"|3/6/2008
|align = "right"|8/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''39'''
|align = "center"|US20080077464A1
|align = "right"|3/27/2008
|align = "right"|9/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''40'''
|align = "center"|US20080091502A1
|align = "right"|4/17/2008
|align = "right"|9/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''41'''
|align = "center"|US20080083023A1
|align = "right"|4/3/2008
|align = "right"|9/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''42'''
|align = "center"|US20080082660A1
|align = "right"|4/3/2008
|align = "right"|9/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''43'''
|align = "center"|US20080127110A1
|align = "right"|5/29/2008
|align = "right"|9/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''44'''
|align = "center"|US20080127109A1
|align = "right"|5/29/2008
|align = "right"|9/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''45'''
|align = "center"|US20080127108A1
|align = "right"|5/29/2008
|align = "right"|9/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''46'''
|align = "center"|US20080098358A1
|align = "right"|4/24/2008
|align = "right"|9/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''47'''
|align = "center"|US20080086354A1
|align = "right"|4/10/2008
|align = "right"|10/5/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''48'''
|align = "center"|US20080120597A1
|align = "right"|5/22/2008
|align = "right"|10/27/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''49'''
|align = "center"|US20080104501A1
|align = "right"|5/1/2008
|align = "right"|10/27/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''50'''
|align = "center"|US20080103843A1
|align = "right"|5/1/2008
|align = "right"|10/27/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''51'''
|align = "center"|US20080120206A1
|align = "right"|5/22/2008
|align = "right"|10/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''52'''
|align = "center"|US20080104579A1
|align = "right"|5/1/2008
|align = "right"|10/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

=Examination Information Not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''53'''
|align = "center"|US20080103815A1
|align = "right"|5/1/2008
|align = "right"|10/31/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''54'''
|align = "center"|US20080109714A1
|align = "right"|5/8/2008
|align = "right"|11/3/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''55'''
|align = "center"|US20080109292A1
|align = "right"|5/8/2008
|align = "right"|11/3/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''56'''
|align = "center"|US20080126164A1
|align = "right"|5/29/2008
|align = "right"|11/7/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''57'''
|align = "center"|US20080114627A1
|align = "right"|5/15/2008
|align = "right"|11/15/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''58'''
|align = "center"|US20080114626A1
|align = "right"|5/15/2008
|align = "right"|11/15/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''59'''
|align = "center"|US20080120616A1
|align = "right"|5/22/2008
|align = "right"|11/17/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''60'''
|align = "center"|US20080098355A1
|align = "right"|4/24/2008
|align = "right"|11/21/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''61'''
|align = "center"|US20080120111A1
|align = "right"|5/22/2008
|align = "right"|11/21/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''62'''
|align = "center"|US20080126155A1
|align = "right"|5/29/2008
|align = "right"|11/27/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''63'''
|align = "center"|US20080133677A1
|align = "right"|6/5/2008
|align = "right"|12/1/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''64'''
|align = "center"|US20080148264A1
|align = "right"|6/19/2008
|align = "right"|12/13/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''65'''
|align = "center"|US20080148166A1
|align = "right"|6/19/2008
|align = "right"|12/14/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''66'''
|align = "center"|US20080147455A1
|align = "right"|6/19/2008
|align = "right"|12/14/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''67'''
|align = "center"|US20080148006A1
|align = "right"|6/19/2008
|align = "right"|12/18/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''68'''
|align = "center"|US20080144653A1
|align = "right"|6/19/2008
|align = "right"|12/18/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''69'''
|align = "center"|US20080146258A1
|align = "right"|6/19/2008
|align = "right"|12/19/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''70'''
|align = "center"|US20080155457A1
|align = "right"|6/26/2008
|align = "right"|12/20/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''71'''
|align = "center"|US20080098085A1
|align = "right"|4/24/2008
|align = "right"|12/20/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''72'''
|align = "center"|US20080155367A1
|align = "right"|6/26/2008
|align = "right"|12/21/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''73'''
|align = "center"|US20080155356A1
|align = "right"|6/26/2008
|align = "right"|12/21/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''74'''
|align = "center"|US20080155355A1
|align = "right"|6/26/2008
|align = "right"|12/21/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''75'''
|align = "center"|US20080155506A1
|align = "right"|6/26/2008
|align = "right"|12/21/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''76'''
|align = "center"|US20080155561A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''77'''
|align = "center"|US20080155556A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''78'''
|align = "center"|US20080155391A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''79'''
|align = "center"|US20080155014A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''80'''
|align = "center"|US20080154619A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''81'''
|align = "center"|US20080154414A1
|align = "right"|6/26/2008
|align = "right"|12/22/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''82'''
|align = "center"|US20080127052A1
|align = "right"|5/29/2008
|align = "right"|12/26/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''83'''
|align = "center"|US20080162508A1
|align = "right"|7/3/2008
|align = "right"|12/27/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''84'''
|align = "center"|US20080163165A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''85'''
|align = "center"|US20080162564A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''86'''
|align = "center"|US20080162379A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''87'''
|align = "center"|US20080159317A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''88'''
|align = "center"|US20080163253A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''89'''
|align = "center"|US20080162539A1
|align = "right"|7/3/2008
|align = "right"|12/28/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''90'''
|align = "center"|US20080163177A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''91'''
|align = "center"|US20080163091A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''92'''
|align = "center"|US20080162777A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''93'''
|align = "center"|US20080162616A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''94'''
|align = "center"|US20080162266A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''95'''
|align = "center"|US20080162207A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''96'''
|align = "center"|US20080162205A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''97'''
|align = "center"|US20080162164A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''98'''
|align = "center"|US20080158161A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''99'''
|align = "center"|US20080157969A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''100'''
|align = "center"|US20080162749A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''101'''
|align = "center"|US20080162297A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''102'''
|align = "center"|US20080162278A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

=Examination Information Not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''103'''
|align = "center"|US20080163198A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''104'''
|align = "center"|US20080163197A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''105'''
|align = "center"|US20080163092A1
|align = "right"|7/3/2008
|align = "right"|12/30/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''106'''
|align = "center"|US20080178101A1
|align = "right"|7/24/2008
|align = "right"|1/19/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''107'''
|align = "center"|US20080183661A1
|align = "right"|7/31/2008
|align = "right"|1/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''108'''
|align = "center"|US20080189438A1
|align = "right"|8/7/2008
|align = "right"|2/6/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''109'''
|align = "center"|US20080195598A1
|align = "right"|8/14/2008
|align = "right"|2/8/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''110'''
|align = "center"|US20080059949A1
|align = "right"|3/6/2008
|align = "right"|2/8/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''111'''
|align = "center"|US20080208894A1
|align = "right"|8/28/2008
|align = "right"|2/26/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''112'''
|align = "center"|US20080215389A1
|align = "right"|9/4/2008
|align = "right"|3/1/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''113'''
|align = "center"|US20080184334A1
|align = "right"|7/31/2008
|align = "right"|3/6/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''114'''
|align = "center"|US20080229280A1
|align = "right"|9/18/2008
|align = "right"|3/12/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''115'''
|align = "center"|US20080228536A1
|align = "right"|9/18/2008
|align = "right"|3/13/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''116'''
|align = "center"|US20080228851A1
|align = "right"|9/18/2008
|align = "right"|3/14/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''117'''
|align = "center"|US20080229275A1
|align = "right"|9/18/2008
|align = "right"|3/16/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''118'''
|align = "center"|US20080229242A1
|align = "right"|9/18/2008
|align = "right"|3/16/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''119'''
|align = "center"|US20080235663A1
|align = "right"|9/25/2008
|align = "right"|3/21/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''120'''
|align = "center"|US20080235772A1
|align = "right"|9/25/2008
|align = "right"|3/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''121'''
|align = "center"|US20080235130A1
|align = "right"|9/25/2008
|align = "right"|3/23/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''122'''
|align = "center"|US20080244427A1
|align = "right"|10/2/2008
|align = "right"|3/28/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''123'''
|align = "center"|US20080244423A1
|align = "right"|10/2/2008
|align = "right"|3/28/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''124'''
|align = "center"|US20080244422A1
|align = "right"|10/2/2008
|align = "right"|3/28/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''125'''
|align = "center"|US20080244399A1
|align = "right"|10/2/2008
|align = "right"|3/28/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''126'''
|align = "center"|US20080244616A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''127'''
|align = "center"|US20080244547A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''128'''
|align = "center"|US20080244546A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''129'''
|align = "center"|US20080244537A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''130'''
|align = "center"|US20080244531A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''131'''
|align = "center"|US20080244324A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''132'''
|align = "center"|US20080243980A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''133'''
|align = "center"|US20080243970A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''134'''
|align = "center"|US20080243969A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''135'''
|align = "center"|US20080243968A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''136'''
|align = "center"|US20080244379A1
|align = "right"|10/2/2008
|align = "right"|3/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''137'''
|align = "center"|US20080250318A1
|align = "right"|10/9/2008
|align = "right"|4/3/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''138'''
|align = "center"|US20080250387A1
|align = "right"|10/9/2008
|align = "right"|4/4/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''139'''
|align = "center"|US20080249781A1
|align = "right"|10/9/2008
|align = "right"|4/4/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''140'''
|align = "center"|US20080249992A1
|align = "right"|10/9/2008
|align = "right"|4/9/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''141'''
|align = "center"|US20080256554A1
|align = "right"|10/16/2008
|align = "right"|4/10/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''142'''
|align = "center"|US20080215957A1
|align = "right"|9/4/2008
|align = "right"|4/12/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''143'''
|align = "center"|US20080256454A1
|align = "right"|10/16/2008
|align = "right"|4/13/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''144'''
|align = "center"|US20080256200A1
|align = "right"|10/16/2008
|align = "right"|4/13/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''145'''
|align = "center"|US20080255865A1
|align = "right"|10/16/2008
|align = "right"|4/16/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''146'''
|align = "center"|US20080263503A1
|align = "right"|10/23/2008
|align = "right"|4/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''147'''
|align = "center"|US20080263195A1
|align = "right"|10/23/2008
|align = "right"|4/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''148'''
|align = "center"|US20080263007A1
|align = "right"|10/23/2008
|align = "right"|4/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''149'''
|align = "center"|US20080263006A1
|align = "right"|10/23/2008
|align = "right"|4/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''150'''
|align = "center"|US20080262891A1
|align = "right"|10/23/2008
|align = "right"|4/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''151'''
|align = "center"|US20080262860A1
|align = "right"|10/23/2008
|align = "right"|4/20/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''152'''
|align = "center"|US20080208900A1
|align = "right"|8/28/2008
|align = "right"|5/1/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

=Examination Information Not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''153'''
|align = "center"|US20080276221A1
|align = "right"|11/6/2008
|align = "right"|5/2/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''154'''
|align = "center"|US20080275900A1
|align = "right"|11/6/2008
|align = "right"|5/2/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''155'''
|align = "center"|US20080276225A1
|align = "right"|11/6/2008
|align = "right"|5/4/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''156'''
|align = "center"|US20080278198A1
|align = "right"|11/13/2008
|align = "right"|5/10/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''157'''
|align = "center"|US20080288549A1
|align = "right"|11/20/2008
|align = "right"|5/14/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''158'''
|align = "center"|US20080288472A1
|align = "right"|11/20/2008
|align = "right"|5/14/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''159'''
|align = "center"|US20080288533A1
|align = "right"|11/20/2008
|align = "right"|5/18/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''160'''
|align = "center"|US20080294494A1
|align = "right"|11/27/2008
|align = "right"|5/22/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''161'''
|align = "center"|US20080301628A1
|align = "right"|12/4/2008
|align = "right"|5/29/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''162'''
|align = "center"|US20080301243A1
|align = "right"|12/4/2008
|align = "right"|5/29/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''163'''
|align = "center"|US20080104616A1
|align = "right"|5/1/2008
|align = "right"|5/31/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''164'''
|align = "center"|US20080301648A1
|align = "right"|12/4/2008
|align = "right"|6/1/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''165'''
|align = "center"|US20080307433A1
|align = "right"|12/11/2008
|align = "right"|6/8/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''166'''
|align = "center"|US20080307395A1
|align = "right"|12/11/2008
|align = "right"|6/8/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''167'''
|align = "center"|US20080313189A1
|align = "right"|12/18/2008
|align = "right"|6/15/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''168'''
|align = "center"|US20080319770A1
|align = "right"|12/25/2008
|align = "right"|6/19/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''169'''
|align = "center"|US20080319947A1
|align = "right"|12/25/2008
|align = "right"|6/25/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''170'''
|align = "center"|US20080319937A1
|align = "right"|12/25/2008
|align = "right"|6/25/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''171'''
|align = "center"|US20080288877A1
|align = "right"|11/20/2008
|align = "right"|7/6/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''172'''
|align = "center"|US20080270475A1
|align = "right"|10/30/2008
|align = "right"|7/18/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''173'''
|align = "center"|US20080215688A1
|align = "right"|9/4/2008
|align = "right"|7/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''174'''
|align = "center"|US20080216072A1
|align = "right"|9/4/2008
|align = "right"|10/16/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''175'''
|align = "center"|US20080126980A1
|align = "right"|5/29/2008
|align = "right"|11/28/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''176'''
|align = "center"|US20080134220A1
|align = "right"|6/5/2008
|align = "right"|12/4/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''177'''
|align = "center"|US20080147647A1
|align = "right"|6/19/2008
|align = "right"|12/14/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''178'''
|align = "center"|US20080263509A1
|align = "right"|10/23/2008
|align = "right"|4/16/2008
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''179'''
|align = "center"|US20080313353A1
|align = "right"|12/18/2008
|align = "right"|7/21/2008
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''180'''
|align = "center"|US20080065984A1
|align = "right"|3/13/2008
|align = "right"|10/30/2007
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''181'''
|align = "center"|US20080215179A1
|align = "right"|9/4/2008
|align = "right"|4/9/2008
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''182'''
|align = "center"|US20080163267A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''183'''
|align = "center"|US20080163124A1
|align = "right"|7/3/2008
|align = "right"|12/29/2006
|align = "center"|N/A
|align = "center"|N/A
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

SAP Software Patents Sample

2009-04-18T13:00:04Z

Naveen: /* */

SAP Software Patents Sample

2009-04-18T12:59:17Z

Naveen: /* */

SAP Software Patents Sample

2009-04-18T12:57:56Z

Naveen: /* */

SAP Software Patents Sample

2009-04-18T12:52:30Z

Naveen: /* */

SAP Software Patents Sample

2009-04-18T12:49:47Z

Naveen: /* */

SAP Software Patents Sample

2009-04-18T12:23:23Z

Naveen: /* */

SAP Software Patents Sample

2009-04-18T12:16:52Z

Naveen:

= =
= =
= =
= =
= =
= =

SAP Software Patents Sample(6 months before and after October 2008)

2009-04-18T11:47:26Z

Naveen: /* Examination Information Not Available */

SAP Software Patents Sample(6 months before and after October 2008)

2009-04-18T11:45:45Z

Naveen: /* Rejections */

SAP Software Patents Sample(6 months before and after October 2008)

2009-04-18T11:44:03Z

Naveen:

=Rejections=
=Examination Information Not Available=

Bilski Diagnostic Methods Big Sample Sheet

2009-04-18T11:35:13Z

Naveen: /* */

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''S.No.'''
|align = "center" bgcolor = "#808080"|'''Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Rejection'''
|align = "center" bgcolor = "#808080"|'''Filing date'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|align = "center"|US 20080091086
|align = "center"|3/2/2009
|align = "center"|10/9/2007
|101 and 102 rejections
|Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 01185021 A1 to Aguilera et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|align = "center"|US 20080086045
|align = "center"|10/22/2008
|align = "center"|12/7/2007
|101, 103 and 112 rejections
|1. Claims 1-30 and 58-1 06 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-45 of U.S. Patent No. 7,309,607. 2. Claims 1-6, 10-15,21-33,35, 58-63, 67-72, 76, 82-84, 88 and 95-105 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 25,28,33-47 and 49-5 1 of copending Application No. 1 11409,735.
|N/A
|1. Claims 58-67,70-71,78-88 and 105-107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (US 5,372,946, submitted in the IDS filed on December 7,2007). 2. Claims 68-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (5,372,946) in view of Blake (US 5,3 16,730, also cited in the IDS filed on December 7,2007). 3. Claims 72-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Jaeger (US 4,116,635, also cited in the IDS filed on December 7,2007). 4. Claims 76-77 and 95-1 04 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Beythien et a1 (article submitted in the IDS filed on December 7,2007). 5. Claims 89-94 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Applicant<nowiki>’</nowiki>s admitted prior art in the specification.
|Claims 16 and 95 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''3'''
|align = "center"|US 20080086035
|align = "center"|11/14/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''4'''
|align = "center"|US 20080086038
|align = "center"|3/6/2009
|align = "center"|9/18/2007
|101 rejection
|Claims 1-2 and 4-1 2 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 - 82 of U.S. Patent No. 6,859,280.
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|align = "center"|US 20080083414
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|align = "center"|US 20080082022
|align = "center"|11/26/2008
|align = "center"|9/8/2006
|101, 102 and 103 rejections
|Claims 1-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619).
|1. Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619). 2. Claims 12-1 9 and 21 -24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer as applied to claims 1-8 and 10 above, and further in view of Rollema (US 5,377,101). 3. Claims 9 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer in view of Rollema as applied to claim 12 above, and further in view of Alyfuku (US 5,410,471).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|align = "center"|US 20080139953
|align = "center"|12/12/2008
|align = "center"|11/1/2006
|101, 102 and 103 rejections
|Claims 1-44 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-3 & 15-18 rejected under 35 U.S.C. 102(b) as being anticipated by Abreu (US 2004/0242976)
|1. Claims 4-7 & 9-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 2. Claims 30-32,39 & 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 3. Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 4. Claim 19-24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Schraag (US 5,309,918). 5. Claims 25-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Ortega et al. (US 200610 13600 1). 6. Claims 33-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Westra et al. (US 200610183434). 7. Claim 38 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Eshelman et al. (US 200310001742). 8. Claim 40 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Cooper et al. (US 5,294,928)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|align = "center"|US 20080132777
|align = "center"|3/3/2009
|align = "center"|2/1/2005
|101, 103 and 112 rejections
|Claims 21 - 40 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over Claims 1 - 17 of copending Application No. 11/044,239.
|N/A
|1. Claims 21 - 40 and 45 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,4 70,204 Bl). 2. Claims 41 - 44 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,470,204 Bl), in view of Tsujita (US 5,8 79,284).
|Claims 1, 34, 36, and 41 are rejected under 35 U.S.C. 112,firstparagraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''9'''
|align = "center"|US 20080119709
|align = "center"|10/8/2008
|align = "center"|10/31/2006
|101, 102 and 103 rejections
|Claims 1-1 8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-30 of copending Application No. 1115551 56.
|1. Claims I, 4, 6, 7, and 10 are rejected under 35 U.S.C. 102(e) as being anticipated by Zocchi (US Patent Application Publication 200610040333). 2. Claims 1 and 5-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Rasdal (US Patent Application Publication 2005101 54271 ).
|Claims 11 -1 5 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causey (US Patent Application Publication 200410073095) in view of Zocchi.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''10'''
|align = "center"|US 20080119705
|align = "center"|10/2/2008
|align = "center"|10/31/2007
|101, 102, 103 and 112 rejections
|Claim 20 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|1. Claims 1-2, 4-7 and 9-19 are rejected under 35 U.S.C. 102(a) as being anticipated by "eDiab: A system for Monitoring, Assisting and Educating People with Diabetes", ICCHP, 2006 to Luque et al (Hereinafter "Luque"). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being anticipated by 2002101 93679 to Malave et al (Hereinafter "Malave").
|1. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 2002101 93679 to Malave et al (Hereinafter "Malave"). 2. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 200610025663 to Talbot et al (Hereinafter "Talbot").
|Claims I I, 16 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''11'''
|align = "center"|US 20080114214
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-10 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|align = "center"|US 20080114212
|align = "center"|11/13/2008
|align = "center"|10/10/2006
|101 and 102 rejections
|Claims 10-18 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|align = "center"|US 20080097240
|align = "center"|10/22/2008
|align = "center"|4/11/2007
|102 and 103 rejections
|N/A
|Claims 1,4-7, 80 and 81 are rejected under 35 U.S.C. 102(b) as being anticipated by Henning et al .(US 6,155,992).
|1. Claims 6 is alternately rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 2. Claims 76 and 82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 2002101 69394 Al). 3. Claims 77-79 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 200210169394 Al) and in further view of Bojan et al. (US 200210099308 Al). 4. Claims 84-87 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 5. Claim 83 is rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Roe et al. (US 200410236251 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|align = "center"|US 20080097231
|align = "center"|12/2/2008
|align = "center"|10/18/2006
|102 and 103 rejections
|N/A
|Claims 1-2, 4-1 3, 15-25 are rejected under 35 U.S.C. 102(e) as being anticipated by Geva (US 7222054).
|Claims 3, 14, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Geva (7222054) in view of Budde (3556084).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|align = "center"|US 20080097226
|align = "center"|2/2/2009
|align = "center"|6/9/2006
|102, 103 and 112 rejections
|N/A
|Claims 1 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Kurtz et al. (US 4,231,354, hereinafter Kurtz).
|1. Claims 2, 10-1 2 and 14-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz in view of Recchia et al. ("Reduced Nitric Oxide Production and Altered Myocardial Metabolism During the Decompensation of Pacing-Induced Heart Failure in the Conscious Dog," hereinafter Recchia). 2. Claims 5-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz.
|Claims 9 and 13 are rejected under 35 U.S.C. 1 12, first paragraph, as failing to comply with the enablement requirement.
|-
|align = "center" bgcolor = "#808080"|'''16'''
|align = "center"|US 20080097175
|align = "center"|11/24/2008
|align = "center"|9/29/2006
|102 and 103 rejections
|N/A
|Claims 10-1 6, 23, 24, and 26-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Ali et al. (US 20051006541 7).
|Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20051006541 7) in view of Mechlenburg (US 200110018547).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|align = "center"|US 20080097169
|align = "center"|12/9/2008
|align = "center"|8/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-2, 4, 6, 9, 13-1 4, 16, 21 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack et al. (US 56661 04) in view of Rosenfeld (US 58271 91 ). 2. Claims 3 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claim 1 above, and further in view of Daly et al. 3. Claims 5, 22, 24, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 above, and further in view of Butte et al. 4. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 6 and 9 above, and further in view of Policker et al. (US 7330753). 5. Claims 8, I I, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack, Rosenfeld and Policker as applied to claims 6 and 9 above, and further in view of Ganguly et al. (US 4926871 ). 6. Claims 12 and 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 and 9 above, and further in view of Mault et al. (US 200302081 13). 7. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack and Rosenfeld as applied to claim 1 above, and further in view of Bowman et al. (US 20050283327). 8. Claims 23, 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld and Butte as applied to claims 22 and 24 above, and further in view of Shalon et al. (US 20060064037).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|align = "center"|US 20080091121
|align = "center"|12/1/2008
|align = "center"|3/20/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-9, 13-14 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Asada (U.S. Patent No. 6,236,037 BI).
|Claims 10-1 2, 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Asada (U.S. Patent No. 6,236,037 Bl).
|Claim 15 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''19'''
|align = "center"|US 20080091114
|align = "center"|2/19/2009
|align = "center"|12/29/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 8, 10, 22-26, 30, 31 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Hess (2007101 56061 ). 2. Claims 34, 35, 36 and 38 are rejected under 35 U.S.C. 102(e) as being anticipated by Stahmann (200610258952).
|1. Claims 1-6, 9, 11 -21, 27-29, and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (2007101 56061) in view of Stahmann (200610258952). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (200710156061) in view of Stahmann (200610258952) as applied to claim 1 above, and further in view of Pitts Crick (6,104,949). 3. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sta hmann (200610258952).
|Claims I, 4, 5, 7, 9, I I, and 12 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''20'''
|align = "center"|US 20080091092
|align = "center"|2/9/2009
|align = "center"|10/12/2007
|103 and 112 rejections
|N/A
|N/A
|Claims 1-8 and 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20021003531 5).
|Claims 4-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''21'''
|align = "center"|US 20080091090
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 5 and 7 - 19 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|align = "center"|US 20080091089
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 3,5,7 - 16, and 18 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''23'''
|align = "center"|US 20080082016
|align = "center"|2/5/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-1 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hardahl (US 2005101 77049) in view of Reinhoff, Jr et al. (US 2002/0133495)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''24'''
|align = "center"|US 20080082015
|align = "center"|3/4/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable by Fischell et al. (PG Publication 200410059238) in view of Aversano et al. (200410034284)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''25'''
|align = "center"|US 20080082005
|align = "center"|12/17/2008
|align = "center"|7/3/2007
|103 and 112 rejections
|N/A
|N/A
|Claims I, 4, 5, and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over O<nowiki>’</nowiki>Brien in view of Penner, U.S. Patent Application Publication No. 200510288727A1 ("Penner").
|Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''26'''
|align = "center"|US 20080081979
|align = "center"|2/17/2009
|align = "center"|9/15/2006
|103 rejection
|N/A
|N/A
|Claims 1-3, 5-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kim et al. (Kim) (US 200610025670 Al), and further in view of Chen et al. (Chen) (US 2007101 00952 A1 ).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''27'''
|align = "center"|US 20080081975
|align = "center"|2/13/2009
|align = "center"|9/28/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-1 3 and 15-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2). 2. Claims 19-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Schmitt et al. (US 200410230106). 3. Claims 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Yamamoto et al. (US 200310088162 AI). 4. Claims 13, 15, 27 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah in view of Wenzel as applied to claims 13 and 19 above, and further in view of Giller (US 6,567,690).
|Claims 19-28 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for isobestic wavelengths of water 11 80 and 1300, does not reasonably provide enablement for isobestic wavelengths in general.
|-
|align = "center" bgcolor = "#808080"|'''28'''
|align = "center"|US 20080081973
|align = "center"|10/28/2008
|align = "center"|9/28/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 4, 5, 12, 17 and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Swedlow et a1.<nowiki>’</nowiki>417 (cited by Applicant).
|1. Claims 8, 19 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>4 17, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825 (USPN 5,10 1,825). 2. Claims 7, 10, 18, 20, 26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>417, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825, further in view of Aldrich<nowiki>’</nowiki>064. 3. Claims 1-3, 5, 7, 9- 13, 16, 17, 18, 20, 21, 23, 25, 26, 28, 29 and 3 1 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldberger et a1.<nowiki>’</nowiki>464 (USPN 4,685,464) further in view of Hecke1<nowiki>’</nowiki>995 (US Pub No. 200210 137995) further in view of Aldrich<nowiki>’</nowiki>064.
|Claims 14, 15, 22 and 30 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''29'''
|align = "center"|US 20080183104
|align = "center"|1/30/2009
|align = "center"|1/11/2008
|102 and 103 rejections
|N/A
|Claims 12-14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia, Ill et al. (US 6,002,859, hereinafter DiGioia) as broadly as claimed.
|Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over DiGioia in view of Taylor et al. (US 6,231,526 Bl , hereinafter Taylor).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''30'''
|align = "center"|US 20080171949
|align = "center"|3/23/2009
|align = "center"|1/18/2007
|102 and 103 rejections
|N/A
|Claim 30 is rejected under 35 U.S.C. 102(b) as being anticipated by Alfano (US 5042494)
|1. Claims 1-4, 7-9, and 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. (US 5800350) in view of Nordstrom et al. (US71 27282). 2. Claims 5 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. modified by Nordstrom as applied to claim 2 above, and further in view of Baharav et al. (US 697271 4). 3. Claims 10-1 6 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al (US 6972714) in view of Nordstrom et al. (US 7127282). 4. Claims 17-22, 24, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al. modified by Nordstrom as applied to claim 10 above, and further in view of Coppleson et al. (US 5800350). 5. Claims 23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav modified by Nordstrom and Coppleson as applied to claim 17 above, and further in view of Jacques (US 4364008). 6. Claims 31 -32 is rejected under 35 U.S.C. 103(a) as being unpatentable over Alfano as applied to claim 30 above, and further in view of Coppleson (US 5800350) and Nordstrom et al. (US 7127282).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''31'''
|align = "center"|US 20080167565
|align = "center"|1/8/2009
|align = "center"|1/9/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-7, 12, 15-21, 25, and 26 are rejected under 35 U.S.C. 102(e) as being anticipated by Burton (US 200710032733).
|Claims 8-1 0, 13-1 4, 22-24, and 27-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Burton (US 200710032733) in view of Flick et al. (US 6993377).
|1. Claims 15-28 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''32'''
|align = "center"|US 20080161731
|align = "center"|12/10/2008
|align = "center"|12/27/2006
|103 rejection
|N/A
|N/A
|1. Claims I, 2, I I, 29, 30 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 A1 ) 2. Claims 3, 5, 12, 31, 33 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29 above, an in further view of Solomonow et al. (US 5628722) 3. Claims 4, 6, 32 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) and Solomonow et al. (US 5628722) as applied to claims 3,5,31 and 33 above, and in further view of Vosch (US 2007100731 32). 4. Claims 7, 8, 13, 35, 36 and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29, and in further view of Vosch (US 2007100731 32) 5. Claims 9, 10 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) as applied to claims 1 and 29, and in further view of Brann (US 6,059,576). 6. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) and Vosch (US 2007100731 32) as applied to claim 35 above and in further view of Brann (US 6,059,576).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''33'''
|align = "center"|US 20080161709
|align = "center"|12/24/2008
|align = "center"|10/13/2006
|102 and 103 rejections
|N/A
|Claims 1-3, 7-1 2, 14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Mault (US 20021-1 73728).
|1. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Yasushi et al. (6,485,418). 2. Claims 4-6, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Jones, Jr. et al. (US 5,076,093).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''34'''
|align = "center"|US 20080161701
|align = "center"|11/13/2008
|align = "center"|12/28/2006
|102 and 112 rejections
|N/A
|Claims 1-9 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Haller et al. (US 200210052539).
|N/A
|Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''35'''
|align = "center"|US 20080161668
|align = "center"|2/12/2009
|align = "center"|12/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ben-Haim (US 20020087089) in view of Rosenberg et al. (US 20060275775). 2. Claims I, 2, and 6-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Ben-Haim (WO 97124981). 3. Claims 13-1 6, and 22-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Rosenberg et al. (US 200610276775). 4. Claims 17-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir in view of Ben-Haim and Further in view of Hilton et al. (US 3250012).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''36'''
|align = "center"|US 20080161653
|align = "center"|2/5/2009
|align = "center"|4/16/2007
|102 and 103 rejections
|N/A
|Claims 1-6 are rejected under 35 U.S.C. 102(b) as being anticipated by TW 357077. <nowiki>’</nowiki>707 discloses in the English translation, and by applicant<nowiki>’</nowiki>s admission in the disclosure, all of the limitations of the instant invention
|Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lubell.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''37'''
|align = "center"|US 20080154143
|align = "center"|2/5/2009
|align = "center"|1/11/2007
|102 and 103 rejections
|N/A
|Claims 1, 2, 4-7, 9, 10, 12-1 4 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Xue et al. U.S. Patent Publication No. 200510038352 Al. Xue et al. <nowiki>’</nowiki>352 anticipates:
|1. Claims 3 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Arnold et al. U.S. Patent No. 5,713,367. 2. Claims 8 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Xue et al. U.S. Patent No. 5,792,065.
|N/A
|-
|}

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''38'''
|align = "center"|US 20080146956
|align = "center"|2/12/2009
|align = "center"|12/17/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1,4-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628. 2. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257. 3. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 I), in view of Ohara et al., Journal of Gastroenterology 2004: 39:62 1-628 and further in view of Aygen (U.S. Patent Application Publication 20060 17 1887). 4. Claims 6, 8- 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori. 5. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori, in view of Aygen (U.S. Patent Application Publication 20060 17 1887) 6. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257,
|Claim 1 is rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''39'''
|align = "center"|US 20080146905
|align = "center"|3/19/2009
|align = "center"|10/4/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 6-1 1, 19, 20, 26, 27, 28, 31, and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Weinberg (US 5,519,221).
|Claims 5, 12-1 8, 21 -25, and 29-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weinberg (US 5,519 221) in view of Nelson et al (US 7,291,841 B2).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''40'''
|align = "center"|US 20080146897
|align = "center"|3/13/2009
|align = "center"|12/7/2005
|103 rejection
|N/A
|N/A
|1. Claims 1-6, 8, 9, 11, 12, 14, 15, 21-23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen et a1 (Two-dimensional near-infrared transillumination imaging of biomedical media with a chromium-doped forsterite laser. Applied Optics 37(22) p. 5327-5336. 1998), hereinafter Gayen (1998), of record, in view of Levenson et al (US Patent No. 6,750,964), hereinafter Levenson (<nowiki>’</nowiki>964). 2. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claim 1 above, and further in view of Alfano (US Patent No. , 5,371,368), hereinafter Alfano (<nowiki>’</nowiki>368), of record. 3. Claims 13, 16-19 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen . (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claims 2 and 15 above, and further in view of Wang et al (Ballistic 2-D Imaging Through Scattering Walls Using an Ultrafast Optical Kerr Gate. Science. 253:p. 769-771. 1991), hereinafter Wang (1991), of record.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''41'''
|align = "center"|US 20080139967
|align = "center"|2/4/2009
|align = "center"|10/18/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 5-10, and 14-17 are rejected under 35 U.S.C. 102(b) as being anticipated by United States Patent Publication 2002101 93670 (Garfield et al.).
|1. Claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over United States Patent Publication 2002101 93670 (Garfield et al.) as modified by United States Patent 6421558 (Huey et al.). 2. Claims 3, 4, 19 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 6663570 (Mott et al.). 3. Claims 7-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5301 680 (Rosenberg). 4. Claims 12 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 4781 200 (Baker). 5. Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. and Mott et al. as applied to claims 3, 4, 19 and 23 above, and further in view of Baker. 6. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5442940 (Secker et al.). 6. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5670749 (Hon). 7. Claims 2-4 and I I are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al.
|1. Claim 8 contains the trademarksltrade names Bluetooth, Wi-Fi, Zigbie, and wireless USB. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph.
|-
|align = "center" bgcolor = "#808080"|'''42'''
|align = "center"|US 20080139951
|align = "center"|11/26/2008
|align = "center"|12/8/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-9, 1 1-1 2, & 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Porat et al. (USP<nowiki> </nowiki> 6,277,078; hereinafter "Porat").
|1. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078). Porat describes trending the cardiac flow turbulence over a time period; however, the detection of complete occlusion of the blood vessel is not specified. 2. Claims 6 & 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Benedict et al.(USP<nowiki> </nowiki> 5,520,190; hereinafter "Benedict"). 3. Claims 13, 14, & 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Kadhiresan(USP<nowiki> </nowiki> 5,935,081).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''43'''
|align = "center"|US 20080139898
|align = "center"|10/28/2008
|align = "center"|12/7/2006
|102 rejection
|N/A
|Claims 1-1 4, and 29-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Sunvit et al. US Patent Number 6,024,699.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''44'''
|align = "center"|US 20080132800
|align = "center"|1/30/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|1. Claims 1,3,4,5 are rejected under 35 U.S.C. 102(b) as being anticipated by Denker et al (6,592,518). 2. Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by Dimmer et al (2004101 38554).
|1. Claims 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Chinchoy (2004101 72079). 2. Claims 6-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chinchoy (2004101 72079) in view of Denker et al (6,592,518). 3. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898). 4. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898), and further in view of Chinchoy (2004101 72079). 5. Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dimmer et al (2004101 38554) in view of Chinchoy (2004101 72079).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''45'''
|align = "center"|US 20080132799
|align = "center"|3/19/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-8, 10-18, and 20 are rejected under 35 U.S. C. 102(b) as being anticipated by Brunner et a1 (US Patent Application Publication 2003/0004652).
|1. Claims 6 and 9 are rejected under 35 U.S. C. 103(a) as being unpatentable over Brunner et a1 in view of Karjalainen et a1 (Karjalainen, P. A,; Tarvainen, M. R.; Laitinen, T., "Principal Component Regression Approach for QT Variability Estimation, " Engineering in Medicine and Biology Society, 2005. IEEE-EMBS 2005. 27th Annual International Conference, vol., no., pp. 1145-1 147, 17-18 Jan. 2006) 2. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brunner et a1 in view of Berger (US Patent No. 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''46'''
|align = "center"|US 20080132797
|align = "center"|3/6/2009
|align = "center"|10/31/2007
|103 rejection
|N/A
|Claims 1-19 are rejected under 35 U.S.C. 102(e) as being anticiapated by U. S. Publication No. 200210172323 to Karellas et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''47'''
|align = "center"|US 20080119724
|align = "center"|3/18/2009
|align = "center"|11/17/2006
|102 and 103 rejections
|N/A
|1. Claims 1, 10-1 1 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia Ill et al. (US Patent No. 5,880,976). 2. Claims 1-4, 7-1 4 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Mire et al. (US Pub No. 2004101 71 924). 3. Claim 1, 6-7, 9-1 1, 15-1 6, 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Sahay et al. (US Patent No. 5,824,085).
|Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mire et al. as applied to claim 1 above, and further in view of Bisek et al. (US Patent No. 5,306,306)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''48'''
|align = "center"|US 20080119708
|align = "center"|3/17/2009
|align = "center"|10/25/2006
|103 and 112 rejections
|N/A
|N/A
|Claims 21 -30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent Application Publication No. 200310050546 to Desai et al in view of US Patent Application Publication No. 2003101 3061 6 to Steil et al. Regarding claim 21, Desai discloses a method comprising monitoring a data stream associated with an analyte level, wherein a current signal is generated associated with the data stream.
|Claims 27 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''49'''
|align = "center"|US 20080119702
|align = "center"|3/23/2009
|align = "center"|10/31/2006
|102 and 103 rejections
|N/A
|Claims 1-9 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Saidara (US 200510038332).
|1. Claims 10 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Peterka (US 200610004603). 2. Claims 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Morrison (US 200610293577).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''50'''
|align = "center"|US 20080108913
|align = "center"|11/7/2008
|align = "center"|11/6/2006
|102 and 103 rejections
|N/A
|Claims 1-8, 10-1 8 and 20-25 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Billing (applicant submitted Foreign Reference WO 200510371 03).
|Claims 9 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Billing as applied in claims 1 and 12 above, and further in view of Guan (US 200510046 1 39).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''51'''
|align = "center"|US 20080108910
|align = "center"|12/29/2008
|align = "center"|10/7/2007
|102 rejection
|N/A
|Claims 22-44 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Deck et al (US 200810082023).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''52'''
|align = "center"|US 20080108906
|align = "center"|12/24/2008
|align = "center"|11/8/2006
|102, 103 and 112 rejections
|N/A
|Claims 1-6, 1 1-1 3, and 18-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Albrecht et al. (U.S. Patent No. 5,755,671).
|Claims 7-1 0 and 14-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Albrecht et al.
|Claims 1-1 9 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''53'''
|align = "center"|US 20080108884
|align = "center"|3/3/2009
|align = "center"|9/24/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-5, 11, and 13-14 are rejected under 35 U.S.C. 102(e) as being anticipated by Smith (US Patent Number 6,980,419 B2).
|N/A
|Claims 1-5, 1 1, 13 and 14 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''54'''
|align = "center"|US 20080108883
|align = "center"|1/8/2009
|align = "center"|11/2/2007
|102 and 103 rejections
|N/A
|1. Claims 1-6, and 9-1 0 are rejected under 35 U.S.C. 102(b) as being anticipated by Kiselik (US 7066896). 2. Claims 11, and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Shenoy et al. (US 660901 7).
|1. Claims 1-2, 4-6, 9-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik (US 7066896) in view of Einav et al. (US 2006029361 7). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik modified by Einav as applied to claim 4 above, and further in view of Brown (US 6692449). 3. Claims 14-17, 19-20, and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scott (US 61 55993) in view of Brown (US 6692449). 4. Claims 18 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shenoy and Brown as applied to claims 14 and 15 above, and further in view of Scott (US 61 55993).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''55'''
|align = "center"|US 20080103416
|align = "center"|2/4/2009
|align = "center"|12/17/2007
|103 rejection
|N/A
|N/A
|Claims 1-4, 7-1 1, 14-17, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,916,179 to Sharrock ("Sharrock") in view of US Pat. No. 4,739,211 to Strachan ("Strachan").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''56'''
|align = "center"|US 20080103402
|align = "center"|3/18/2009
|align = "center"|10/30/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 7-1 6, 18-23, and 26 are rejected under 35 U.S.C. 102(b) as being anticipated by Morgan (US 461 0254).
|1. Claims 5, 6, 17, 24, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254). 2. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254) in view of Tamura (US 200310080712).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''57'''
|align = "center"|US 20080166031
|align = "center"|8/21/2008
|align = "center"|3/14/2008
|101, 102 and 103 rejections
|Claims I , 2 and 23are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim claims I , 3 and 43 of copending Application No. 10/873,660 in view of Moriyama et a/. (U.S. Publication number 2004/0086163A1)
|Claims 1-5, 7-10, 12-15, 17-20, 22 and 23 are rejected under 35 U.S.C. 102(e) as being anticipated by Moriyama et a/., "Moriyama" (U.S. Publication number 2004/0086163A1)
|Claims 6, 11, 16 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Moriyama as applied to claim 1 above in view of (Nonlinear Dynamics Ltd., TotalLab Applications, image analysis software for ID, electrophoresis gels, blots and colonies, www.nonlinear.com website, published 9/21/2004 from IDS).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''58'''
|align = "center"|US 20080161698
|align = "center"|8/28/2008
|align = "center"|1/3/2007
|101, 102 and 103 rejections
|Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim language is drawn to method of "determining", "analyzing", and "locating" and have no tangible, useful, or concrete result, and are hence non-statutory.
|Claims 1-3, 5-13, 15-20, are rejected under 35 U.S.C. 102(b) as being anticipated by Tearney et al. (U.S. 2003/0028100 Al) hereinafter "Tearney".
|Claims 4 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tearney et al. (U.S. 200310028 100 Al) in view of Nordstrom et al. (U.S. 200210177777 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''59'''
|align = "center"|US 20080139899
|align = "center"|4/23/2008
|align = "center"|11/2/2007
|101, 102, 103 and 112 rejections
|Claims 1-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-9 and 12-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen).
|Claims 10-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen) as applied to claim 1 above.
|1. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 2. Claim 3 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 3. Claim 12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 4. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''60'''
|align = "center"|US 20070244373
|align = "center"|4/30/2008
|align = "center"|5/2/2006
|101, 102 and 103 rejections
|1. Claims 1-25 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 18 and 25 are rejected under 35 U.S.C. 101, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and to overcome the 101 rejection
|1. Claims 1, 4, 6, 8, 9, 12, and 19 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent Application Publication No. 200410050394 to Jin.
|1. Claims I, 10, I I, 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 6,442,413 to Silver in view of US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 7, 13, 14, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jin, as applied to claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 above, and further in view of US Patent No. 6,477,406 to Turcott. 3. Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lewkowicz, as applied to Claims I, 4, 6, 8, 9, 12, and 19 above, and further in view of US Patent No. 6,689,056 to Kilcoyne et al.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''61'''
|align = "center"|US 20080097237
|align = "center"|4/8/2008
|align = "center"|9/29/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-6, 8, 29, 30, and 32-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410243207 to Olson et al. ("Olson") in view of US Pat. No. 5,035,247 to Heimann ("Heimann"). 2. Claims I I, 15, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410198469 to Bridger et al. ("Bridger") in view of US Pat. No.5,594,638 to lliff ("Illiff<nowiki>’</nowiki>), Olson, and Heimann. 3. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bridger in view of Illiff, Olson, and Heimann as applied to claim 1 1 above, and further in view of US. Pat. No. 6,409,684 to Wilk ("Wilk").
|Claims 28 and 31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''62'''
|align = "center"|US 20080097196
|align = "center"|6/5/2008
|align = "center"|8/30/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 7 and 14 are rejected under 35 U.S.C. 102(b) as being unpatentable over Kalender (US Patent No. 5,301,672). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being unpatentable over Chenevert et al. (US Patent No. 6,167,293).
|1. Claims 1-6, 10, I I, 13, 15, 16 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992). 2. Claims 8, 9, 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992) as applied to claims 7, 10 and 15 above, and further in view of Brown (US Patent No. 5,459,769). 3. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Heuscher (US Patent No. 5,262,946).
|Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''63'''
|align = "center"|US 20080097173
|align = "center"|6/12/2008
|align = "center"|5/30/2007
|102 and 103 rejections
|N/A
|Claims 1 - 3, 11, 16 - 19, 22, 23, 25 - 27, and 32 - 38 are rejected under 35 U.S.C. 102(b) as being anticipated by Tsuchiya.
|1. Claims 4 - 10, 12 - 15, 24, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya, as applied to claims 1, 3 and 38 above. 2. Claims 20 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 32 above, and further in view of Arakaki et al. 3. Claims 21, 41, and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 34 above, and further in view of Pologe. 4. Claims 28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pologe in view of Takatani et al. 5. Claims 30 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya for the reasons given in paragraphs 2 and 4 above.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''64'''
|align = "center"|US 20080091122
|align = "center"|6/30/2008
|align = "center"|11/13/2007
|102 and 103 rejections
|N/A
|1. Claims 50 - 52, 62, 64 66, 68,70,72 and 74 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,448,996 to Bellin et al. 2. Claims 47,49 - 52, 62, 64 - 68, 70, 72 and 74 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent No. 5,846,206 to Bader.
|Claims 48 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,846,206 to Bader.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''65'''
|align = "center"|US 20080086060
|align = "center"|8/21/2008
|align = "center"|12/3/2007
|112 rejection
|N/A
|N/A
|N/A
|1. Claims 1-7, 9-20 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for quaternary amines, does not reasonably provide enablement for "an ion-balance reagent". 2. Claims 1-20 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''66'''
|align = "center"|US 20080086044
|align = "center"|9/25/2008
|align = "center"|3/26/2007
|102 and 103 rejections
|N/A
|1. Claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 6,128,519 to Say. 2. Claims 1-3, 5-7, 13, 14, 22, and 25-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,335,658 to Bedingham.
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 6,123,827 to Wong et al. Say lacks allowing a temperature of the reference solution to equilibrate with a temperature of the host. 2. Claims 9, 10, 20, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 3. Claims 9-1 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bedingham, as applied to claims 1-3, 5-7, 13, 14, 22, and 25-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 4. Claims 28 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,976,085 to Kimball et al. in view of US Patent No. 6,123,827 to Wong et al. 5. Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 4,119,406 to Clemens in view of US Patent No. 6,123,827 to Wong et al. and US Patent No. 5,976,085 to Kimball et al..
|N/A
|-
|align = "center" bgcolor = "#808080"|'''67'''
|align = "center"|US 20080082012
|align = "center"|8/26/2008
|align = "center"|9/28/2006
|102 rejection
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Zhou et al (2006101 16596)
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''68'''
|align = "center"|US 20080082011
|align = "center"|1/9/2008
|align = "center"|9/14/2006
|102 and 103 rejections
|N/A
|Claims 1,3 - 15, and 19 - 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Goodman U.S. Patent No. 6,616,613.
|Claims 2 and 16 - 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodman U.S. Patent No. 6,616,613 in view of Ranta U.S. Patent No. 7,050,798.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''69'''
|align = "center"|US 20080161708
|align = "center"|9/8/2008
|align = "center"|8/4/2006
|102 and 103 rejections
|N/A
|1.Claims 1-3, 5-7, 22-27, 30-32 and 35-37 are rejected under 35 U.S.C. 102(e) as being anticipated by Taha et al. (US patent 6,564,090). 2. Claims 7, 9, 25, 29, 30, 34, 35 and 39 are rejected under 35 U.S.C. 102(b) as being anticipated by Berger (US Patent 5,560,368). 3. Claims 10-1 3 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Starobin et al. (US Patent 6,361,503).
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Morganroth (US Pub. 20030097077). 2. Claims 8, 28, 33 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Millar et al. (Correlation between refractory periods.. .). 3. Claims 14 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Millar et al. (Correlation between refractory periods.. .). 4. Claims 15 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Berger (US Patent 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''70'''
|align = "center"|US 20080154122
|align = "center"|1/10/2008
|align = "center"|12/21/2006
|102 and 103 rejections
|N/A
|Claims 1-2 and 7-1 0, 12, 16-1 7, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Slager (USPN 5,771,895).
|1. Claims 3, I I, and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Walczak et al. (Pub. No. 2006101 551 88). 2. Claims 4-5, 13-14, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim et al. (Pub. No. 2002101 36440) and Cohen-Solal (USPN 5,933,518). 3. Claims 6 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim and Cohen-Solal as applied to claims 4 and 13 above, and further in view of Kohle (Pub. No. 200410096088).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''71'''
|align = "center"|US 20080154098
|align = "center"|5/19/2008
|align = "center"|12/20/2006
|102 and 112 rejections
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Suzuki et al. US Patent Number 6,569,094 B2.
|N/A
|Claims 7 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''72'''
|align = "center"|US 20080132782
|align = "center"|8/20/2008
|align = "center"|1/27/2005
|103 rejection
|N/A
|N/A
|Claims 1 - 20 are rejected under 35 USC 103(a) as being obvious over Uzgris et al. (US 6470,204 Bl) in view of Greenleaf et al. (US 2001/0053384 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''73'''
|align = "center"|US 20080139891
|align = "center"|8/26/2008
|align = "center"|10/25/2006
|102 and 103 rejections
|N/A
|Claims 1-6, and 8-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Walker et al. US Patent Number 6,302,844 Bl.
|Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Walker et al. US Patent Number 6,302,844 Bl as applied to claim 1 above, and further in view of Lang 6,758,812 B2
|N/A
|-
|align = "center" bgcolor = "#808080"|'''74'''
|align = "center"|US 20080114269
|align = "center"|6/24/2008
|align = "center"|10/10/2007
|102 and 103 rejections
|N/A
|Claims 1-6 and 9-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|N/A
|-
|}

=Examination Information not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''75'''
|align = "center"|US 20080097249
|align = "center"|N/A
|align = "center"|4/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''76'''
|align = "center"|US 20080097235
|align = "center"|N/A
|align = "center"|8/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''77'''
|align = "center"|US 20080097234
|align = "center"|N/A
|align = "center"|9/28/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''78'''
|align = "center"|US 20080097230
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''79'''
|align = "center"|US 20080097194
|align = "center"|N/A
|align = "center"|10/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''80'''
|align = "center"|US 20080097183
|align = "center"|N/A
|align = "center"|9/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''81'''
|align = "center"|US 20080097174
|align = "center"|N/A
|align = "center"|12/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''82'''
|align = "center"|US 20080097170
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''83'''
|align = "center"|US 20080097168
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''84'''
|align = "center"|US 20080097166
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''85'''
|align = "center"|US 20080097165
|align = "center"|N/A
|align = "center"|10/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''86'''
|align = "center"|US 20080095421
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''87'''
|align = "center"|US 20080091472
|align = "center"|N/A
|align = "center"|10/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''88'''
|align = "center"|US 20080091118
|align = "center"|N/A
|align = "center"|7/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''89'''
|align = "center"|US 20080091115
|align = "center"|N/A
|align = "center"|8/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''90'''
|align = "center"|US 20080091110
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''91'''
|align = "center"|US 20080091099
|align = "center"|N/A
|align = "center"|3/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''92'''
|align = "center"|US 20080091098
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''93'''
|align = "center"|US 20080091093
|align = "center"|N/A
|align = "center"|10/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''94'''
|align = "center"|US 20080091091
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''95'''
|align = "center"|US 20080091088
|align = "center"|N/A
|align = "center"|5/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''96'''
|align = "center"|US 20080091087
|align = "center"|N/A
|align = "center"|7/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''97'''
|align = "center"|US 20080089846
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''98'''
|align = "center"|US 20080086037
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''99'''
|align = "center"|US 20080082023
|align = "center"|N/A
|align = "center"|9/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''100'''
|align = "center"|US 20080082018
|align = "center"|N/A
|align = "center"|8/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''101'''
|align = "center"|US 20080082013
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''102'''
|align = "center"|US 20080082009
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''103'''
|align = "center"|US 20080082004
|align = "center"|N/A
|align = "center"|9/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''104'''
|align = "center"|US 20080082003
|align = "center"|N/A
|align = "center"|12/1/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''105'''
|align = "center"|US 20080081991
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''106'''
|align = "center"|US 20080081980
|align = "center"|N/A
|align = "center"|9/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''107'''
|align = "center"|US 20080081977
|align = "center"|N/A
|align = "center"|10/2/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''108'''
|align = "center"|US 20080081974
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''109'''
|align = "center"|US 20080183101
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''110'''
|align = "center"|US 20080183097
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''111'''
|align = "center"|US 20080183096
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''112'''
|align = "center"|US 20080183095
|align = "center"|N/A
|align = "center"|1/29/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''113'''
|align = "center"|US 20080183093
|align = "center"|N/A
|align = "center"|8/20/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''114'''
|align = "center"|US 20080183090
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''115'''
|align = "center"|US 20080183087
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''116'''
|align = "center"|US 20080183086
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''117'''
|align = "center"|US 20080183085
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''118'''
|align = "center"|US 20080183083
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''119'''
|align = "center"|US 20080183082
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''120'''
|align = "center"|US 20080183074
|align = "center"|N/A
|align = "center"|1/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''121'''
|align = "center"|US 20080183072
|align = "center"|N/A
|align = "center"|3/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''122'''
|align = "center"|US 20080183071
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''123'''
|align = "center"|US 20080183064
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''124'''
|align = "center"|US 20080183062
|align = "center"|N/A
|align = "center"|12/5/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''125'''
|align = "center"|US 20080183061
|align = "center"|N/A
|align = "center"|4/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''126'''
|align = "center"|US 20080183060
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''127'''
|align = "center"|US 20080183058
|align = "center"|N/A
|align = "center"|3/31/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''128'''
|align = "center"|US 20080183053
|align = "center"|N/A
|align = "center"|11/21/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''129'''
|align = "center"|US 20080183050
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''130'''
|align = "center"|US 20080183049
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''131'''
|align = "center"|US 20080183047
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''132'''
|align = "center"|US 20080181470
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''133'''
|align = "center"|US 20080177341
|align = "center"|N/A
|align = "center"|10/29/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''134'''
|align = "center"|US 20080177197
|align = "center"|N/A
|align = "center"|1/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''135'''
|align = "center"|US 20080177196
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''136'''
|align = "center"|US 20080177194
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''137'''
|align = "center"|US 20080177193
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''138'''
|align = "center"|US 20080177191
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''139'''
|align = "center"|US 20080177188
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''140'''
|align = "center"|US 20080177178
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''141'''
|align = "center"|US 20080177177
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''142'''
|align = "center"|US 20080177176
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''143'''
|align = "center"|US 20080177174
|align = "center"|N/A
|align = "center"|10/11/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''144'''
|align = "center"|US 20080177170
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''145'''
|align = "center"|US 20080177164
|align = "center"|N/A
|align = "center"|11/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''146'''
|align = "center"|US 20080177163
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''147'''
|align = "center"|US 20080177162
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''148'''
|align = "center"|US 20080177160
|align = "center"|N/A
|align = "center"|2/28/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''149'''
|align = "center"|US 20080177159
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''150'''
|align = "center"|US 20080177157
|align = "center"|N/A
|align = "center"|4/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''151'''
|align = "center"|US 20080177156
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''152'''
|align = "center"|US 20080172253
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''153'''
|align = "center"|US 20080171950
|align = "center"|N/A
|align = "center"|12/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''154'''
|align = "center"|US 20080171948
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''155'''
|align = "center"|US 20080171946
|align = "center"|N/A
|align = "center"|12/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''156'''
|align = "center"|US 20080171943
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''157'''
|align = "center"|US 20080171941
|align = "center"|N/A
|align = "center"|1/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''158'''
|align = "center"|US 20080171934
|align = "center"|N/A
|align = "center"|1/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''159'''
|align = "center"|US 20080171933
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''160'''
|align = "center"|US 20080171932
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''161'''
|align = "center"|US 20080171925
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''162'''
|align = "center"|US 20080171923
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''163'''
|align = "center"|US 20080171916
|align = "center"|N/A
|align = "center"|3/13/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''164'''
|align = "center"|US 20080171913
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''165'''
|align = "center"|US 20080167583
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''166'''
|align = "center"|US 20080167578
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''167'''
|align = "center"|US 20080167575
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''168'''
|align = "center"|US 20080167574
|align = "center"|N/A
|align = "center"|12/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''169'''
|align = "center"|US 20080167571
|align = "center"|N/A
|align = "center"|12/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''170'''
|align = "center"|US 20080167569
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''171'''
|align = "center"|US 20080167567
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''172'''
|align = "center"|US 20080167566
|align = "center"|N/A
|align = "center"|1/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''173'''
|align = "center"|US 20080167564
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''174'''
|align = "center"|US 20080167552
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''175'''
|align = "center"|US 20080167549
|align = "center"|N/A
|align = "center"|12/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''176'''
|align = "center"|US 20080167545
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''177'''
|align = "center"|US 20080167544
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''178'''
|align = "center"|US 20080167543
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''179'''
|align = "center"|US 20080167540
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''180'''
|align = "center"|US 20080167532
|align = "center"|N/A
|align = "center"|10/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''181'''
|align = "center"|US 20080165017
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''182'''
|align = "center"|US 20080161729
|align = "center"|N/A
|align = "center"|10/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''183'''
|align = "center"|US 20080161714
|align = "center"|N/A
|align = "center"|1/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''184'''
|align = "center"|US 20080161713
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''185'''
|align = "center"|US 20080161712
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

=Examination Information Not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''186'''
|align = "center"|US 20080161707
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''187'''
|align = "center"|US 20080161706
|align = "center"|N/A
|align = "center"|2/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''188'''
|align = "center"|US 20080161705
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''189'''
|align = "center"|US 20080161703
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''190'''
|align = "center"|US 20080161681
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''191'''
|align = "center"|US 20080161674
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''192'''
|align = "center"|US 20080161666
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''193'''
|align = "center"|US 20080161665
|align = "center"|N/A
|align = "center"|2/21/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''194'''
|align = "center"|US 20080161662
|align = "center"|N/A
|align = "center"|8/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''195'''
|align = "center"|US 20080161661
|align = "center"|N/A
|align = "center"|1/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''196'''
|align = "center"|US 20080161660
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''197'''
|align = "center"|US 20080161657
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''198'''
|align = "center"|US 20080161652
|align = "center"|N/A
|align = "center"|3/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''199'''
|align = "center"|US 20080161651
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''200'''
|align = "center"|US 20080154154
|align = "center"|N/A
|align = "center"|2/27/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''201'''
|align = "center"|US 20080154149
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''202'''
|align = "center"|US 20080154144
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''203'''
|align = "center"|US 20080154128
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''204'''
|align = "center"|US 20080154125
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''205'''
|align = "center"|US 20080154123
|align = "center"|N/A
|align = "center"|12/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''206'''
|align = "center"|US 20080154121
|align = "center"|N/A
|align = "center"|10/24/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''207'''
|align = "center"|US 20080154107
|align = "center"|N/A
|align = "center"|12/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''208'''
|align = "center"|US 20080154106
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''209'''
|align = "center"|US 20080154101
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''210'''
|align = "center"|US 20080154099
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''211'''
|align = "center"|US 20080146960
|align = "center"|N/A
|align = "center"|2/19/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''212'''
|align = "center"|US 20080146958
|align = "center"|N/A
|align = "center"|7/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''213'''
|align = "center"|US 20080146914
|align = "center"|N/A
|align = "center"|12/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''214'''
|align = "center"|US 20080146911
|align = "center"|N/A
|align = "center"|4/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''215'''
|align = "center"|US 20080146906
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''216'''
|align = "center"|US 20080146901
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''217'''
|align = "center"|US 20080146899
|align = "center"|N/A
|align = "center"|2/7/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''218'''
|align = "center"|US 20080146896
|align = "center"|N/A
|align = "center"|7/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''219'''
|align = "center"|US 20080146892
|align = "center"|N/A
|align = "center"|8/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''220'''
|align = "center"|US 20080146891
|align = "center"|N/A
|align = "center"|6/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''221'''
|align = "center"|US 20080146889
|align = "center"|N/A
|align = "center"|12/13/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''222'''
|align = "center"|US 20080139966
|align = "center"|N/A
|align = "center"|12/7/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''223'''
|align = "center"|US 20080139963
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''224'''
|align = "center"|US 20080139956
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''225'''
|align = "center"|US 20080139952
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''226'''
|align = "center"|US 20080139948
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''227'''
|align = "center"|US 20080139927
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''228'''
|align = "center"|US 20080139926
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''229'''
|align = "center"|US 20080139925
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''230'''
|align = "center"|US 20080139921
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''231'''
|align = "center"|US 20080139920
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''232'''
|align = "center"|US 20080139917
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''233'''
|align = "center"|US 20080139910
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''234'''
|align = "center"|US 20080139906
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''235'''
|align = "center"|US 20080139901
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''236'''
|align = "center"|US 20080137929
|align = "center"|N/A
|align = "center"|7/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''237'''
|align = "center"|US 20080132808
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''238'''
|align = "center"|US 20080132802
|align = "center"|N/A
|align = "center"|2/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''239'''
|align = "center"|US 20080132801
|align = "center"|N/A
|align = "center"|6/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''240'''
|align = "center"|US 20080132784
|align = "center"|N/A
|align = "center"|11/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''241'''
|align = "center"|US 20080132783
|align = "center"|N/A
|align = "center"|12/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''242'''
|align = "center"|US 20080132781
|align = "center"|N/A
|align = "center"|11/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''243'''
|align = "center"|US 20080132775
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''244'''
|align = "center"|US 20080125678
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''245'''
|align = "center"|US 20080125666
|align = "center"|N/A
|align = "center"|6/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''246'''
|align = "center"|US 20080125663
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''247'''
|align = "center"|US 20080125646
|align = "center"|N/A
|align = "center"|8/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''248'''
|align = "center"|US 20080125644
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''249'''
|align = "center"|US 20080125641
|align = "center"|N/A
|align = "center"|8/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''250'''
|align = "center"|US 20080125636
|align = "center"|N/A
|align = "center"|3/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''251'''
|align = "center"|US 20080119760
|align = "center"|N/A
|align = "center"|6/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''252'''
|align = "center"|US 20080119755
|align = "center"|N/A
|align = "center"|12/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''253'''
|align = "center"|US 20080119753
|align = "center"|N/A
|align = "center"|11/16/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''254'''
|align = "center"|US 20080119749
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''255'''
|align = "center"|US 20080119748
|align = "center"|N/A
|align = "center"|11/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''256'''
|align = "center"|US 20080119747
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''257'''
|align = "center"|US 20080119746
|align = "center"|N/A
|align = "center"|11/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''258'''
|align = "center"|US 20080119743
|align = "center"|N/A
|align = "center"|10/23/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''259'''
|align = "center"|US 20080119741
|align = "center"|N/A
|align = "center"|11/22/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''260'''
|align = "center"|US 20080119726
|align = "center"|N/A
|align = "center"|10/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''261'''
|align = "center"|US 20080119717
|align = "center"|N/A
|align = "center"|9/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''262'''
|align = "center"|US 20080119716
|align = "center"|N/A
|align = "center"|5/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''263'''
|align = "center"|US 20080119706
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''264'''
|align = "center"|US 20080119704
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''265'''
|align = "center"|US 20080119703
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''266'''
|align = "center"|US 20080119701
|align = "center"|N/A
|align = "center"|11/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''267'''
|align = "center"|US 20080119699
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''268'''
|align = "center"|US 20080119698
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''269'''
|align = "center"|US 20080119697
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''270'''
|align = "center"|US 20080118135
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''271'''
|align = "center"|US 20080114614
|align = "center"|N/A
|align = "center"|11/15/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''272'''
|align = "center"|US 20080114261
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''273'''
|align = "center"|US 20080114260
|align = "center"|N/A
|align = "center"|5/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''274'''
|align = "center"|US 20080114256
|align = "center"|N/A
|align = "center"|11/14/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''275'''
|align = "center"|US 20080114231
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''276'''
|align = "center"|US 20080114229
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''277'''
|align = "center"|US 20080114228
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''278'''
|align = "center"|US 20080114225
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''279'''
|align = "center"|US 20080114224
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''280'''
|align = "center"|US 20080114223
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''281'''
|align = "center"|US 20080114219
|align = "center"|N/A
|align = "center"|10/31/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''282'''
|align = "center"|US 20080110461
|align = "center"|N/A
|align = "center"|4/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''283'''
|align = "center"|US 20080108909
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''284'''
|align = "center"|US 20080108907
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''285'''
|align = "center"|US 20080108905
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''286'''
|align = "center"|US 20080108903
|align = "center"|N/A
|align = "center"|11/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''287'''
|align = "center"|US 20080108894
|align = "center"|N/A
|align = "center"|5/7/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''288'''
|align = "center"|US 20080108892
|align = "center"|N/A
|align = "center"|11/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''289'''
|align = "center"|US 20080103406
|align = "center"|N/A
|align = "center"|10/26/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''290'''
|align = "center"|US 20080103404
|align = "center"|N/A
|align = "center"|10/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''291'''
|align = "center"|US 20080103403
|align = "center"|N/A
|align = "center"|9/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''292'''
|align = "center"|US 20080103397
|align = "center"|N/A
|align = "center"|10/26/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''293'''
|align = "center"|US 20080103390
|align = "center"|N/A
|align = "center"|10/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''294'''
|align = "center"|US 20080103377
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''295'''
|align = "center"|US 20080103376
|align = "center"|N/A
|align = "center"|10/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''296'''
|align = "center"|US 20080103375
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''297'''
|align = "center"|US 20080103371
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''298'''
|align = "center"|US 20080103370
|align = "center"|N/A
|align = "center"|10/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''299'''
|align = "center"|US 20080103369
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''300'''
|align = "center"|US 20080103368
|align = "center"|N/A
|align = "center"|10/17/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''301'''
|align = "center"|US 20080101675
|align = "center"|N/A
|align = "center"|8/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

Bilski Diagnostic Methods Big Sample Sheet

2009-04-18T11:34:18Z

Naveen: /* */

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''S.No.'''
|align = "center" bgcolor = "#808080"|'''Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Rejection'''
|align = "center" bgcolor = "#808080"|'''Filing date'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|align = "center"|US 20080091086
|align = "center"|3/2/2009
|align = "center"|10/9/2007
|101 and 102 rejections
|Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 01185021 A1 to Aguilera et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|align = "center"|US 20080086045
|align = "center"|10/22/2008
|align = "center"|12/7/2007
|101, 103 and 112 rejections
|1. Claims 1-30 and 58-1 06 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-45 of U.S. Patent No. 7,309,607. 2. Claims 1-6, 10-15,21-33,35, 58-63, 67-72, 76, 82-84, 88 and 95-105 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 25,28,33-47 and 49-5 1 of copending Application No. 1 11409,735.
|N/A
|1. Claims 58-67,70-71,78-88 and 105-107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (US 5,372,946, submitted in the IDS filed on December 7,2007). 2. Claims 68-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (5,372,946) in view of Blake (US 5,3 16,730, also cited in the IDS filed on December 7,2007). 3. Claims 72-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Jaeger (US 4,116,635, also cited in the IDS filed on December 7,2007). 4. Claims 76-77 and 95-1 04 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Beythien et a1 (article submitted in the IDS filed on December 7,2007). 5. Claims 89-94 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Applicant<nowiki>’</nowiki>s admitted prior art in the specification.
|Claims 16 and 95 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''3'''
|align = "center"|US 20080086035
|align = "center"|11/14/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''4'''
|align = "center"|US 20080086038
|align = "center"|3/6/2009
|align = "center"|9/18/2007
|101 rejection
|Claims 1-2 and 4-1 2 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 - 82 of U.S. Patent No. 6,859,280.
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|align = "center"|US 20080083414
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|align = "center"|US 20080082022
|align = "center"|11/26/2008
|align = "center"|9/8/2006
|101, 102 and 103 rejections
|Claims 1-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619).
|1. Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619). 2. Claims 12-1 9 and 21 -24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer as applied to claims 1-8 and 10 above, and further in view of Rollema (US 5,377,101). 3. Claims 9 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer in view of Rollema as applied to claim 12 above, and further in view of Alyfuku (US 5,410,471).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|align = "center"|US 20080139953
|align = "center"|12/12/2008
|align = "center"|11/1/2006
|101, 102 and 103 rejections
|Claims 1-44 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-3 & 15-18 rejected under 35 U.S.C. 102(b) as being anticipated by Abreu (US 2004/0242976)
|1. Claims 4-7 & 9-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 2. Claims 30-32,39 & 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 3. Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 4. Claim 19-24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Schraag (US 5,309,918). 5. Claims 25-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Ortega et al. (US 200610 13600 1). 6. Claims 33-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Westra et al. (US 200610183434). 7. Claim 38 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Eshelman et al. (US 200310001742). 8. Claim 40 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Cooper et al. (US 5,294,928)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|align = "center"|US 20080132777
|align = "center"|3/3/2009
|align = "center"|2/1/2005
|101, 103 and 112 rejections
|Claims 21 - 40 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over Claims 1 - 17 of copending Application No. 11/044,239.
|N/A
|1. Claims 21 - 40 and 45 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,4 70,204 Bl). 2. Claims 41 - 44 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,470,204 Bl), in view of Tsujita (US 5,8 79,284).
|Claims 1, 34, 36, and 41 are rejected under 35 U.S.C. 112,firstparagraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''9'''
|align = "center"|US 20080119709
|align = "center"|10/8/2008
|align = "center"|10/31/2006
|101, 102 and 103 rejections
|Claims 1-1 8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-30 of copending Application No. 1115551 56.
|1. Claims I, 4, 6, 7, and 10 are rejected under 35 U.S.C. 102(e) as being anticipated by Zocchi (US Patent Application Publication 200610040333). 2. Claims 1 and 5-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Rasdal (US Patent Application Publication 2005101 54271 ).
|Claims 11 -1 5 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causey (US Patent Application Publication 200410073095) in view of Zocchi.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''10'''
|align = "center"|US 20080119705
|align = "center"|10/2/2008
|align = "center"|10/31/2007
|101, 102, 103 and 112 rejections
|Claim 20 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|1. Claims 1-2, 4-7 and 9-19 are rejected under 35 U.S.C. 102(a) as being anticipated by "eDiab: A system for Monitoring, Assisting and Educating People with Diabetes", ICCHP, 2006 to Luque et al (Hereinafter "Luque"). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being anticipated by 2002101 93679 to Malave et al (Hereinafter "Malave").
|1. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 2002101 93679 to Malave et al (Hereinafter "Malave"). 2. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 200610025663 to Talbot et al (Hereinafter "Talbot").
|Claims I I, 16 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''11'''
|align = "center"|US 20080114214
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-10 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|align = "center"|US 20080114212
|align = "center"|11/13/2008
|align = "center"|10/10/2006
|101 and 102 rejections
|Claims 10-18 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|align = "center"|US 20080097240
|align = "center"|10/22/2008
|align = "center"|4/11/2007
|102 and 103 rejections
|N/A
|Claims 1,4-7, 80 and 81 are rejected under 35 U.S.C. 102(b) as being anticipated by Henning et al .(US 6,155,992).
|1. Claims 6 is alternately rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 2. Claims 76 and 82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 2002101 69394 Al). 3. Claims 77-79 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 200210169394 Al) and in further view of Bojan et al. (US 200210099308 Al). 4. Claims 84-87 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 5. Claim 83 is rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Roe et al. (US 200410236251 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|align = "center"|US 20080097231
|align = "center"|12/2/2008
|align = "center"|10/18/2006
|102 and 103 rejections
|N/A
|Claims 1-2, 4-1 3, 15-25 are rejected under 35 U.S.C. 102(e) as being anticipated by Geva (US 7222054).
|Claims 3, 14, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Geva (7222054) in view of Budde (3556084).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|align = "center"|US 20080097226
|align = "center"|2/2/2009
|align = "center"|6/9/2006
|102, 103 and 112 rejections
|N/A
|Claims 1 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Kurtz et al. (US 4,231,354, hereinafter Kurtz).
|1. Claims 2, 10-1 2 and 14-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz in view of Recchia et al. ("Reduced Nitric Oxide Production and Altered Myocardial Metabolism During the Decompensation of Pacing-Induced Heart Failure in the Conscious Dog," hereinafter Recchia). 2. Claims 5-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz.
|Claims 9 and 13 are rejected under 35 U.S.C. 1 12, first paragraph, as failing to comply with the enablement requirement.
|-
|align = "center" bgcolor = "#808080"|'''16'''
|align = "center"|US 20080097175
|align = "center"|11/24/2008
|align = "center"|9/29/2006
|102 and 103 rejections
|N/A
|Claims 10-1 6, 23, 24, and 26-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Ali et al. (US 20051006541 7).
|Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20051006541 7) in view of Mechlenburg (US 200110018547).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|align = "center"|US 20080097169
|align = "center"|12/9/2008
|align = "center"|8/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-2, 4, 6, 9, 13-1 4, 16, 21 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack et al. (US 56661 04) in view of Rosenfeld (US 58271 91 ). 2. Claims 3 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claim 1 above, and further in view of Daly et al. 3. Claims 5, 22, 24, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 above, and further in view of Butte et al. 4. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 6 and 9 above, and further in view of Policker et al. (US 7330753). 5. Claims 8, I I, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack, Rosenfeld and Policker as applied to claims 6 and 9 above, and further in view of Ganguly et al. (US 4926871 ). 6. Claims 12 and 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 and 9 above, and further in view of Mault et al. (US 200302081 13). 7. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack and Rosenfeld as applied to claim 1 above, and further in view of Bowman et al. (US 20050283327). 8. Claims 23, 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld and Butte as applied to claims 22 and 24 above, and further in view of Shalon et al. (US 20060064037).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|align = "center"|US 20080091121
|align = "center"|12/1/2008
|align = "center"|3/20/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-9, 13-14 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Asada (U.S. Patent No. 6,236,037 BI).
|Claims 10-1 2, 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Asada (U.S. Patent No. 6,236,037 Bl).
|Claim 15 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''19'''
|align = "center"|US 20080091114
|align = "center"|2/19/2009
|align = "center"|12/29/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 8, 10, 22-26, 30, 31 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Hess (2007101 56061 ). 2. Claims 34, 35, 36 and 38 are rejected under 35 U.S.C. 102(e) as being anticipated by Stahmann (200610258952).
|1. Claims 1-6, 9, 11 -21, 27-29, and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (2007101 56061) in view of Stahmann (200610258952). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (200710156061) in view of Stahmann (200610258952) as applied to claim 1 above, and further in view of Pitts Crick (6,104,949). 3. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sta hmann (200610258952).
|Claims I, 4, 5, 7, 9, I I, and 12 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''20'''
|align = "center"|US 20080091092
|align = "center"|2/9/2009
|align = "center"|10/12/2007
|103 and 112 rejections
|N/A
|N/A
|Claims 1-8 and 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20021003531 5).
|Claims 4-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''21'''
|align = "center"|US 20080091090
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 5 and 7 - 19 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|align = "center"|US 20080091089
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 3,5,7 - 16, and 18 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''23'''
|align = "center"|US 20080082016
|align = "center"|2/5/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-1 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hardahl (US 2005101 77049) in view of Reinhoff, Jr et al. (US 2002/0133495)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''24'''
|align = "center"|US 20080082015
|align = "center"|3/4/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable by Fischell et al. (PG Publication 200410059238) in view of Aversano et al. (200410034284)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''25'''
|align = "center"|US 20080082005
|align = "center"|12/17/2008
|align = "center"|7/3/2007
|103 and 112 rejections
|N/A
|N/A
|Claims I, 4, 5, and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over O<nowiki>’</nowiki>Brien in view of Penner, U.S. Patent Application Publication No. 200510288727A1 ("Penner").
|Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''26'''
|align = "center"|US 20080081979
|align = "center"|2/17/2009
|align = "center"|9/15/2006
|103 rejection
|N/A
|N/A
|Claims 1-3, 5-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kim et al. (Kim) (US 200610025670 Al), and further in view of Chen et al. (Chen) (US 2007101 00952 A1 ).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''27'''
|align = "center"|US 20080081975
|align = "center"|2/13/2009
|align = "center"|9/28/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-1 3 and 15-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2). 2. Claims 19-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Schmitt et al. (US 200410230106). 3. Claims 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Yamamoto et al. (US 200310088162 AI). 4. Claims 13, 15, 27 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah in view of Wenzel as applied to claims 13 and 19 above, and further in view of Giller (US 6,567,690).
|Claims 19-28 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for isobestic wavelengths of water 11 80 and 1300, does not reasonably provide enablement for isobestic wavelengths in general.
|-
|align = "center" bgcolor = "#808080"|'''28'''
|align = "center"|US 20080081973
|align = "center"|10/28/2008
|align = "center"|9/28/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 4, 5, 12, 17 and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Swedlow et a1.<nowiki>’</nowiki>417 (cited by Applicant).
|1. Claims 8, 19 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>4 17, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825 (USPN 5,10 1,825). 2. Claims 7, 10, 18, 20, 26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>417, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825, further in view of Aldrich<nowiki>’</nowiki>064. 3. Claims 1-3, 5, 7, 9- 13, 16, 17, 18, 20, 21, 23, 25, 26, 28, 29 and 3 1 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldberger et a1.<nowiki>’</nowiki>464 (USPN 4,685,464) further in view of Hecke1<nowiki>’</nowiki>995 (US Pub No. 200210 137995) further in view of Aldrich<nowiki>’</nowiki>064.
|Claims 14, 15, 22 and 30 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''29'''
|align = "center"|US 20080183104
|align = "center"|1/30/2009
|align = "center"|1/11/2008
|102 and 103 rejections
|N/A
|Claims 12-14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia, Ill et al. (US 6,002,859, hereinafter DiGioia) as broadly as claimed.
|Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over DiGioia in view of Taylor et al. (US 6,231,526 Bl , hereinafter Taylor).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''30'''
|align = "center"|US 20080171949
|align = "center"|3/23/2009
|align = "center"|1/18/2007
|102 and 103 rejections
|N/A
|Claim 30 is rejected under 35 U.S.C. 102(b) as being anticipated by Alfano (US 5042494)
|1. Claims 1-4, 7-9, and 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. (US 5800350) in view of Nordstrom et al. (US71 27282). 2. Claims 5 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. modified by Nordstrom as applied to claim 2 above, and further in view of Baharav et al. (US 697271 4). 3. Claims 10-1 6 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al (US 6972714) in view of Nordstrom et al. (US 7127282). 4. Claims 17-22, 24, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al. modified by Nordstrom as applied to claim 10 above, and further in view of Coppleson et al. (US 5800350). 5. Claims 23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav modified by Nordstrom and Coppleson as applied to claim 17 above, and further in view of Jacques (US 4364008). 6. Claims 31 -32 is rejected under 35 U.S.C. 103(a) as being unpatentable over Alfano as applied to claim 30 above, and further in view of Coppleson (US 5800350) and Nordstrom et al. (US 7127282).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''31'''
|align = "center"|US 20080167565
|align = "center"|1/8/2009
|align = "center"|1/9/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-7, 12, 15-21, 25, and 26 are rejected under 35 U.S.C. 102(e) as being anticipated by Burton (US 200710032733).
|Claims 8-1 0, 13-1 4, 22-24, and 27-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Burton (US 200710032733) in view of Flick et al. (US 6993377).
|1. Claims 15-28 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''32'''
|align = "center"|US 20080161731
|align = "center"|12/10/2008
|align = "center"|12/27/2006
|103 rejection
|N/A
|N/A
|1. Claims I, 2, I I, 29, 30 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 A1 ) 2. Claims 3, 5, 12, 31, 33 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29 above, an in further view of Solomonow et al. (US 5628722) 3. Claims 4, 6, 32 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) and Solomonow et al. (US 5628722) as applied to claims 3,5,31 and 33 above, and in further view of Vosch (US 2007100731 32). 4. Claims 7, 8, 13, 35, 36 and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29, and in further view of Vosch (US 2007100731 32) 5. Claims 9, 10 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) as applied to claims 1 and 29, and in further view of Brann (US 6,059,576). 6. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) and Vosch (US 2007100731 32) as applied to claim 35 above and in further view of Brann (US 6,059,576).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''33'''
|align = "center"|US 20080161709
|align = "center"|12/24/2008
|align = "center"|10/13/2006
|102 and 103 rejections
|N/A
|Claims 1-3, 7-1 2, 14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Mault (US 20021-1 73728).
|1. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Yasushi et al. (6,485,418). 2. Claims 4-6, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Jones, Jr. et al. (US 5,076,093).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''34'''
|align = "center"|US 20080161701
|align = "center"|11/13/2008
|align = "center"|12/28/2006
|102 and 112 rejections
|N/A
|Claims 1-9 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Haller et al. (US 200210052539).
|N/A
|Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''35'''
|align = "center"|US 20080161668
|align = "center"|2/12/2009
|align = "center"|12/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ben-Haim (US 20020087089) in view of Rosenberg et al. (US 20060275775). 2. Claims I, 2, and 6-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Ben-Haim (WO 97124981). 3. Claims 13-1 6, and 22-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Rosenberg et al. (US 200610276775). 4. Claims 17-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir in view of Ben-Haim and Further in view of Hilton et al. (US 3250012).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''36'''
|align = "center"|US 20080161653
|align = "center"|2/5/2009
|align = "center"|4/16/2007
|102 and 103 rejections
|N/A
|Claims 1-6 are rejected under 35 U.S.C. 102(b) as being anticipated by TW 357077. <nowiki>’</nowiki>707 discloses in the English translation, and by applicant<nowiki>’</nowiki>s admission in the disclosure, all of the limitations of the instant invention
|Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lubell.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''37'''
|align = "center"|US 20080154143
|align = "center"|2/5/2009
|align = "center"|1/11/2007
|102 and 103 rejections
|N/A
|Claims 1, 2, 4-7, 9, 10, 12-1 4 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Xue et al. U.S. Patent Publication No. 200510038352 Al. Xue et al. <nowiki>’</nowiki>352 anticipates:
|1. Claims 3 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Arnold et al. U.S. Patent No. 5,713,367. 2. Claims 8 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Xue et al. U.S. Patent No. 5,792,065.
|N/A
|-
|}

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''38'''
|align = "center"|US 20080146956
|align = "center"|2/12/2009
|align = "center"|12/17/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1,4-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628. 2. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257. 3. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 I), in view of Ohara et al., Journal of Gastroenterology 2004: 39:62 1-628 and further in view of Aygen (U.S. Patent Application Publication 20060 17 1887). 4. Claims 6, 8- 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori. 5. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori, in view of Aygen (U.S. Patent Application Publication 20060 17 1887) 6. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257,
|Claim 1 is rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''39'''
|align = "center"|US 20080146905
|align = "center"|3/19/2009
|align = "center"|10/4/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 6-1 1, 19, 20, 26, 27, 28, 31, and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Weinberg (US 5,519,221).
|Claims 5, 12-1 8, 21 -25, and 29-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weinberg (US 5,519 221) in view of Nelson et al (US 7,291,841 B2).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''40'''
|align = "center"|US 20080146897
|align = "center"|3/13/2009
|align = "center"|12/7/2005
|103 rejection
|N/A
|N/A
|1. Claims 1-6, 8, 9, 11, 12, 14, 15, 21-23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen et a1 (Two-dimensional near-infrared transillumination imaging of biomedical media with a chromium-doped forsterite laser. Applied Optics 37(22) p. 5327-5336. 1998), hereinafter Gayen (1998), of record, in view of Levenson et al (US Patent No. 6,750,964), hereinafter Levenson (<nowiki>’</nowiki>964). 2. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claim 1 above, and further in view of Alfano (US Patent No. , 5,371,368), hereinafter Alfano (<nowiki>’</nowiki>368), of record. 3. Claims 13, 16-19 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen . (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claims 2 and 15 above, and further in view of Wang et al (Ballistic 2-D Imaging Through Scattering Walls Using an Ultrafast Optical Kerr Gate. Science. 253:p. 769-771. 1991), hereinafter Wang (1991), of record.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''41'''
|align = "center"|US 20080139967
|align = "center"|2/4/2009
|align = "center"|10/18/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 5-10, and 14-17 are rejected under 35 U.S.C. 102(b) as being anticipated by United States Patent Publication 2002101 93670 (Garfield et al.).
|1. Claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over United States Patent Publication 2002101 93670 (Garfield et al.) as modified by United States Patent 6421558 (Huey et al.). 2. Claims 3, 4, 19 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 6663570 (Mott et al.). 3. Claims 7-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5301 680 (Rosenberg). 4. Claims 12 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 4781 200 (Baker). 5. Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. and Mott et al. as applied to claims 3, 4, 19 and 23 above, and further in view of Baker. 6. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5442940 (Secker et al.). 6. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5670749 (Hon). 7. Claims 2-4 and I I are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al.
|1. Claim 8 contains the trademarksltrade names Bluetooth, Wi-Fi, Zigbie, and wireless USB. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph.
|-
|align = "center" bgcolor = "#808080"|'''42'''
|align = "center"|US 20080139951
|align = "center"|11/26/2008
|align = "center"|12/8/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-9, 1 1-1 2, & 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Porat et al. (USP<nowiki> </nowiki> 6,277,078; hereinafter "Porat").
|1. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078). Porat describes trending the cardiac flow turbulence over a time period; however, the detection of complete occlusion of the blood vessel is not specified. 2. Claims 6 & 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Benedict et al.(USP<nowiki> </nowiki> 5,520,190; hereinafter "Benedict"). 3. Claims 13, 14, & 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Kadhiresan(USP<nowiki> </nowiki> 5,935,081).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''43'''
|align = "center"|US 20080139898
|align = "center"|10/28/2008
|align = "center"|12/7/2006
|102 rejection
|N/A
|Claims 1-1 4, and 29-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Sunvit et al. US Patent Number 6,024,699.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''44'''
|align = "center"|US 20080132800
|align = "center"|1/30/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|1. Claims 1,3,4,5 are rejected under 35 U.S.C. 102(b) as being anticipated by Denker et al (6,592,518). 2. Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by Dimmer et al (2004101 38554).
|1. Claims 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Chinchoy (2004101 72079). 2. Claims 6-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chinchoy (2004101 72079) in view of Denker et al (6,592,518). 3. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898). 4. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898), and further in view of Chinchoy (2004101 72079). 5. Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dimmer et al (2004101 38554) in view of Chinchoy (2004101 72079).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''45'''
|align = "center"|US 20080132799
|align = "center"|3/19/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-8, 10-18, and 20 are rejected under 35 U.S. C. 102(b) as being anticipated by Brunner et a1 (US Patent Application Publication 2003/0004652).
|1. Claims 6 and 9 are rejected under 35 U.S. C. 103(a) as being unpatentable over Brunner et a1 in view of Karjalainen et a1 (Karjalainen, P. A,; Tarvainen, M. R.; Laitinen, T., "Principal Component Regression Approach for QT Variability Estimation, " Engineering in Medicine and Biology Society, 2005. IEEE-EMBS 2005. 27th Annual International Conference, vol., no., pp. 1145-1 147, 17-18 Jan. 2006) 2. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brunner et a1 in view of Berger (US Patent No. 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''46'''
|align = "center"|US 20080132797
|align = "center"|3/6/2009
|align = "center"|10/31/2007
|103 rejection
|N/A
|Claims 1-19 are rejected under 35 U.S.C. 102(e) as being anticiapated by U. S. Publication No. 200210172323 to Karellas et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''47'''
|align = "center"|US 20080119724
|align = "center"|3/18/2009
|align = "center"|11/17/2006
|102 and 103 rejections
|N/A
|1. Claims 1, 10-1 1 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia Ill et al. (US Patent No. 5,880,976). 2. Claims 1-4, 7-1 4 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Mire et al. (US Pub No. 2004101 71 924). 3. Claim 1, 6-7, 9-1 1, 15-1 6, 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Sahay et al. (US Patent No. 5,824,085).
|Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mire et al. as applied to claim 1 above, and further in view of Bisek et al. (US Patent No. 5,306,306)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''48'''
|align = "center"|US 20080119708
|align = "center"|3/17/2009
|align = "center"|10/25/2006
|103 and 112 rejections
|N/A
|N/A
|Claims 21 -30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent Application Publication No. 200310050546 to Desai et al in view of US Patent Application Publication No. 2003101 3061 6 to Steil et al. Regarding claim 21, Desai discloses a method comprising monitoring a data stream associated with an analyte level, wherein a current signal is generated associated with the data stream.
|Claims 27 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''49'''
|align = "center"|US 20080119702
|align = "center"|3/23/2009
|align = "center"|10/31/2006
|102 and 103 rejections
|N/A
|Claims 1-9 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Saidara (US 200510038332).
|1. Claims 10 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Peterka (US 200610004603). 2. Claims 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Morrison (US 200610293577).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''50'''
|align = "center"|US 20080108913
|align = "center"|11/7/2008
|align = "center"|11/6/2006
|102 and 103 rejections
|N/A
|Claims 1-8, 10-1 8 and 20-25 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Billing (applicant submitted Foreign Reference WO 200510371 03).
|Claims 9 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Billing as applied in claims 1 and 12 above, and further in view of Guan (US 200510046 1 39).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''51'''
|align = "center"|US 20080108910
|align = "center"|12/29/2008
|align = "center"|10/7/2007
|102 rejection
|N/A
|Claims 22-44 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Deck et al (US 200810082023).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''52'''
|align = "center"|US 20080108906
|align = "center"|12/24/2008
|align = "center"|11/8/2006
|102, 103 and 112 rejections
|N/A
|Claims 1-6, 1 1-1 3, and 18-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Albrecht et al. (U.S. Patent No. 5,755,671).
|Claims 7-1 0 and 14-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Albrecht et al.
|Claims 1-1 9 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''53'''
|align = "center"|US 20080108884
|align = "center"|3/3/2009
|align = "center"|9/24/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-5, 11, and 13-14 are rejected under 35 U.S.C. 102(e) as being anticipated by Smith (US Patent Number 6,980,419 B2).
|N/A
|Claims 1-5, 1 1, 13 and 14 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''54'''
|align = "center"|US 20080108883
|align = "center"|1/8/2009
|align = "center"|11/2/2007
|102 and 103 rejections
|N/A
|1. Claims 1-6, and 9-1 0 are rejected under 35 U.S.C. 102(b) as being anticipated by Kiselik (US 7066896). 2. Claims 11, and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Shenoy et al. (US 660901 7).
|1. Claims 1-2, 4-6, 9-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik (US 7066896) in view of Einav et al. (US 2006029361 7). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik modified by Einav as applied to claim 4 above, and further in view of Brown (US 6692449). 3. Claims 14-17, 19-20, and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scott (US 61 55993) in view of Brown (US 6692449). 4. Claims 18 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shenoy and Brown as applied to claims 14 and 15 above, and further in view of Scott (US 61 55993).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''55'''
|align = "center"|US 20080103416
|align = "center"|2/4/2009
|align = "center"|12/17/2007
|103 rejection
|N/A
|N/A
|Claims 1-4, 7-1 1, 14-17, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,916,179 to Sharrock ("Sharrock") in view of US Pat. No. 4,739,211 to Strachan ("Strachan").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''56'''
|align = "center"|US 20080103402
|align = "center"|3/18/2009
|align = "center"|10/30/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 7-1 6, 18-23, and 26 are rejected under 35 U.S.C. 102(b) as being anticipated by Morgan (US 461 0254).
|1. Claims 5, 6, 17, 24, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254). 2. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254) in view of Tamura (US 200310080712).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''57'''
|align = "center"|US 20080166031
|align = "center"|8/21/2008
|align = "center"|3/14/2008
|101, 102 and 103 rejections
|Claims I , 2 and 23are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim claims I , 3 and 43 of copending Application No. 10/873,660 in view of Moriyama et a/. (U.S. Publication number 2004/0086163A1)
|Claims 1-5, 7-10, 12-15, 17-20, 22 and 23 are rejected under 35 U.S.C. 102(e) as being anticipated by Moriyama et a/., "Moriyama" (U.S. Publication number 2004/0086163A1)
|Claims 6, 11, 16 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Moriyama as applied to claim 1 above in view of (Nonlinear Dynamics Ltd., TotalLab Applications, image analysis software for ID, electrophoresis gels, blots and colonies, www.nonlinear.com website, published 9/21/2004 from IDS).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''58'''
|align = "center"|US 20080161698
|align = "center"|8/28/2008
|align = "center"|1/3/2007
|101, 102 and 103 rejections
|Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim language is drawn to method of "determining", "analyzing", and "locating" and have no tangible, useful, or concrete result, and are hence non-statutory.
|Claims 1-3, 5-13, 15-20, are rejected under 35 U.S.C. 102(b) as being anticipated by Tearney et al. (U.S. 2003/0028100 Al) hereinafter "Tearney".
|Claims 4 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tearney et al. (U.S. 200310028 100 Al) in view of Nordstrom et al. (U.S. 200210177777 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''59'''
|align = "center"|US 20080139899
|align = "center"|4/23/2008
|align = "center"|11/2/2007
|101, 102, 103 and 112 rejections
|Claims 1-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-9 and 12-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen).
|Claims 10-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen) as applied to claim 1 above.
|1. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 2. Claim 3 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 3. Claim 12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 4. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''60'''
|align = "center"|US 20070244373
|align = "center"|4/30/2008
|align = "center"|5/2/2006
|101, 102 and 103 rejections
|1. Claims 1-25 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 18 and 25 are rejected under 35 U.S.C. 101, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and to overcome the 101 rejection
|1. Claims 1, 4, 6, 8, 9, 12, and 19 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent Application Publication No. 200410050394 to Jin.
|1. Claims I, 10, I I, 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 6,442,413 to Silver in view of US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 7, 13, 14, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jin, as applied to claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 above, and further in view of US Patent No. 6,477,406 to Turcott. 3. Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lewkowicz, as applied to Claims I, 4, 6, 8, 9, 12, and 19 above, and further in view of US Patent No. 6,689,056 to Kilcoyne et al.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''61'''
|align = "center"|US 20080097237
|align = "center"|4/8/2008
|align = "center"|9/29/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-6, 8, 29, 30, and 32-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410243207 to Olson et al. ("Olson") in view of US Pat. No. 5,035,247 to Heimann ("Heimann"). 2. Claims I I, 15, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410198469 to Bridger et al. ("Bridger") in view of US Pat. No.5,594,638 to lliff ("Illiff<nowiki>’</nowiki>), Olson, and Heimann. 3. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bridger in view of Illiff, Olson, and Heimann as applied to claim 1 1 above, and further in view of US. Pat. No. 6,409,684 to Wilk ("Wilk").
|Claims 28 and 31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''62'''
|align = "center"|US 20080097196
|align = "center"|6/5/2008
|align = "center"|8/30/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 7 and 14 are rejected under 35 U.S.C. 102(b) as being unpatentable over Kalender (US Patent No. 5,301,672). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being unpatentable over Chenevert et al. (US Patent No. 6,167,293).
|1. Claims 1-6, 10, I I, 13, 15, 16 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992). 2. Claims 8, 9, 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992) as applied to claims 7, 10 and 15 above, and further in view of Brown (US Patent No. 5,459,769). 3. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Heuscher (US Patent No. 5,262,946).
|Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''63'''
|align = "center"|US 20080097173
|align = "center"|6/12/2008
|align = "center"|5/30/2007
|102 and 103 rejections
|N/A
|Claims 1 - 3, 11, 16 - 19, 22, 23, 25 - 27, and 32 - 38 are rejected under 35 U.S.C. 102(b) as being anticipated by Tsuchiya.
|1. Claims 4 - 10, 12 - 15, 24, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya, as applied to claims 1, 3 and 38 above. 2. Claims 20 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 32 above, and further in view of Arakaki et al. 3. Claims 21, 41, and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 34 above, and further in view of Pologe. 4. Claims 28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pologe in view of Takatani et al. 5. Claims 30 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya for the reasons given in paragraphs 2 and 4 above.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''64'''
|align = "center"|US 20080091122
|align = "center"|6/30/2008
|align = "center"|11/13/2007
|102 and 103 rejections
|N/A
|1. Claims 50 - 52, 62, 64 66, 68,70,72 and 74 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,448,996 to Bellin et al. 2. Claims 47,49 - 52, 62, 64 - 68, 70, 72 and 74 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent No. 5,846,206 to Bader.
|Claims 48 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,846,206 to Bader.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''65'''
|align = "center"|US 20080086060
|align = "center"|8/21/2008
|align = "center"|12/3/2007
|112 rejection
|N/A
|N/A
|N/A
|1. Claims 1-7, 9-20 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for quaternary amines, does not reasonably provide enablement for "an ion-balance reagent". 2. Claims 1-20 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''66'''
|align = "center"|US 20080086044
|align = "center"|9/25/2008
|align = "center"|3/26/2007
|102 and 103 rejections
|N/A
|1. Claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 6,128,519 to Say. 2. Claims 1-3, 5-7, 13, 14, 22, and 25-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,335,658 to Bedingham.
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 6,123,827 to Wong et al. Say lacks allowing a temperature of the reference solution to equilibrate with a temperature of the host. 2. Claims 9, 10, 20, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 3. Claims 9-1 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bedingham, as applied to claims 1-3, 5-7, 13, 14, 22, and 25-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 4. Claims 28 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,976,085 to Kimball et al. in view of US Patent No. 6,123,827 to Wong et al. 5. Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 4,119,406 to Clemens in view of US Patent No. 6,123,827 to Wong et al. and US Patent No. 5,976,085 to Kimball et al..
|N/A
|-
|align = "center" bgcolor = "#808080"|'''67'''
|align = "center"|US 20080082012
|align = "center"|8/26/2008
|align = "center"|9/28/2006
|102 rejection
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Zhou et al (2006101 16596)
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''68'''
|align = "center"|US 20080082011
|align = "center"|1/9/2008
|align = "center"|9/14/2006
|102 and 103 rejections
|N/A
|Claims 1,3 - 15, and 19 - 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Goodman U.S. Patent No. 6,616,613.
|Claims 2 and 16 - 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodman U.S. Patent No. 6,616,613 in view of Ranta U.S. Patent No. 7,050,798.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''69'''
|align = "center"|US 20080161708
|align = "center"|9/8/2008
|align = "center"|8/4/2006
|102 and 103 rejections
|N/A
|1.Claims 1-3, 5-7, 22-27, 30-32 and 35-37 are rejected under 35 U.S.C. 102(e) as being anticipated by Taha et al. (US patent 6,564,090). 2. Claims 7, 9, 25, 29, 30, 34, 35 and 39 are rejected under 35 U.S.C. 102(b) as being anticipated by Berger (US Patent 5,560,368). 3. Claims 10-1 3 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Starobin et al. (US Patent 6,361,503).
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Morganroth (US Pub. 20030097077). 2. Claims 8, 28, 33 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Millar et al. (Correlation between refractory periods.. .). 3. Claims 14 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Millar et al. (Correlation between refractory periods.. .). 4. Claims 15 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Berger (US Patent 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''70'''
|align = "center"|US 20080154122
|align = "center"|1/10/2008
|align = "center"|12/21/2006
|102 and 103 rejections
|N/A
|Claims 1-2 and 7-1 0, 12, 16-1 7, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Slager (USPN 5,771,895).
|1. Claims 3, I I, and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Walczak et al. (Pub. No. 2006101 551 88). 2. Claims 4-5, 13-14, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim et al. (Pub. No. 2002101 36440) and Cohen-Solal (USPN 5,933,518). 3. Claims 6 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim and Cohen-Solal as applied to claims 4 and 13 above, and further in view of Kohle (Pub. No. 200410096088).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''71'''
|align = "center"|US 20080154098
|align = "center"|5/19/2008
|align = "center"|12/20/2006
|102 and 112 rejections
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Suzuki et al. US Patent Number 6,569,094 B2.
|N/A
|Claims 7 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''72'''
|align = "center"|US 20080132782
|align = "center"|8/20/2008
|align = "center"|1/27/2005
|103 rejection
|N/A
|N/A
|Claims 1 - 20 are rejected under 35 USC 103(a) as being obvious over Uzgris et al. (US 6470,204 Bl) in view of Greenleaf et al. (US 2001/0053384 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''73'''
|align = "center"|US 20080139891
|align = "center"|8/26/2008
|align = "center"|10/25/2006
|102 and 103 rejections
|N/A
|Claims 1-6, and 8-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Walker et al. US Patent Number 6,302,844 Bl.
|Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Walker et al. US Patent Number 6,302,844 Bl as applied to claim 1 above, and further in view of Lang 6,758,812 B2
|N/A
|-
|align = "center" bgcolor = "#808080"|'''74'''
|align = "center"|US 20080114269
|align = "center"|6/24/2008
|align = "center"|10/10/2007
|102 and 103 rejections
|N/A
|Claims 1-6 and 9-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|N/A
|-
|}

=Examination Information not Available=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''75'''
|align = "center"|US 20080097249
|align = "center"|N/A
|align = "center"|4/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''76'''
|align = "center"|US 20080097235
|align = "center"|N/A
|align = "center"|8/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''77'''
|align = "center"|US 20080097234
|align = "center"|N/A
|align = "center"|9/28/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''78'''
|align = "center"|US 20080097230
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''79'''
|align = "center"|US 20080097194
|align = "center"|N/A
|align = "center"|10/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''80'''
|align = "center"|US 20080097183
|align = "center"|N/A
|align = "center"|9/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''81'''
|align = "center"|US 20080097174
|align = "center"|N/A
|align = "center"|12/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''82'''
|align = "center"|US 20080097170
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''83'''
|align = "center"|US 20080097168
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''84'''
|align = "center"|US 20080097166
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''85'''
|align = "center"|US 20080097165
|align = "center"|N/A
|align = "center"|10/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''86'''
|align = "center"|US 20080095421
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''87'''
|align = "center"|US 20080091472
|align = "center"|N/A
|align = "center"|10/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''88'''
|align = "center"|US 20080091118
|align = "center"|N/A
|align = "center"|7/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''89'''
|align = "center"|US 20080091115
|align = "center"|N/A
|align = "center"|8/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''90'''
|align = "center"|US 20080091110
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''91'''
|align = "center"|US 20080091099
|align = "center"|N/A
|align = "center"|3/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''92'''
|align = "center"|US 20080091098
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''93'''
|align = "center"|US 20080091093
|align = "center"|N/A
|align = "center"|10/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''94'''
|align = "center"|US 20080091091
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''95'''
|align = "center"|US 20080091088
|align = "center"|N/A
|align = "center"|5/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''96'''
|align = "center"|US 20080091087
|align = "center"|N/A
|align = "center"|7/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''97'''
|align = "center"|US 20080089846
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''98'''
|align = "center"|US 20080086037
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''99'''
|align = "center"|US 20080082023
|align = "center"|N/A
|align = "center"|9/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''100'''
|align = "center"|US 20080082018
|align = "center"|N/A
|align = "center"|8/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''101'''
|align = "center"|US 20080082013
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''102'''
|align = "center"|US 20080082009
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''103'''
|align = "center"|US 20080082004
|align = "center"|N/A
|align = "center"|9/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''104'''
|align = "center"|US 20080082003
|align = "center"|N/A
|align = "center"|12/1/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''105'''
|align = "center"|US 20080081991
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''106'''
|align = "center"|US 20080081980
|align = "center"|N/A
|align = "center"|9/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''107'''
|align = "center"|US 20080081977
|align = "center"|N/A
|align = "center"|10/2/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''108'''
|align = "center"|US 20080081974
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''109'''
|align = "center"|US 20080183101
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''110'''
|align = "center"|US 20080183097
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''111'''
|align = "center"|US 20080183096
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''112'''
|align = "center"|US 20080183095
|align = "center"|N/A
|align = "center"|1/29/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''113'''
|align = "center"|US 20080183093
|align = "center"|N/A
|align = "center"|8/20/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''114'''
|align = "center"|US 20080183090
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''115'''
|align = "center"|US 20080183087
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''116'''
|align = "center"|US 20080183086
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''117'''
|align = "center"|US 20080183085
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''118'''
|align = "center"|US 20080183083
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''119'''
|align = "center"|US 20080183082
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''120'''
|align = "center"|US 20080183074
|align = "center"|N/A
|align = "center"|1/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''121'''
|align = "center"|US 20080183072
|align = "center"|N/A
|align = "center"|3/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''122'''
|align = "center"|US 20080183071
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''123'''
|align = "center"|US 20080183064
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''124'''
|align = "center"|US 20080183062
|align = "center"|N/A
|align = "center"|12/5/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''125'''
|align = "center"|US 20080183061
|align = "center"|N/A
|align = "center"|4/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''126'''
|align = "center"|US 20080183060
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''127'''
|align = "center"|US 20080183058
|align = "center"|N/A
|align = "center"|3/31/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''128'''
|align = "center"|US 20080183053
|align = "center"|N/A
|align = "center"|11/21/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''129'''
|align = "center"|US 20080183050
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''130'''
|align = "center"|US 20080183049
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''131'''
|align = "center"|US 20080183047
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''132'''
|align = "center"|US 20080181470
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''133'''
|align = "center"|US 20080177341
|align = "center"|N/A
|align = "center"|10/29/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''134'''
|align = "center"|US 20080177197
|align = "center"|N/A
|align = "center"|1/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''135'''
|align = "center"|US 20080177196
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''136'''
|align = "center"|US 20080177194
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''137'''
|align = "center"|US 20080177193
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''138'''
|align = "center"|US 20080177191
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''139'''
|align = "center"|US 20080177188
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''140'''
|align = "center"|US 20080177178
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''141'''
|align = "center"|US 20080177177
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''142'''
|align = "center"|US 20080177176
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''143'''
|align = "center"|US 20080177174
|align = "center"|N/A
|align = "center"|10/11/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''144'''
|align = "center"|US 20080177170
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''145'''
|align = "center"|US 20080177164
|align = "center"|N/A
|align = "center"|11/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''146'''
|align = "center"|US 20080177163
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''147'''
|align = "center"|US 20080177162
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''148'''
|align = "center"|US 20080177160
|align = "center"|N/A
|align = "center"|2/28/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''149'''
|align = "center"|US 20080177159
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''150'''
|align = "center"|US 20080177157
|align = "center"|N/A
|align = "center"|4/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''151'''
|align = "center"|US 20080177156
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''152'''
|align = "center"|US 20080172253
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''153'''
|align = "center"|US 20080171950
|align = "center"|N/A
|align = "center"|12/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''154'''
|align = "center"|US 20080171948
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''155'''
|align = "center"|US 20080171946
|align = "center"|N/A
|align = "center"|12/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''156'''
|align = "center"|US 20080171943
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''157'''
|align = "center"|US 20080171941
|align = "center"|N/A
|align = "center"|1/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''158'''
|align = "center"|US 20080171934
|align = "center"|N/A
|align = "center"|1/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''159'''
|align = "center"|US 20080171933
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''160'''
|align = "center"|US 20080171932
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''161'''
|align = "center"|US 20080171925
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''162'''
|align = "center"|US 20080171923
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''163'''
|align = "center"|US 20080171916
|align = "center"|N/A
|align = "center"|3/13/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''164'''
|align = "center"|US 20080171913
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''165'''
|align = "center"|US 20080167583
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''166'''
|align = "center"|US 20080167578
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''167'''
|align = "center"|US 20080167575
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''168'''
|align = "center"|US 20080167574
|align = "center"|N/A
|align = "center"|12/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''169'''
|align = "center"|US 20080167571
|align = "center"|N/A
|align = "center"|12/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''170'''
|align = "center"|US 20080167569
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''171'''
|align = "center"|US 20080167567
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''172'''
|align = "center"|US 20080167566
|align = "center"|N/A
|align = "center"|1/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''173'''
|align = "center"|US 20080167564
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''174'''
|align = "center"|US 20080167552
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''175'''
|align = "center"|US 20080167549
|align = "center"|N/A
|align = "center"|12/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''176'''
|align = "center"|US 20080167545
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''177'''
|align = "center"|US 20080167544
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''178'''
|align = "center"|US 20080167543
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''179'''
|align = "center"|US 20080167540
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''180'''
|align = "center"|US 20080167532
|align = "center"|N/A
|align = "center"|10/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''181'''
|align = "center"|US 20080165017
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''182'''
|align = "center"|US 20080161729
|align = "center"|N/A
|align = "center"|10/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''183'''
|align = "center"|US 20080161714
|align = "center"|N/A
|align = "center"|1/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''184'''
|align = "center"|US 20080161713
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''185'''
|align = "center"|US 20080161712
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

= =
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''186'''
|align = "center"|US 20080161707
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''187'''
|align = "center"|US 20080161706
|align = "center"|N/A
|align = "center"|2/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''188'''
|align = "center"|US 20080161705
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''189'''
|align = "center"|US 20080161703
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''190'''
|align = "center"|US 20080161681
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''191'''
|align = "center"|US 20080161674
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''192'''
|align = "center"|US 20080161666
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''193'''
|align = "center"|US 20080161665
|align = "center"|N/A
|align = "center"|2/21/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''194'''
|align = "center"|US 20080161662
|align = "center"|N/A
|align = "center"|8/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''195'''
|align = "center"|US 20080161661
|align = "center"|N/A
|align = "center"|1/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''196'''
|align = "center"|US 20080161660
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''197'''
|align = "center"|US 20080161657
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''198'''
|align = "center"|US 20080161652
|align = "center"|N/A
|align = "center"|3/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''199'''
|align = "center"|US 20080161651
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''200'''
|align = "center"|US 20080154154
|align = "center"|N/A
|align = "center"|2/27/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''201'''
|align = "center"|US 20080154149
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''202'''
|align = "center"|US 20080154144
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''203'''
|align = "center"|US 20080154128
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''204'''
|align = "center"|US 20080154125
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''205'''
|align = "center"|US 20080154123
|align = "center"|N/A
|align = "center"|12/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''206'''
|align = "center"|US 20080154121
|align = "center"|N/A
|align = "center"|10/24/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''207'''
|align = "center"|US 20080154107
|align = "center"|N/A
|align = "center"|12/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''208'''
|align = "center"|US 20080154106
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''209'''
|align = "center"|US 20080154101
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''210'''
|align = "center"|US 20080154099
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''211'''
|align = "center"|US 20080146960
|align = "center"|N/A
|align = "center"|2/19/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''212'''
|align = "center"|US 20080146958
|align = "center"|N/A
|align = "center"|7/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''213'''
|align = "center"|US 20080146914
|align = "center"|N/A
|align = "center"|12/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''214'''
|align = "center"|US 20080146911
|align = "center"|N/A
|align = "center"|4/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''215'''
|align = "center"|US 20080146906
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''216'''
|align = "center"|US 20080146901
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''217'''
|align = "center"|US 20080146899
|align = "center"|N/A
|align = "center"|2/7/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''218'''
|align = "center"|US 20080146896
|align = "center"|N/A
|align = "center"|7/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''219'''
|align = "center"|US 20080146892
|align = "center"|N/A
|align = "center"|8/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''220'''
|align = "center"|US 20080146891
|align = "center"|N/A
|align = "center"|6/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''221'''
|align = "center"|US 20080146889
|align = "center"|N/A
|align = "center"|12/13/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''222'''
|align = "center"|US 20080139966
|align = "center"|N/A
|align = "center"|12/7/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''223'''
|align = "center"|US 20080139963
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''224'''
|align = "center"|US 20080139956
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''225'''
|align = "center"|US 20080139952
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''226'''
|align = "center"|US 20080139948
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''227'''
|align = "center"|US 20080139927
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''228'''
|align = "center"|US 20080139926
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''229'''
|align = "center"|US 20080139925
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''230'''
|align = "center"|US 20080139921
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''231'''
|align = "center"|US 20080139920
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''232'''
|align = "center"|US 20080139917
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''233'''
|align = "center"|US 20080139910
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''234'''
|align = "center"|US 20080139906
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''235'''
|align = "center"|US 20080139901
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''236'''
|align = "center"|US 20080137929
|align = "center"|N/A
|align = "center"|7/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''237'''
|align = "center"|US 20080132808
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''238'''
|align = "center"|US 20080132802
|align = "center"|N/A
|align = "center"|2/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''239'''
|align = "center"|US 20080132801
|align = "center"|N/A
|align = "center"|6/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''240'''
|align = "center"|US 20080132784
|align = "center"|N/A
|align = "center"|11/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''241'''
|align = "center"|US 20080132783
|align = "center"|N/A
|align = "center"|12/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''242'''
|align = "center"|US 20080132781
|align = "center"|N/A
|align = "center"|11/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''243'''
|align = "center"|US 20080132775
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''244'''
|align = "center"|US 20080125678
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''245'''
|align = "center"|US 20080125666
|align = "center"|N/A
|align = "center"|6/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''246'''
|align = "center"|US 20080125663
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''247'''
|align = "center"|US 20080125646
|align = "center"|N/A
|align = "center"|8/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''248'''
|align = "center"|US 20080125644
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''249'''
|align = "center"|US 20080125641
|align = "center"|N/A
|align = "center"|8/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''250'''
|align = "center"|US 20080125636
|align = "center"|N/A
|align = "center"|3/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''251'''
|align = "center"|US 20080119760
|align = "center"|N/A
|align = "center"|6/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''252'''
|align = "center"|US 20080119755
|align = "center"|N/A
|align = "center"|12/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''253'''
|align = "center"|US 20080119753
|align = "center"|N/A
|align = "center"|11/16/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''254'''
|align = "center"|US 20080119749
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''255'''
|align = "center"|US 20080119748
|align = "center"|N/A
|align = "center"|11/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''256'''
|align = "center"|US 20080119747
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''257'''
|align = "center"|US 20080119746
|align = "center"|N/A
|align = "center"|11/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''258'''
|align = "center"|US 20080119743
|align = "center"|N/A
|align = "center"|10/23/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''259'''
|align = "center"|US 20080119741
|align = "center"|N/A
|align = "center"|11/22/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''260'''
|align = "center"|US 20080119726
|align = "center"|N/A
|align = "center"|10/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''261'''
|align = "center"|US 20080119717
|align = "center"|N/A
|align = "center"|9/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''262'''
|align = "center"|US 20080119716
|align = "center"|N/A
|align = "center"|5/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''263'''
|align = "center"|US 20080119706
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''264'''
|align = "center"|US 20080119704
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''265'''
|align = "center"|US 20080119703
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''266'''
|align = "center"|US 20080119701
|align = "center"|N/A
|align = "center"|11/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''267'''
|align = "center"|US 20080119699
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''268'''
|align = "center"|US 20080119698
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''269'''
|align = "center"|US 20080119697
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''270'''
|align = "center"|US 20080118135
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''271'''
|align = "center"|US 20080114614
|align = "center"|N/A
|align = "center"|11/15/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''272'''
|align = "center"|US 20080114261
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''273'''
|align = "center"|US 20080114260
|align = "center"|N/A
|align = "center"|5/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''274'''
|align = "center"|US 20080114256
|align = "center"|N/A
|align = "center"|11/14/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''275'''
|align = "center"|US 20080114231
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''276'''
|align = "center"|US 20080114229
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''277'''
|align = "center"|US 20080114228
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''278'''
|align = "center"|US 20080114225
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''279'''
|align = "center"|US 20080114224
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''280'''
|align = "center"|US 20080114223
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''281'''
|align = "center"|US 20080114219
|align = "center"|N/A
|align = "center"|10/31/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''282'''
|align = "center"|US 20080110461
|align = "center"|N/A
|align = "center"|4/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''283'''
|align = "center"|US 20080108909
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''284'''
|align = "center"|US 20080108907
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''285'''
|align = "center"|US 20080108905
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''286'''
|align = "center"|US 20080108903
|align = "center"|N/A
|align = "center"|11/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''287'''
|align = "center"|US 20080108894
|align = "center"|N/A
|align = "center"|5/7/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''288'''
|align = "center"|US 20080108892
|align = "center"|N/A
|align = "center"|11/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''289'''
|align = "center"|US 20080103406
|align = "center"|N/A
|align = "center"|10/26/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''290'''
|align = "center"|US 20080103404
|align = "center"|N/A
|align = "center"|10/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''291'''
|align = "center"|US 20080103403
|align = "center"|N/A
|align = "center"|9/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''292'''
|align = "center"|US 20080103397
|align = "center"|N/A
|align = "center"|10/26/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''293'''
|align = "center"|US 20080103390
|align = "center"|N/A
|align = "center"|10/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''294'''
|align = "center"|US 20080103377
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''295'''
|align = "center"|US 20080103376
|align = "center"|N/A
|align = "center"|10/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''296'''
|align = "center"|US 20080103375
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''297'''
|align = "center"|US 20080103371
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''298'''
|align = "center"|US 20080103370
|align = "center"|N/A
|align = "center"|10/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''299'''
|align = "center"|US 20080103369
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''300'''
|align = "center"|US 20080103368
|align = "center"|N/A
|align = "center"|10/17/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''301'''
|align = "center"|US 20080101675
|align = "center"|N/A
|align = "center"|8/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

Bilski Diagnostic Methods Big Sample Sheet

2009-04-18T11:33:32Z

Naveen: /* */

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''S.No.'''
|align = "center" bgcolor = "#808080"|'''Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Rejection'''
|align = "center" bgcolor = "#808080"|'''Filing date'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|align = "center"|US 20080091086
|align = "center"|3/2/2009
|align = "center"|10/9/2007
|101 and 102 rejections
|Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 01185021 A1 to Aguilera et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|align = "center"|US 20080086045
|align = "center"|10/22/2008
|align = "center"|12/7/2007
|101, 103 and 112 rejections
|1. Claims 1-30 and 58-1 06 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-45 of U.S. Patent No. 7,309,607. 2. Claims 1-6, 10-15,21-33,35, 58-63, 67-72, 76, 82-84, 88 and 95-105 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 25,28,33-47 and 49-5 1 of copending Application No. 1 11409,735.
|N/A
|1. Claims 58-67,70-71,78-88 and 105-107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (US 5,372,946, submitted in the IDS filed on December 7,2007). 2. Claims 68-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (5,372,946) in view of Blake (US 5,3 16,730, also cited in the IDS filed on December 7,2007). 3. Claims 72-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Jaeger (US 4,116,635, also cited in the IDS filed on December 7,2007). 4. Claims 76-77 and 95-1 04 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Beythien et a1 (article submitted in the IDS filed on December 7,2007). 5. Claims 89-94 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Applicant<nowiki>’</nowiki>s admitted prior art in the specification.
|Claims 16 and 95 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''3'''
|align = "center"|US 20080086035
|align = "center"|11/14/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''4'''
|align = "center"|US 20080086038
|align = "center"|3/6/2009
|align = "center"|9/18/2007
|101 rejection
|Claims 1-2 and 4-1 2 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 - 82 of U.S. Patent No. 6,859,280.
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|align = "center"|US 20080083414
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|align = "center"|US 20080082022
|align = "center"|11/26/2008
|align = "center"|9/8/2006
|101, 102 and 103 rejections
|Claims 1-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619).
|1. Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619). 2. Claims 12-1 9 and 21 -24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer as applied to claims 1-8 and 10 above, and further in view of Rollema (US 5,377,101). 3. Claims 9 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer in view of Rollema as applied to claim 12 above, and further in view of Alyfuku (US 5,410,471).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|align = "center"|US 20080139953
|align = "center"|12/12/2008
|align = "center"|11/1/2006
|101, 102 and 103 rejections
|Claims 1-44 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-3 & 15-18 rejected under 35 U.S.C. 102(b) as being anticipated by Abreu (US 2004/0242976)
|1. Claims 4-7 & 9-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 2. Claims 30-32,39 & 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 3. Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 4. Claim 19-24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Schraag (US 5,309,918). 5. Claims 25-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Ortega et al. (US 200610 13600 1). 6. Claims 33-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Westra et al. (US 200610183434). 7. Claim 38 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Eshelman et al. (US 200310001742). 8. Claim 40 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Cooper et al. (US 5,294,928)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|align = "center"|US 20080132777
|align = "center"|3/3/2009
|align = "center"|2/1/2005
|101, 103 and 112 rejections
|Claims 21 - 40 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over Claims 1 - 17 of copending Application No. 11/044,239.
|N/A
|1. Claims 21 - 40 and 45 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,4 70,204 Bl). 2. Claims 41 - 44 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,470,204 Bl), in view of Tsujita (US 5,8 79,284).
|Claims 1, 34, 36, and 41 are rejected under 35 U.S.C. 112,firstparagraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''9'''
|align = "center"|US 20080119709
|align = "center"|10/8/2008
|align = "center"|10/31/2006
|101, 102 and 103 rejections
|Claims 1-1 8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-30 of copending Application No. 1115551 56.
|1. Claims I, 4, 6, 7, and 10 are rejected under 35 U.S.C. 102(e) as being anticipated by Zocchi (US Patent Application Publication 200610040333). 2. Claims 1 and 5-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Rasdal (US Patent Application Publication 2005101 54271 ).
|Claims 11 -1 5 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causey (US Patent Application Publication 200410073095) in view of Zocchi.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''10'''
|align = "center"|US 20080119705
|align = "center"|10/2/2008
|align = "center"|10/31/2007
|101, 102, 103 and 112 rejections
|Claim 20 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|1. Claims 1-2, 4-7 and 9-19 are rejected under 35 U.S.C. 102(a) as being anticipated by "eDiab: A system for Monitoring, Assisting and Educating People with Diabetes", ICCHP, 2006 to Luque et al (Hereinafter "Luque"). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being anticipated by 2002101 93679 to Malave et al (Hereinafter "Malave").
|1. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 2002101 93679 to Malave et al (Hereinafter "Malave"). 2. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 200610025663 to Talbot et al (Hereinafter "Talbot").
|Claims I I, 16 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''11'''
|align = "center"|US 20080114214
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-10 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|align = "center"|US 20080114212
|align = "center"|11/13/2008
|align = "center"|10/10/2006
|101 and 102 rejections
|Claims 10-18 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|align = "center"|US 20080097240
|align = "center"|10/22/2008
|align = "center"|4/11/2007
|102 and 103 rejections
|N/A
|Claims 1,4-7, 80 and 81 are rejected under 35 U.S.C. 102(b) as being anticipated by Henning et al .(US 6,155,992).
|1. Claims 6 is alternately rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 2. Claims 76 and 82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 2002101 69394 Al). 3. Claims 77-79 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 200210169394 Al) and in further view of Bojan et al. (US 200210099308 Al). 4. Claims 84-87 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 5. Claim 83 is rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Roe et al. (US 200410236251 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|align = "center"|US 20080097231
|align = "center"|12/2/2008
|align = "center"|10/18/2006
|102 and 103 rejections
|N/A
|Claims 1-2, 4-1 3, 15-25 are rejected under 35 U.S.C. 102(e) as being anticipated by Geva (US 7222054).
|Claims 3, 14, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Geva (7222054) in view of Budde (3556084).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|align = "center"|US 20080097226
|align = "center"|2/2/2009
|align = "center"|6/9/2006
|102, 103 and 112 rejections
|N/A
|Claims 1 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Kurtz et al. (US 4,231,354, hereinafter Kurtz).
|1. Claims 2, 10-1 2 and 14-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz in view of Recchia et al. ("Reduced Nitric Oxide Production and Altered Myocardial Metabolism During the Decompensation of Pacing-Induced Heart Failure in the Conscious Dog," hereinafter Recchia). 2. Claims 5-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz.
|Claims 9 and 13 are rejected under 35 U.S.C. 1 12, first paragraph, as failing to comply with the enablement requirement.
|-
|align = "center" bgcolor = "#808080"|'''16'''
|align = "center"|US 20080097175
|align = "center"|11/24/2008
|align = "center"|9/29/2006
|102 and 103 rejections
|N/A
|Claims 10-1 6, 23, 24, and 26-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Ali et al. (US 20051006541 7).
|Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20051006541 7) in view of Mechlenburg (US 200110018547).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|align = "center"|US 20080097169
|align = "center"|12/9/2008
|align = "center"|8/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-2, 4, 6, 9, 13-1 4, 16, 21 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack et al. (US 56661 04) in view of Rosenfeld (US 58271 91 ). 2. Claims 3 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claim 1 above, and further in view of Daly et al. 3. Claims 5, 22, 24, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 above, and further in view of Butte et al. 4. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 6 and 9 above, and further in view of Policker et al. (US 7330753). 5. Claims 8, I I, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack, Rosenfeld and Policker as applied to claims 6 and 9 above, and further in view of Ganguly et al. (US 4926871 ). 6. Claims 12 and 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 and 9 above, and further in view of Mault et al. (US 200302081 13). 7. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack and Rosenfeld as applied to claim 1 above, and further in view of Bowman et al. (US 20050283327). 8. Claims 23, 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld and Butte as applied to claims 22 and 24 above, and further in view of Shalon et al. (US 20060064037).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|align = "center"|US 20080091121
|align = "center"|12/1/2008
|align = "center"|3/20/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-9, 13-14 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Asada (U.S. Patent No. 6,236,037 BI).
|Claims 10-1 2, 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Asada (U.S. Patent No. 6,236,037 Bl).
|Claim 15 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''19'''
|align = "center"|US 20080091114
|align = "center"|2/19/2009
|align = "center"|12/29/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 8, 10, 22-26, 30, 31 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Hess (2007101 56061 ). 2. Claims 34, 35, 36 and 38 are rejected under 35 U.S.C. 102(e) as being anticipated by Stahmann (200610258952).
|1. Claims 1-6, 9, 11 -21, 27-29, and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (2007101 56061) in view of Stahmann (200610258952). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (200710156061) in view of Stahmann (200610258952) as applied to claim 1 above, and further in view of Pitts Crick (6,104,949). 3. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sta hmann (200610258952).
|Claims I, 4, 5, 7, 9, I I, and 12 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''20'''
|align = "center"|US 20080091092
|align = "center"|2/9/2009
|align = "center"|10/12/2007
|103 and 112 rejections
|N/A
|N/A
|Claims 1-8 and 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20021003531 5).
|Claims 4-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''21'''
|align = "center"|US 20080091090
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 5 and 7 - 19 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|align = "center"|US 20080091089
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 3,5,7 - 16, and 18 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''23'''
|align = "center"|US 20080082016
|align = "center"|2/5/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-1 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hardahl (US 2005101 77049) in view of Reinhoff, Jr et al. (US 2002/0133495)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''24'''
|align = "center"|US 20080082015
|align = "center"|3/4/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable by Fischell et al. (PG Publication 200410059238) in view of Aversano et al. (200410034284)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''25'''
|align = "center"|US 20080082005
|align = "center"|12/17/2008
|align = "center"|7/3/2007
|103 and 112 rejections
|N/A
|N/A
|Claims I, 4, 5, and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over O<nowiki>’</nowiki>Brien in view of Penner, U.S. Patent Application Publication No. 200510288727A1 ("Penner").
|Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''26'''
|align = "center"|US 20080081979
|align = "center"|2/17/2009
|align = "center"|9/15/2006
|103 rejection
|N/A
|N/A
|Claims 1-3, 5-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kim et al. (Kim) (US 200610025670 Al), and further in view of Chen et al. (Chen) (US 2007101 00952 A1 ).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''27'''
|align = "center"|US 20080081975
|align = "center"|2/13/2009
|align = "center"|9/28/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-1 3 and 15-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2). 2. Claims 19-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Schmitt et al. (US 200410230106). 3. Claims 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Yamamoto et al. (US 200310088162 AI). 4. Claims 13, 15, 27 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah in view of Wenzel as applied to claims 13 and 19 above, and further in view of Giller (US 6,567,690).
|Claims 19-28 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for isobestic wavelengths of water 11 80 and 1300, does not reasonably provide enablement for isobestic wavelengths in general.
|-
|align = "center" bgcolor = "#808080"|'''28'''
|align = "center"|US 20080081973
|align = "center"|10/28/2008
|align = "center"|9/28/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 4, 5, 12, 17 and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Swedlow et a1.<nowiki>’</nowiki>417 (cited by Applicant).
|1. Claims 8, 19 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>4 17, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825 (USPN 5,10 1,825). 2. Claims 7, 10, 18, 20, 26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>417, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825, further in view of Aldrich<nowiki>’</nowiki>064. 3. Claims 1-3, 5, 7, 9- 13, 16, 17, 18, 20, 21, 23, 25, 26, 28, 29 and 3 1 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldberger et a1.<nowiki>’</nowiki>464 (USPN 4,685,464) further in view of Hecke1<nowiki>’</nowiki>995 (US Pub No. 200210 137995) further in view of Aldrich<nowiki>’</nowiki>064.
|Claims 14, 15, 22 and 30 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''29'''
|align = "center"|US 20080183104
|align = "center"|1/30/2009
|align = "center"|1/11/2008
|102 and 103 rejections
|N/A
|Claims 12-14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia, Ill et al. (US 6,002,859, hereinafter DiGioia) as broadly as claimed.
|Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over DiGioia in view of Taylor et al. (US 6,231,526 Bl , hereinafter Taylor).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''30'''
|align = "center"|US 20080171949
|align = "center"|3/23/2009
|align = "center"|1/18/2007
|102 and 103 rejections
|N/A
|Claim 30 is rejected under 35 U.S.C. 102(b) as being anticipated by Alfano (US 5042494)
|1. Claims 1-4, 7-9, and 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. (US 5800350) in view of Nordstrom et al. (US71 27282). 2. Claims 5 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. modified by Nordstrom as applied to claim 2 above, and further in view of Baharav et al. (US 697271 4). 3. Claims 10-1 6 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al (US 6972714) in view of Nordstrom et al. (US 7127282). 4. Claims 17-22, 24, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al. modified by Nordstrom as applied to claim 10 above, and further in view of Coppleson et al. (US 5800350). 5. Claims 23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav modified by Nordstrom and Coppleson as applied to claim 17 above, and further in view of Jacques (US 4364008). 6. Claims 31 -32 is rejected under 35 U.S.C. 103(a) as being unpatentable over Alfano as applied to claim 30 above, and further in view of Coppleson (US 5800350) and Nordstrom et al. (US 7127282).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''31'''
|align = "center"|US 20080167565
|align = "center"|1/8/2009
|align = "center"|1/9/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-7, 12, 15-21, 25, and 26 are rejected under 35 U.S.C. 102(e) as being anticipated by Burton (US 200710032733).
|Claims 8-1 0, 13-1 4, 22-24, and 27-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Burton (US 200710032733) in view of Flick et al. (US 6993377).
|1. Claims 15-28 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''32'''
|align = "center"|US 20080161731
|align = "center"|12/10/2008
|align = "center"|12/27/2006
|103 rejection
|N/A
|N/A
|1. Claims I, 2, I I, 29, 30 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 A1 ) 2. Claims 3, 5, 12, 31, 33 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29 above, an in further view of Solomonow et al. (US 5628722) 3. Claims 4, 6, 32 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) and Solomonow et al. (US 5628722) as applied to claims 3,5,31 and 33 above, and in further view of Vosch (US 2007100731 32). 4. Claims 7, 8, 13, 35, 36 and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29, and in further view of Vosch (US 2007100731 32) 5. Claims 9, 10 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) as applied to claims 1 and 29, and in further view of Brann (US 6,059,576). 6. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) and Vosch (US 2007100731 32) as applied to claim 35 above and in further view of Brann (US 6,059,576).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''33'''
|align = "center"|US 20080161709
|align = "center"|12/24/2008
|align = "center"|10/13/2006
|102 and 103 rejections
|N/A
|Claims 1-3, 7-1 2, 14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Mault (US 20021-1 73728).
|1. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Yasushi et al. (6,485,418). 2. Claims 4-6, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Jones, Jr. et al. (US 5,076,093).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''34'''
|align = "center"|US 20080161701
|align = "center"|11/13/2008
|align = "center"|12/28/2006
|102 and 112 rejections
|N/A
|Claims 1-9 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Haller et al. (US 200210052539).
|N/A
|Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''35'''
|align = "center"|US 20080161668
|align = "center"|2/12/2009
|align = "center"|12/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ben-Haim (US 20020087089) in view of Rosenberg et al. (US 20060275775). 2. Claims I, 2, and 6-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Ben-Haim (WO 97124981). 3. Claims 13-1 6, and 22-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Rosenberg et al. (US 200610276775). 4. Claims 17-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir in view of Ben-Haim and Further in view of Hilton et al. (US 3250012).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''36'''
|align = "center"|US 20080161653
|align = "center"|2/5/2009
|align = "center"|4/16/2007
|102 and 103 rejections
|N/A
|Claims 1-6 are rejected under 35 U.S.C. 102(b) as being anticipated by TW 357077. <nowiki>’</nowiki>707 discloses in the English translation, and by applicant<nowiki>’</nowiki>s admission in the disclosure, all of the limitations of the instant invention
|Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lubell.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''37'''
|align = "center"|US 20080154143
|align = "center"|2/5/2009
|align = "center"|1/11/2007
|102 and 103 rejections
|N/A
|Claims 1, 2, 4-7, 9, 10, 12-1 4 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Xue et al. U.S. Patent Publication No. 200510038352 Al. Xue et al. <nowiki>’</nowiki>352 anticipates:
|1. Claims 3 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Arnold et al. U.S. Patent No. 5,713,367. 2. Claims 8 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Xue et al. U.S. Patent No. 5,792,065.
|N/A
|-
|}

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''38'''
|align = "center"|US 20080146956
|align = "center"|2/12/2009
|align = "center"|12/17/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1,4-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628. 2. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257. 3. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 I), in view of Ohara et al., Journal of Gastroenterology 2004: 39:62 1-628 and further in view of Aygen (U.S. Patent Application Publication 20060 17 1887). 4. Claims 6, 8- 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori. 5. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori, in view of Aygen (U.S. Patent Application Publication 20060 17 1887) 6. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257,
|Claim 1 is rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''39'''
|align = "center"|US 20080146905
|align = "center"|3/19/2009
|align = "center"|10/4/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 6-1 1, 19, 20, 26, 27, 28, 31, and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Weinberg (US 5,519,221).
|Claims 5, 12-1 8, 21 -25, and 29-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weinberg (US 5,519 221) in view of Nelson et al (US 7,291,841 B2).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''40'''
|align = "center"|US 20080146897
|align = "center"|3/13/2009
|align = "center"|12/7/2005
|103 rejection
|N/A
|N/A
|1. Claims 1-6, 8, 9, 11, 12, 14, 15, 21-23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen et a1 (Two-dimensional near-infrared transillumination imaging of biomedical media with a chromium-doped forsterite laser. Applied Optics 37(22) p. 5327-5336. 1998), hereinafter Gayen (1998), of record, in view of Levenson et al (US Patent No. 6,750,964), hereinafter Levenson (<nowiki>’</nowiki>964). 2. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claim 1 above, and further in view of Alfano (US Patent No. , 5,371,368), hereinafter Alfano (<nowiki>’</nowiki>368), of record. 3. Claims 13, 16-19 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen . (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claims 2 and 15 above, and further in view of Wang et al (Ballistic 2-D Imaging Through Scattering Walls Using an Ultrafast Optical Kerr Gate. Science. 253:p. 769-771. 1991), hereinafter Wang (1991), of record.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''41'''
|align = "center"|US 20080139967
|align = "center"|2/4/2009
|align = "center"|10/18/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 5-10, and 14-17 are rejected under 35 U.S.C. 102(b) as being anticipated by United States Patent Publication 2002101 93670 (Garfield et al.).
|1. Claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over United States Patent Publication 2002101 93670 (Garfield et al.) as modified by United States Patent 6421558 (Huey et al.). 2. Claims 3, 4, 19 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 6663570 (Mott et al.). 3. Claims 7-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5301 680 (Rosenberg). 4. Claims 12 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 4781 200 (Baker). 5. Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. and Mott et al. as applied to claims 3, 4, 19 and 23 above, and further in view of Baker. 6. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5442940 (Secker et al.). 6. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5670749 (Hon). 7. Claims 2-4 and I I are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al.
|1. Claim 8 contains the trademarksltrade names Bluetooth, Wi-Fi, Zigbie, and wireless USB. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph.
|-
|align = "center" bgcolor = "#808080"|'''42'''
|align = "center"|US 20080139951
|align = "center"|11/26/2008
|align = "center"|12/8/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-9, 1 1-1 2, & 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Porat et al. (USP<nowiki> </nowiki> 6,277,078; hereinafter "Porat").
|1. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078). Porat describes trending the cardiac flow turbulence over a time period; however, the detection of complete occlusion of the blood vessel is not specified. 2. Claims 6 & 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Benedict et al.(USP<nowiki> </nowiki> 5,520,190; hereinafter "Benedict"). 3. Claims 13, 14, & 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Kadhiresan(USP<nowiki> </nowiki> 5,935,081).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''43'''
|align = "center"|US 20080139898
|align = "center"|10/28/2008
|align = "center"|12/7/2006
|102 rejection
|N/A
|Claims 1-1 4, and 29-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Sunvit et al. US Patent Number 6,024,699.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''44'''
|align = "center"|US 20080132800
|align = "center"|1/30/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|1. Claims 1,3,4,5 are rejected under 35 U.S.C. 102(b) as being anticipated by Denker et al (6,592,518). 2. Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by Dimmer et al (2004101 38554).
|1. Claims 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Chinchoy (2004101 72079). 2. Claims 6-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chinchoy (2004101 72079) in view of Denker et al (6,592,518). 3. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898). 4. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898), and further in view of Chinchoy (2004101 72079). 5. Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dimmer et al (2004101 38554) in view of Chinchoy (2004101 72079).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''45'''
|align = "center"|US 20080132799
|align = "center"|3/19/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-8, 10-18, and 20 are rejected under 35 U.S. C. 102(b) as being anticipated by Brunner et a1 (US Patent Application Publication 2003/0004652).
|1. Claims 6 and 9 are rejected under 35 U.S. C. 103(a) as being unpatentable over Brunner et a1 in view of Karjalainen et a1 (Karjalainen, P. A,; Tarvainen, M. R.; Laitinen, T., "Principal Component Regression Approach for QT Variability Estimation, " Engineering in Medicine and Biology Society, 2005. IEEE-EMBS 2005. 27th Annual International Conference, vol., no., pp. 1145-1 147, 17-18 Jan. 2006) 2. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brunner et a1 in view of Berger (US Patent No. 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''46'''
|align = "center"|US 20080132797
|align = "center"|3/6/2009
|align = "center"|10/31/2007
|103 rejection
|N/A
|Claims 1-19 are rejected under 35 U.S.C. 102(e) as being anticiapated by U. S. Publication No. 200210172323 to Karellas et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''47'''
|align = "center"|US 20080119724
|align = "center"|3/18/2009
|align = "center"|11/17/2006
|102 and 103 rejections
|N/A
|1. Claims 1, 10-1 1 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia Ill et al. (US Patent No. 5,880,976). 2. Claims 1-4, 7-1 4 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Mire et al. (US Pub No. 2004101 71 924). 3. Claim 1, 6-7, 9-1 1, 15-1 6, 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Sahay et al. (US Patent No. 5,824,085).
|Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mire et al. as applied to claim 1 above, and further in view of Bisek et al. (US Patent No. 5,306,306)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''48'''
|align = "center"|US 20080119708
|align = "center"|3/17/2009
|align = "center"|10/25/2006
|103 and 112 rejections
|N/A
|N/A
|Claims 21 -30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent Application Publication No. 200310050546 to Desai et al in view of US Patent Application Publication No. 2003101 3061 6 to Steil et al. Regarding claim 21, Desai discloses a method comprising monitoring a data stream associated with an analyte level, wherein a current signal is generated associated with the data stream.
|Claims 27 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''49'''
|align = "center"|US 20080119702
|align = "center"|3/23/2009
|align = "center"|10/31/2006
|102 and 103 rejections
|N/A
|Claims 1-9 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Saidara (US 200510038332).
|1. Claims 10 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Peterka (US 200610004603). 2. Claims 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Morrison (US 200610293577).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''50'''
|align = "center"|US 20080108913
|align = "center"|11/7/2008
|align = "center"|11/6/2006
|102 and 103 rejections
|N/A
|Claims 1-8, 10-1 8 and 20-25 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Billing (applicant submitted Foreign Reference WO 200510371 03).
|Claims 9 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Billing as applied in claims 1 and 12 above, and further in view of Guan (US 200510046 1 39).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''51'''
|align = "center"|US 20080108910
|align = "center"|12/29/2008
|align = "center"|10/7/2007
|102 rejection
|N/A
|Claims 22-44 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Deck et al (US 200810082023).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''52'''
|align = "center"|US 20080108906
|align = "center"|12/24/2008
|align = "center"|11/8/2006
|102, 103 and 112 rejections
|N/A
|Claims 1-6, 1 1-1 3, and 18-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Albrecht et al. (U.S. Patent No. 5,755,671).
|Claims 7-1 0 and 14-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Albrecht et al.
|Claims 1-1 9 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''53'''
|align = "center"|US 20080108884
|align = "center"|3/3/2009
|align = "center"|9/24/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-5, 11, and 13-14 are rejected under 35 U.S.C. 102(e) as being anticipated by Smith (US Patent Number 6,980,419 B2).
|N/A
|Claims 1-5, 1 1, 13 and 14 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''54'''
|align = "center"|US 20080108883
|align = "center"|1/8/2009
|align = "center"|11/2/2007
|102 and 103 rejections
|N/A
|1. Claims 1-6, and 9-1 0 are rejected under 35 U.S.C. 102(b) as being anticipated by Kiselik (US 7066896). 2. Claims 11, and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Shenoy et al. (US 660901 7).
|1. Claims 1-2, 4-6, 9-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik (US 7066896) in view of Einav et al. (US 2006029361 7). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik modified by Einav as applied to claim 4 above, and further in view of Brown (US 6692449). 3. Claims 14-17, 19-20, and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scott (US 61 55993) in view of Brown (US 6692449). 4. Claims 18 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shenoy and Brown as applied to claims 14 and 15 above, and further in view of Scott (US 61 55993).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''55'''
|align = "center"|US 20080103416
|align = "center"|2/4/2009
|align = "center"|12/17/2007
|103 rejection
|N/A
|N/A
|Claims 1-4, 7-1 1, 14-17, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,916,179 to Sharrock ("Sharrock") in view of US Pat. No. 4,739,211 to Strachan ("Strachan").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''56'''
|align = "center"|US 20080103402
|align = "center"|3/18/2009
|align = "center"|10/30/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 7-1 6, 18-23, and 26 are rejected under 35 U.S.C. 102(b) as being anticipated by Morgan (US 461 0254).
|1. Claims 5, 6, 17, 24, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254). 2. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254) in view of Tamura (US 200310080712).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''57'''
|align = "center"|US 20080166031
|align = "center"|8/21/2008
|align = "center"|3/14/2008
|101, 102 and 103 rejections
|Claims I , 2 and 23are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim claims I , 3 and 43 of copending Application No. 10/873,660 in view of Moriyama et a/. (U.S. Publication number 2004/0086163A1)
|Claims 1-5, 7-10, 12-15, 17-20, 22 and 23 are rejected under 35 U.S.C. 102(e) as being anticipated by Moriyama et a/., "Moriyama" (U.S. Publication number 2004/0086163A1)
|Claims 6, 11, 16 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Moriyama as applied to claim 1 above in view of (Nonlinear Dynamics Ltd., TotalLab Applications, image analysis software for ID, electrophoresis gels, blots and colonies, www.nonlinear.com website, published 9/21/2004 from IDS).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''58'''
|align = "center"|US 20080161698
|align = "center"|8/28/2008
|align = "center"|1/3/2007
|101, 102 and 103 rejections
|Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim language is drawn to method of "determining", "analyzing", and "locating" and have no tangible, useful, or concrete result, and are hence non-statutory.
|Claims 1-3, 5-13, 15-20, are rejected under 35 U.S.C. 102(b) as being anticipated by Tearney et al. (U.S. 2003/0028100 Al) hereinafter "Tearney".
|Claims 4 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tearney et al. (U.S. 200310028 100 Al) in view of Nordstrom et al. (U.S. 200210177777 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''59'''
|align = "center"|US 20080139899
|align = "center"|4/23/2008
|align = "center"|11/2/2007
|101, 102, 103 and 112 rejections
|Claims 1-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-9 and 12-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen).
|Claims 10-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen) as applied to claim 1 above.
|1. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 2. Claim 3 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 3. Claim 12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 4. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''60'''
|align = "center"|US 20070244373
|align = "center"|4/30/2008
|align = "center"|5/2/2006
|101, 102 and 103 rejections
|1. Claims 1-25 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 18 and 25 are rejected under 35 U.S.C. 101, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and to overcome the 101 rejection
|1. Claims 1, 4, 6, 8, 9, 12, and 19 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent Application Publication No. 200410050394 to Jin.
|1. Claims I, 10, I I, 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 6,442,413 to Silver in view of US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 7, 13, 14, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jin, as applied to claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 above, and further in view of US Patent No. 6,477,406 to Turcott. 3. Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lewkowicz, as applied to Claims I, 4, 6, 8, 9, 12, and 19 above, and further in view of US Patent No. 6,689,056 to Kilcoyne et al.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''61'''
|align = "center"|US 20080097237
|align = "center"|4/8/2008
|align = "center"|9/29/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-6, 8, 29, 30, and 32-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410243207 to Olson et al. ("Olson") in view of US Pat. No. 5,035,247 to Heimann ("Heimann"). 2. Claims I I, 15, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410198469 to Bridger et al. ("Bridger") in view of US Pat. No.5,594,638 to lliff ("Illiff<nowiki>’</nowiki>), Olson, and Heimann. 3. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bridger in view of Illiff, Olson, and Heimann as applied to claim 1 1 above, and further in view of US. Pat. No. 6,409,684 to Wilk ("Wilk").
|Claims 28 and 31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''62'''
|align = "center"|US 20080097196
|align = "center"|6/5/2008
|align = "center"|8/30/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 7 and 14 are rejected under 35 U.S.C. 102(b) as being unpatentable over Kalender (US Patent No. 5,301,672). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being unpatentable over Chenevert et al. (US Patent No. 6,167,293).
|1. Claims 1-6, 10, I I, 13, 15, 16 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992). 2. Claims 8, 9, 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992) as applied to claims 7, 10 and 15 above, and further in view of Brown (US Patent No. 5,459,769). 3. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Heuscher (US Patent No. 5,262,946).
|Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''63'''
|align = "center"|US 20080097173
|align = "center"|6/12/2008
|align = "center"|5/30/2007
|102 and 103 rejections
|N/A
|Claims 1 - 3, 11, 16 - 19, 22, 23, 25 - 27, and 32 - 38 are rejected under 35 U.S.C. 102(b) as being anticipated by Tsuchiya.
|1. Claims 4 - 10, 12 - 15, 24, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya, as applied to claims 1, 3 and 38 above. 2. Claims 20 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 32 above, and further in view of Arakaki et al. 3. Claims 21, 41, and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 34 above, and further in view of Pologe. 4. Claims 28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pologe in view of Takatani et al. 5. Claims 30 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya for the reasons given in paragraphs 2 and 4 above.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''64'''
|align = "center"|US 20080091122
|align = "center"|6/30/2008
|align = "center"|11/13/2007
|102 and 103 rejections
|N/A
|1. Claims 50 - 52, 62, 64 66, 68,70,72 and 74 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,448,996 to Bellin et al. 2. Claims 47,49 - 52, 62, 64 - 68, 70, 72 and 74 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent No. 5,846,206 to Bader.
|Claims 48 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,846,206 to Bader.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''65'''
|align = "center"|US 20080086060
|align = "center"|8/21/2008
|align = "center"|12/3/2007
|112 rejection
|N/A
|N/A
|N/A
|1. Claims 1-7, 9-20 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for quaternary amines, does not reasonably provide enablement for "an ion-balance reagent". 2. Claims 1-20 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''66'''
|align = "center"|US 20080086044
|align = "center"|9/25/2008
|align = "center"|3/26/2007
|102 and 103 rejections
|N/A
|1. Claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 6,128,519 to Say. 2. Claims 1-3, 5-7, 13, 14, 22, and 25-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,335,658 to Bedingham.
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 6,123,827 to Wong et al. Say lacks allowing a temperature of the reference solution to equilibrate with a temperature of the host. 2. Claims 9, 10, 20, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 3. Claims 9-1 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bedingham, as applied to claims 1-3, 5-7, 13, 14, 22, and 25-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 4. Claims 28 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,976,085 to Kimball et al. in view of US Patent No. 6,123,827 to Wong et al. 5. Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 4,119,406 to Clemens in view of US Patent No. 6,123,827 to Wong et al. and US Patent No. 5,976,085 to Kimball et al..
|N/A
|-
|align = "center" bgcolor = "#808080"|'''67'''
|align = "center"|US 20080082012
|align = "center"|8/26/2008
|align = "center"|9/28/2006
|102 rejection
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Zhou et al (2006101 16596)
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''68'''
|align = "center"|US 20080082011
|align = "center"|1/9/2008
|align = "center"|9/14/2006
|102 and 103 rejections
|N/A
|Claims 1,3 - 15, and 19 - 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Goodman U.S. Patent No. 6,616,613.
|Claims 2 and 16 - 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodman U.S. Patent No. 6,616,613 in view of Ranta U.S. Patent No. 7,050,798.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''69'''
|align = "center"|US 20080161708
|align = "center"|9/8/2008
|align = "center"|8/4/2006
|102 and 103 rejections
|N/A
|1.Claims 1-3, 5-7, 22-27, 30-32 and 35-37 are rejected under 35 U.S.C. 102(e) as being anticipated by Taha et al. (US patent 6,564,090). 2. Claims 7, 9, 25, 29, 30, 34, 35 and 39 are rejected under 35 U.S.C. 102(b) as being anticipated by Berger (US Patent 5,560,368). 3. Claims 10-1 3 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Starobin et al. (US Patent 6,361,503).
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Morganroth (US Pub. 20030097077). 2. Claims 8, 28, 33 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Millar et al. (Correlation between refractory periods.. .). 3. Claims 14 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Millar et al. (Correlation between refractory periods.. .). 4. Claims 15 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Berger (US Patent 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''70'''
|align = "center"|US 20080154122
|align = "center"|1/10/2008
|align = "center"|12/21/2006
|102 and 103 rejections
|N/A
|Claims 1-2 and 7-1 0, 12, 16-1 7, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Slager (USPN 5,771,895).
|1. Claims 3, I I, and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Walczak et al. (Pub. No. 2006101 551 88). 2. Claims 4-5, 13-14, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim et al. (Pub. No. 2002101 36440) and Cohen-Solal (USPN 5,933,518). 3. Claims 6 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim and Cohen-Solal as applied to claims 4 and 13 above, and further in view of Kohle (Pub. No. 200410096088).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''71'''
|align = "center"|US 20080154098
|align = "center"|5/19/2008
|align = "center"|12/20/2006
|102 and 112 rejections
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Suzuki et al. US Patent Number 6,569,094 B2.
|N/A
|Claims 7 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''72'''
|align = "center"|US 20080132782
|align = "center"|8/20/2008
|align = "center"|1/27/2005
|103 rejection
|N/A
|N/A
|Claims 1 - 20 are rejected under 35 USC 103(a) as being obvious over Uzgris et al. (US 6470,204 Bl) in view of Greenleaf et al. (US 2001/0053384 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''73'''
|align = "center"|US 20080139891
|align = "center"|8/26/2008
|align = "center"|10/25/2006
|102 and 103 rejections
|N/A
|Claims 1-6, and 8-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Walker et al. US Patent Number 6,302,844 Bl.
|Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Walker et al. US Patent Number 6,302,844 Bl as applied to claim 1 above, and further in view of Lang 6,758,812 B2
|N/A
|-
|align = "center" bgcolor = "#808080"|'''74'''
|align = "center"|US 20080114269
|align = "center"|6/24/2008
|align = "center"|10/10/2007
|102 and 103 rejections
|N/A
|Claims 1-6 and 9-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|N/A
|-
|}

= =
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''75'''
|align = "center"|US 20080097249
|align = "center"|N/A
|align = "center"|4/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''76'''
|align = "center"|US 20080097235
|align = "center"|N/A
|align = "center"|8/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''77'''
|align = "center"|US 20080097234
|align = "center"|N/A
|align = "center"|9/28/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''78'''
|align = "center"|US 20080097230
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''79'''
|align = "center"|US 20080097194
|align = "center"|N/A
|align = "center"|10/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''80'''
|align = "center"|US 20080097183
|align = "center"|N/A
|align = "center"|9/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''81'''
|align = "center"|US 20080097174
|align = "center"|N/A
|align = "center"|12/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''82'''
|align = "center"|US 20080097170
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''83'''
|align = "center"|US 20080097168
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''84'''
|align = "center"|US 20080097166
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''85'''
|align = "center"|US 20080097165
|align = "center"|N/A
|align = "center"|10/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''86'''
|align = "center"|US 20080095421
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''87'''
|align = "center"|US 20080091472
|align = "center"|N/A
|align = "center"|10/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''88'''
|align = "center"|US 20080091118
|align = "center"|N/A
|align = "center"|7/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''89'''
|align = "center"|US 20080091115
|align = "center"|N/A
|align = "center"|8/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''90'''
|align = "center"|US 20080091110
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''91'''
|align = "center"|US 20080091099
|align = "center"|N/A
|align = "center"|3/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''92'''
|align = "center"|US 20080091098
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''93'''
|align = "center"|US 20080091093
|align = "center"|N/A
|align = "center"|10/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''94'''
|align = "center"|US 20080091091
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''95'''
|align = "center"|US 20080091088
|align = "center"|N/A
|align = "center"|5/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''96'''
|align = "center"|US 20080091087
|align = "center"|N/A
|align = "center"|7/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''97'''
|align = "center"|US 20080089846
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''98'''
|align = "center"|US 20080086037
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''99'''
|align = "center"|US 20080082023
|align = "center"|N/A
|align = "center"|9/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''100'''
|align = "center"|US 20080082018
|align = "center"|N/A
|align = "center"|8/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''101'''
|align = "center"|US 20080082013
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''102'''
|align = "center"|US 20080082009
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''103'''
|align = "center"|US 20080082004
|align = "center"|N/A
|align = "center"|9/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''104'''
|align = "center"|US 20080082003
|align = "center"|N/A
|align = "center"|12/1/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''105'''
|align = "center"|US 20080081991
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''106'''
|align = "center"|US 20080081980
|align = "center"|N/A
|align = "center"|9/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''107'''
|align = "center"|US 20080081977
|align = "center"|N/A
|align = "center"|10/2/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''108'''
|align = "center"|US 20080081974
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''109'''
|align = "center"|US 20080183101
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''110'''
|align = "center"|US 20080183097
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''111'''
|align = "center"|US 20080183096
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''112'''
|align = "center"|US 20080183095
|align = "center"|N/A
|align = "center"|1/29/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''113'''
|align = "center"|US 20080183093
|align = "center"|N/A
|align = "center"|8/20/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''114'''
|align = "center"|US 20080183090
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''115'''
|align = "center"|US 20080183087
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''116'''
|align = "center"|US 20080183086
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''117'''
|align = "center"|US 20080183085
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''118'''
|align = "center"|US 20080183083
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''119'''
|align = "center"|US 20080183082
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''120'''
|align = "center"|US 20080183074
|align = "center"|N/A
|align = "center"|1/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''121'''
|align = "center"|US 20080183072
|align = "center"|N/A
|align = "center"|3/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''122'''
|align = "center"|US 20080183071
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''123'''
|align = "center"|US 20080183064
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''124'''
|align = "center"|US 20080183062
|align = "center"|N/A
|align = "center"|12/5/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''125'''
|align = "center"|US 20080183061
|align = "center"|N/A
|align = "center"|4/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''126'''
|align = "center"|US 20080183060
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''127'''
|align = "center"|US 20080183058
|align = "center"|N/A
|align = "center"|3/31/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''128'''
|align = "center"|US 20080183053
|align = "center"|N/A
|align = "center"|11/21/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''129'''
|align = "center"|US 20080183050
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''130'''
|align = "center"|US 20080183049
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''131'''
|align = "center"|US 20080183047
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''132'''
|align = "center"|US 20080181470
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''133'''
|align = "center"|US 20080177341
|align = "center"|N/A
|align = "center"|10/29/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''134'''
|align = "center"|US 20080177197
|align = "center"|N/A
|align = "center"|1/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''135'''
|align = "center"|US 20080177196
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''136'''
|align = "center"|US 20080177194
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''137'''
|align = "center"|US 20080177193
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''138'''
|align = "center"|US 20080177191
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''139'''
|align = "center"|US 20080177188
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''140'''
|align = "center"|US 20080177178
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''141'''
|align = "center"|US 20080177177
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''142'''
|align = "center"|US 20080177176
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''143'''
|align = "center"|US 20080177174
|align = "center"|N/A
|align = "center"|10/11/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''144'''
|align = "center"|US 20080177170
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''145'''
|align = "center"|US 20080177164
|align = "center"|N/A
|align = "center"|11/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''146'''
|align = "center"|US 20080177163
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''147'''
|align = "center"|US 20080177162
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''148'''
|align = "center"|US 20080177160
|align = "center"|N/A
|align = "center"|2/28/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''149'''
|align = "center"|US 20080177159
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''150'''
|align = "center"|US 20080177157
|align = "center"|N/A
|align = "center"|4/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''151'''
|align = "center"|US 20080177156
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''152'''
|align = "center"|US 20080172253
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''153'''
|align = "center"|US 20080171950
|align = "center"|N/A
|align = "center"|12/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''154'''
|align = "center"|US 20080171948
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''155'''
|align = "center"|US 20080171946
|align = "center"|N/A
|align = "center"|12/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''156'''
|align = "center"|US 20080171943
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''157'''
|align = "center"|US 20080171941
|align = "center"|N/A
|align = "center"|1/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''158'''
|align = "center"|US 20080171934
|align = "center"|N/A
|align = "center"|1/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''159'''
|align = "center"|US 20080171933
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''160'''
|align = "center"|US 20080171932
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''161'''
|align = "center"|US 20080171925
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''162'''
|align = "center"|US 20080171923
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''163'''
|align = "center"|US 20080171916
|align = "center"|N/A
|align = "center"|3/13/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''164'''
|align = "center"|US 20080171913
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''165'''
|align = "center"|US 20080167583
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''166'''
|align = "center"|US 20080167578
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''167'''
|align = "center"|US 20080167575
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''168'''
|align = "center"|US 20080167574
|align = "center"|N/A
|align = "center"|12/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''169'''
|align = "center"|US 20080167571
|align = "center"|N/A
|align = "center"|12/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''170'''
|align = "center"|US 20080167569
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''171'''
|align = "center"|US 20080167567
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''172'''
|align = "center"|US 20080167566
|align = "center"|N/A
|align = "center"|1/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''173'''
|align = "center"|US 20080167564
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''174'''
|align = "center"|US 20080167552
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''175'''
|align = "center"|US 20080167549
|align = "center"|N/A
|align = "center"|12/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''176'''
|align = "center"|US 20080167545
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''177'''
|align = "center"|US 20080167544
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''178'''
|align = "center"|US 20080167543
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''179'''
|align = "center"|US 20080167540
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''180'''
|align = "center"|US 20080167532
|align = "center"|N/A
|align = "center"|10/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''181'''
|align = "center"|US 20080165017
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''182'''
|align = "center"|US 20080161729
|align = "center"|N/A
|align = "center"|10/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''183'''
|align = "center"|US 20080161714
|align = "center"|N/A
|align = "center"|1/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''184'''
|align = "center"|US 20080161713
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''185'''
|align = "center"|US 20080161712
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

= =
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''186'''
|align = "center"|US 20080161707
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''187'''
|align = "center"|US 20080161706
|align = "center"|N/A
|align = "center"|2/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''188'''
|align = "center"|US 20080161705
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''189'''
|align = "center"|US 20080161703
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''190'''
|align = "center"|US 20080161681
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''191'''
|align = "center"|US 20080161674
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''192'''
|align = "center"|US 20080161666
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''193'''
|align = "center"|US 20080161665
|align = "center"|N/A
|align = "center"|2/21/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''194'''
|align = "center"|US 20080161662
|align = "center"|N/A
|align = "center"|8/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''195'''
|align = "center"|US 20080161661
|align = "center"|N/A
|align = "center"|1/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''196'''
|align = "center"|US 20080161660
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''197'''
|align = "center"|US 20080161657
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''198'''
|align = "center"|US 20080161652
|align = "center"|N/A
|align = "center"|3/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''199'''
|align = "center"|US 20080161651
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''200'''
|align = "center"|US 20080154154
|align = "center"|N/A
|align = "center"|2/27/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''201'''
|align = "center"|US 20080154149
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''202'''
|align = "center"|US 20080154144
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''203'''
|align = "center"|US 20080154128
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''204'''
|align = "center"|US 20080154125
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''205'''
|align = "center"|US 20080154123
|align = "center"|N/A
|align = "center"|12/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''206'''
|align = "center"|US 20080154121
|align = "center"|N/A
|align = "center"|10/24/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''207'''
|align = "center"|US 20080154107
|align = "center"|N/A
|align = "center"|12/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''208'''
|align = "center"|US 20080154106
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''209'''
|align = "center"|US 20080154101
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''210'''
|align = "center"|US 20080154099
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''211'''
|align = "center"|US 20080146960
|align = "center"|N/A
|align = "center"|2/19/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''212'''
|align = "center"|US 20080146958
|align = "center"|N/A
|align = "center"|7/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''213'''
|align = "center"|US 20080146914
|align = "center"|N/A
|align = "center"|12/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''214'''
|align = "center"|US 20080146911
|align = "center"|N/A
|align = "center"|4/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''215'''
|align = "center"|US 20080146906
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''216'''
|align = "center"|US 20080146901
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''217'''
|align = "center"|US 20080146899
|align = "center"|N/A
|align = "center"|2/7/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''218'''
|align = "center"|US 20080146896
|align = "center"|N/A
|align = "center"|7/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''219'''
|align = "center"|US 20080146892
|align = "center"|N/A
|align = "center"|8/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''220'''
|align = "center"|US 20080146891
|align = "center"|N/A
|align = "center"|6/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''221'''
|align = "center"|US 20080146889
|align = "center"|N/A
|align = "center"|12/13/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''222'''
|align = "center"|US 20080139966
|align = "center"|N/A
|align = "center"|12/7/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''223'''
|align = "center"|US 20080139963
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''224'''
|align = "center"|US 20080139956
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''225'''
|align = "center"|US 20080139952
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''226'''
|align = "center"|US 20080139948
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''227'''
|align = "center"|US 20080139927
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''228'''
|align = "center"|US 20080139926
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''229'''
|align = "center"|US 20080139925
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''230'''
|align = "center"|US 20080139921
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''231'''
|align = "center"|US 20080139920
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''232'''
|align = "center"|US 20080139917
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''233'''
|align = "center"|US 20080139910
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''234'''
|align = "center"|US 20080139906
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''235'''
|align = "center"|US 20080139901
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''236'''
|align = "center"|US 20080137929
|align = "center"|N/A
|align = "center"|7/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''237'''
|align = "center"|US 20080132808
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''238'''
|align = "center"|US 20080132802
|align = "center"|N/A
|align = "center"|2/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''239'''
|align = "center"|US 20080132801
|align = "center"|N/A
|align = "center"|6/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''240'''
|align = "center"|US 20080132784
|align = "center"|N/A
|align = "center"|11/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''241'''
|align = "center"|US 20080132783
|align = "center"|N/A
|align = "center"|12/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''242'''
|align = "center"|US 20080132781
|align = "center"|N/A
|align = "center"|11/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''243'''
|align = "center"|US 20080132775
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''244'''
|align = "center"|US 20080125678
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''245'''
|align = "center"|US 20080125666
|align = "center"|N/A
|align = "center"|6/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''246'''
|align = "center"|US 20080125663
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''247'''
|align = "center"|US 20080125646
|align = "center"|N/A
|align = "center"|8/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''248'''
|align = "center"|US 20080125644
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''249'''
|align = "center"|US 20080125641
|align = "center"|N/A
|align = "center"|8/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''250'''
|align = "center"|US 20080125636
|align = "center"|N/A
|align = "center"|3/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''251'''
|align = "center"|US 20080119760
|align = "center"|N/A
|align = "center"|6/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''252'''
|align = "center"|US 20080119755
|align = "center"|N/A
|align = "center"|12/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''253'''
|align = "center"|US 20080119753
|align = "center"|N/A
|align = "center"|11/16/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''254'''
|align = "center"|US 20080119749
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''255'''
|align = "center"|US 20080119748
|align = "center"|N/A
|align = "center"|11/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''256'''
|align = "center"|US 20080119747
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''257'''
|align = "center"|US 20080119746
|align = "center"|N/A
|align = "center"|11/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''258'''
|align = "center"|US 20080119743
|align = "center"|N/A
|align = "center"|10/23/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''259'''
|align = "center"|US 20080119741
|align = "center"|N/A
|align = "center"|11/22/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''260'''
|align = "center"|US 20080119726
|align = "center"|N/A
|align = "center"|10/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''261'''
|align = "center"|US 20080119717
|align = "center"|N/A
|align = "center"|9/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''262'''
|align = "center"|US 20080119716
|align = "center"|N/A
|align = "center"|5/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''263'''
|align = "center"|US 20080119706
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''264'''
|align = "center"|US 20080119704
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''265'''
|align = "center"|US 20080119703
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''266'''
|align = "center"|US 20080119701
|align = "center"|N/A
|align = "center"|11/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''267'''
|align = "center"|US 20080119699
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''268'''
|align = "center"|US 20080119698
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''269'''
|align = "center"|US 20080119697
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''270'''
|align = "center"|US 20080118135
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''271'''
|align = "center"|US 20080114614
|align = "center"|N/A
|align = "center"|11/15/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''272'''
|align = "center"|US 20080114261
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''273'''
|align = "center"|US 20080114260
|align = "center"|N/A
|align = "center"|5/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''274'''
|align = "center"|US 20080114256
|align = "center"|N/A
|align = "center"|11/14/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''275'''
|align = "center"|US 20080114231
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''276'''
|align = "center"|US 20080114229
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''277'''
|align = "center"|US 20080114228
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''278'''
|align = "center"|US 20080114225
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''279'''
|align = "center"|US 20080114224
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''280'''
|align = "center"|US 20080114223
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''281'''
|align = "center"|US 20080114219
|align = "center"|N/A
|align = "center"|10/31/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''282'''
|align = "center"|US 20080110461
|align = "center"|N/A
|align = "center"|4/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''283'''
|align = "center"|US 20080108909
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''284'''
|align = "center"|US 20080108907
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''285'''
|align = "center"|US 20080108905
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''286'''
|align = "center"|US 20080108903
|align = "center"|N/A
|align = "center"|11/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''287'''
|align = "center"|US 20080108894
|align = "center"|N/A
|align = "center"|5/7/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''288'''
|align = "center"|US 20080108892
|align = "center"|N/A
|align = "center"|11/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''289'''
|align = "center"|US 20080103406
|align = "center"|N/A
|align = "center"|10/26/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''290'''
|align = "center"|US 20080103404
|align = "center"|N/A
|align = "center"|10/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''291'''
|align = "center"|US 20080103403
|align = "center"|N/A
|align = "center"|9/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''292'''
|align = "center"|US 20080103397
|align = "center"|N/A
|align = "center"|10/26/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''293'''
|align = "center"|US 20080103390
|align = "center"|N/A
|align = "center"|10/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''294'''
|align = "center"|US 20080103377
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''295'''
|align = "center"|US 20080103376
|align = "center"|N/A
|align = "center"|10/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''296'''
|align = "center"|US 20080103375
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''297'''
|align = "center"|US 20080103371
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''298'''
|align = "center"|US 20080103370
|align = "center"|N/A
|align = "center"|10/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''299'''
|align = "center"|US 20080103369
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''300'''
|align = "center"|US 20080103368
|align = "center"|N/A
|align = "center"|10/17/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''301'''
|align = "center"|US 20080101675
|align = "center"|N/A
|align = "center"|8/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

Bilski Diagnostic Methods Big Sample Sheet

2009-04-18T11:32:51Z

Naveen: /* */

=Rejections=
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''S.No.'''
|align = "center" bgcolor = "#808080"|'''Publication No.'''
|align = "center" bgcolor = "#808080"|'''Date of Rejection'''
|align = "center" bgcolor = "#808080"|'''Filing date'''
|align = "center" bgcolor = "#808080"|'''Rejection type'''
|align = "center" bgcolor = "#808080"|'''101 Rejection'''
|align = "center" bgcolor = "#808080"|'''102 Rejection'''
|align = "center" bgcolor = "#808080"|'''103 Rejection'''
|align = "center" bgcolor = "#808080"|'''112 Rejection'''
|-
|align = "center" bgcolor = "#808080"|'''1'''
|align = "center"|US 20080091086
|align = "center"|3/2/2009
|align = "center"|10/9/2007
|101 and 102 rejections
|Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 01185021 A1 to Aguilera et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''2'''
|align = "center"|US 20080086045
|align = "center"|10/22/2008
|align = "center"|12/7/2007
|101, 103 and 112 rejections
|1. Claims 1-30 and 58-1 06 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-45 of U.S. Patent No. 7,309,607. 2. Claims 1-6, 10-15,21-33,35, 58-63, 67-72, 76, 82-84, 88 and 95-105 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 25,28,33-47 and 49-5 1 of copending Application No. 1 11409,735.
|N/A
|1. Claims 58-67,70-71,78-88 and 105-107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (US 5,372,946, submitted in the IDS filed on December 7,2007). 2. Claims 68-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 (5,372,946) in view of Blake (US 5,3 16,730, also cited in the IDS filed on December 7,2007). 3. Claims 72-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Jaeger (US 4,116,635, also cited in the IDS filed on December 7,2007). 4. Claims 76-77 and 95-1 04 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Beythien et a1 (article submitted in the IDS filed on December 7,2007). 5. Claims 89-94 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusak et a1 in view of Applicant<nowiki>’</nowiki>s admitted prior art in the specification.
|Claims 16 and 95 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''3'''
|align = "center"|US 20080086035
|align = "center"|11/14/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''4'''
|align = "center"|US 20080086038
|align = "center"|3/6/2009
|align = "center"|9/18/2007
|101 rejection
|Claims 1-2 and 4-1 2 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 - 82 of U.S. Patent No. 6,859,280.
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''5'''
|align = "center"|US 20080083414
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-1 0 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''6'''
|align = "center"|US 20080082022
|align = "center"|11/26/2008
|align = "center"|9/8/2006
|101, 102 and 103 rejections
|Claims 1-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619).
|1. Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Keitzer (US 3,363,619). 2. Claims 12-1 9 and 21 -24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer as applied to claims 1-8 and 10 above, and further in view of Rollema (US 5,377,101). 3. Claims 9 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kreitzer in view of Rollema as applied to claim 12 above, and further in view of Alyfuku (US 5,410,471).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''7'''
|align = "center"|US 20080139953
|align = "center"|12/12/2008
|align = "center"|11/1/2006
|101, 102 and 103 rejections
|Claims 1-44 are rejected under 35 U.S.C. 10 1 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-3 & 15-18 rejected under 35 U.S.C. 102(b) as being anticipated by Abreu (US 2004/0242976)
|1. Claims 4-7 & 9-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 2. Claims 30-32,39 & 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 3. Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Owen et al. (US 200310055460). 4. Claim 19-24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Schraag (US 5,309,918). 5. Claims 25-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Ortega et al. (US 200610 13600 1). 6. Claims 33-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Westra et al. (US 200610183434). 7. Claim 38 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Eshelman et al. (US 200310001742). 8. Claim 40 is rejected under 35 U.S.C. 103(a) as being unpatentable over Abreu (US 200410242976) in view of Cooper et al. (US 5,294,928)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''8'''
|align = "center"|US 20080132777
|align = "center"|3/3/2009
|align = "center"|2/1/2005
|101, 103 and 112 rejections
|Claims 21 - 40 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over Claims 1 - 17 of copending Application No. 11/044,239.
|N/A
|1. Claims 21 - 40 and 45 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,4 70,204 Bl). 2. Claims 41 - 44 are rejected under 35 USC 103(a) as being obvious over Helfer (US 6,925,322 B2) in view of Uzgiris et al. (US 6,470,204 Bl), in view of Tsujita (US 5,8 79,284).
|Claims 1, 34, 36, and 41 are rejected under 35 U.S.C. 112,firstparagraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''9'''
|align = "center"|US 20080119709
|align = "center"|10/8/2008
|align = "center"|10/31/2006
|101, 102 and 103 rejections
|Claims 1-1 8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-30 of copending Application No. 1115551 56.
|1. Claims I, 4, 6, 7, and 10 are rejected under 35 U.S.C. 102(e) as being anticipated by Zocchi (US Patent Application Publication 200610040333). 2. Claims 1 and 5-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Rasdal (US Patent Application Publication 2005101 54271 ).
|Claims 11 -1 5 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causey (US Patent Application Publication 200410073095) in view of Zocchi.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''10'''
|align = "center"|US 20080119705
|align = "center"|10/2/2008
|align = "center"|10/31/2007
|101, 102, 103 and 112 rejections
|Claim 20 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|1. Claims 1-2, 4-7 and 9-19 are rejected under 35 U.S.C. 102(a) as being anticipated by "eDiab: A system for Monitoring, Assisting and Educating People with Diabetes", ICCHP, 2006 to Luque et al (Hereinafter "Luque"). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being anticipated by 2002101 93679 to Malave et al (Hereinafter "Malave").
|1. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 2002101 93679 to Malave et al (Hereinafter "Malave"). 2. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Luque in view of US 200610025663 to Talbot et al (Hereinafter "Talbot").
|Claims I I, 16 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''11'''
|align = "center"|US 20080114214
|align = "center"|11/13/2008
|align = "center"|10/20/2006
|101 and 102 rejections
|Claims 6-10 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''12'''
|align = "center"|US 20080114212
|align = "center"|11/13/2008
|align = "center"|10/10/2006
|101 and 102 rejections
|Claims 10-18 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a tangible result.
|Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Barrera US Patent Publication No. 200510145257 which incorporates by reference in paragraph 0019 of the specification, Malackowski et al. US Patent Publication No. 200110034530 (hereinafter Malackowski).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''13'''
|align = "center"|US 20080097240
|align = "center"|10/22/2008
|align = "center"|4/11/2007
|102 and 103 rejections
|N/A
|Claims 1,4-7, 80 and 81 are rejected under 35 U.S.C. 102(b) as being anticipated by Henning et al .(US 6,155,992).
|1. Claims 6 is alternately rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 2. Claims 76 and 82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 2002101 69394 Al). 3. Claims 77-79 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al .(US 6,155,992) in view of Eppstein et al. (US 200210169394 Al) and in further view of Bojan et al. (US 200210099308 Al). 4. Claims 84-87 are rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Bojan et al. (US 200210099308 Al). 5. Claim 83 is rejected under 35 U.S.C. 103(a) as being unpatentable over Henning et al. (US 6,155,992) in view of Roe et al. (US 200410236251 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''14'''
|align = "center"|US 20080097231
|align = "center"|12/2/2008
|align = "center"|10/18/2006
|102 and 103 rejections
|N/A
|Claims 1-2, 4-1 3, 15-25 are rejected under 35 U.S.C. 102(e) as being anticipated by Geva (US 7222054).
|Claims 3, 14, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Geva (7222054) in view of Budde (3556084).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''15'''
|align = "center"|US 20080097226
|align = "center"|2/2/2009
|align = "center"|6/9/2006
|102, 103 and 112 rejections
|N/A
|Claims 1 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Kurtz et al. (US 4,231,354, hereinafter Kurtz).
|1. Claims 2, 10-1 2 and 14-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz in view of Recchia et al. ("Reduced Nitric Oxide Production and Altered Myocardial Metabolism During the Decompensation of Pacing-Induced Heart Failure in the Conscious Dog," hereinafter Recchia). 2. Claims 5-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz.
|Claims 9 and 13 are rejected under 35 U.S.C. 1 12, first paragraph, as failing to comply with the enablement requirement.
|-
|align = "center" bgcolor = "#808080"|'''16'''
|align = "center"|US 20080097175
|align = "center"|11/24/2008
|align = "center"|9/29/2006
|102 and 103 rejections
|N/A
|Claims 10-1 6, 23, 24, and 26-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Ali et al. (US 20051006541 7).
|Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20051006541 7) in view of Mechlenburg (US 200110018547).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''17'''
|align = "center"|US 20080097169
|align = "center"|12/9/2008
|align = "center"|8/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-2, 4, 6, 9, 13-1 4, 16, 21 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack et al. (US 56661 04) in view of Rosenfeld (US 58271 91 ). 2. Claims 3 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claim 1 above, and further in view of Daly et al. 3. Claims 5, 22, 24, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 above, and further in view of Butte et al. 4. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 6 and 9 above, and further in view of Policker et al. (US 7330753). 5. Claims 8, I I, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack, Rosenfeld and Policker as applied to claims 6 and 9 above, and further in view of Ganguly et al. (US 4926871 ). 6. Claims 12 and 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld as applied to claims 1 and 9 above, and further in view of Mault et al. (US 200302081 13). 7. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack and Rosenfeld as applied to claim 1 above, and further in view of Bowman et al. (US 20050283327). 8. Claims 23, 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollack modified by Rosenfeld and Butte as applied to claims 22 and 24 above, and further in view of Shalon et al. (US 20060064037).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''18'''
|align = "center"|US 20080091121
|align = "center"|12/1/2008
|align = "center"|3/20/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-9, 13-14 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Asada (U.S. Patent No. 6,236,037 BI).
|Claims 10-1 2, 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Asada (U.S. Patent No. 6,236,037 Bl).
|Claim 15 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''19'''
|align = "center"|US 20080091114
|align = "center"|2/19/2009
|align = "center"|12/29/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 8, 10, 22-26, 30, 31 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Hess (2007101 56061 ). 2. Claims 34, 35, 36 and 38 are rejected under 35 U.S.C. 102(e) as being anticipated by Stahmann (200610258952).
|1. Claims 1-6, 9, 11 -21, 27-29, and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (2007101 56061) in view of Stahmann (200610258952). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hess (200710156061) in view of Stahmann (200610258952) as applied to claim 1 above, and further in view of Pitts Crick (6,104,949). 3. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sta hmann (200610258952).
|Claims I, 4, 5, 7, 9, I I, and 12 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''20'''
|align = "center"|US 20080091092
|align = "center"|2/9/2009
|align = "center"|10/12/2007
|103 and 112 rejections
|N/A
|N/A
|Claims 1-8 and 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ali et al. (US 20021003531 5).
|Claims 4-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''21'''
|align = "center"|US 20080091090
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 5 and 7 - 19 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''22'''
|align = "center"|US 20080091089
|align = "center"|11/28/2008
|align = "center"|7/9/2007
|102 rejection
|N/A
|1. Claims 1,2,4 - 6,8 - 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Segalowitz U.S. Patent No. 5,511,553. 2. Claims 1 - 3,5,7 - 16, and 18 are rejected under 35 U.S.C. 102(e) as being anticipated by Stivoric et al. U.S. Patent No. 7,285,090.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''23'''
|align = "center"|US 20080082016
|align = "center"|2/5/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-1 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hardahl (US 2005101 77049) in view of Reinhoff, Jr et al. (US 2002/0133495)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''24'''
|align = "center"|US 20080082015
|align = "center"|3/4/2009
|align = "center"|10/3/2006
|103 rejection
|N/A
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable by Fischell et al. (PG Publication 200410059238) in view of Aversano et al. (200410034284)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''25'''
|align = "center"|US 20080082005
|align = "center"|12/17/2008
|align = "center"|7/3/2007
|103 and 112 rejections
|N/A
|N/A
|Claims I, 4, 5, and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over O<nowiki>’</nowiki>Brien in view of Penner, U.S. Patent Application Publication No. 200510288727A1 ("Penner").
|Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''26'''
|align = "center"|US 20080081979
|align = "center"|2/17/2009
|align = "center"|9/15/2006
|103 rejection
|N/A
|N/A
|Claims 1-3, 5-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kim et al. (Kim) (US 200610025670 Al), and further in view of Chen et al. (Chen) (US 2007101 00952 A1 ).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''27'''
|align = "center"|US 20080081975
|align = "center"|2/13/2009
|align = "center"|9/28/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-1 3 and 15-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2). 2. Claims 19-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Schmitt et al. (US 200410230106). 3. Claims 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah et al. "Noninvasive Early Detection of Brain Edema in Mice by Near-Infrared Light Scattering," Journal of Neuroscience Research 80:293-299 in view of Wenzel et al. (US 6,668,181 B2) and Yamamoto et al. (US 200310088162 AI). 4. Claims 13, 15, 27 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thiagarajah in view of Wenzel as applied to claims 13 and 19 above, and further in view of Giller (US 6,567,690).
|Claims 19-28 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for isobestic wavelengths of water 11 80 and 1300, does not reasonably provide enablement for isobestic wavelengths in general.
|-
|align = "center" bgcolor = "#808080"|'''28'''
|align = "center"|US 20080081973
|align = "center"|10/28/2008
|align = "center"|9/28/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 4, 5, 12, 17 and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Swedlow et a1.<nowiki>’</nowiki>417 (cited by Applicant).
|1. Claims 8, 19 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>4 17, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825 (USPN 5,10 1,825). 2. Claims 7, 10, 18, 20, 26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Swedlow et a1.<nowiki>’</nowiki>417, as applied to claims 1, 17 and 25, further in view of Gravenstein et a1.<nowiki>’</nowiki>825, further in view of Aldrich<nowiki>’</nowiki>064. 3. Claims 1-3, 5, 7, 9- 13, 16, 17, 18, 20, 21, 23, 25, 26, 28, 29 and 3 1 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldberger et a1.<nowiki>’</nowiki>464 (USPN 4,685,464) further in view of Hecke1<nowiki>’</nowiki>995 (US Pub No. 200210 137995) further in view of Aldrich<nowiki>’</nowiki>064.
|Claims 14, 15, 22 and 30 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''29'''
|align = "center"|US 20080183104
|align = "center"|1/30/2009
|align = "center"|1/11/2008
|102 and 103 rejections
|N/A
|Claims 12-14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia, Ill et al. (US 6,002,859, hereinafter DiGioia) as broadly as claimed.
|Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over DiGioia in view of Taylor et al. (US 6,231,526 Bl , hereinafter Taylor).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''30'''
|align = "center"|US 20080171949
|align = "center"|3/23/2009
|align = "center"|1/18/2007
|102 and 103 rejections
|N/A
|Claim 30 is rejected under 35 U.S.C. 102(b) as being anticipated by Alfano (US 5042494)
|1. Claims 1-4, 7-9, and 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. (US 5800350) in view of Nordstrom et al. (US71 27282). 2. Claims 5 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coppleson et al. modified by Nordstrom as applied to claim 2 above, and further in view of Baharav et al. (US 697271 4). 3. Claims 10-1 6 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al (US 6972714) in view of Nordstrom et al. (US 7127282). 4. Claims 17-22, 24, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav et al. modified by Nordstrom as applied to claim 10 above, and further in view of Coppleson et al. (US 5800350). 5. Claims 23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baharav modified by Nordstrom and Coppleson as applied to claim 17 above, and further in view of Jacques (US 4364008). 6. Claims 31 -32 is rejected under 35 U.S.C. 103(a) as being unpatentable over Alfano as applied to claim 30 above, and further in view of Coppleson (US 5800350) and Nordstrom et al. (US 7127282).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''31'''
|align = "center"|US 20080167565
|align = "center"|1/8/2009
|align = "center"|1/9/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-7, 12, 15-21, 25, and 26 are rejected under 35 U.S.C. 102(e) as being anticipated by Burton (US 200710032733).
|Claims 8-1 0, 13-1 4, 22-24, and 27-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Burton (US 200710032733) in view of Flick et al. (US 6993377).
|1. Claims 15-28 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''32'''
|align = "center"|US 20080161731
|align = "center"|12/10/2008
|align = "center"|12/27/2006
|103 rejection
|N/A
|N/A
|1. Claims I, 2, I I, 29, 30 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 A1 ) 2. Claims 3, 5, 12, 31, 33 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29 above, an in further view of Solomonow et al. (US 5628722) 3. Claims 4, 6, 32 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) and Solomonow et al. (US 5628722) as applied to claims 3,5,31 and 33 above, and in further view of Vosch (US 2007100731 32). 4. Claims 7, 8, 13, 35, 36 and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 Al) in view of Song (US 2004101 67420 Al) as applied to claims 1 and 29, and in further view of Vosch (US 2007100731 32) 5. Claims 9, 10 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) as applied to claims 1 and 29, and in further view of Brann (US 6,059,576). 6. Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kramer (US 200310083596 A1 ) in view of Song (US 2004101 67420 A1 ) and Vosch (US 2007100731 32) as applied to claim 35 above and in further view of Brann (US 6,059,576).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''33'''
|align = "center"|US 20080161709
|align = "center"|12/24/2008
|align = "center"|10/13/2006
|102 and 103 rejections
|N/A
|Claims 1-3, 7-1 2, 14 and 16-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Mault (US 20021-1 73728).
|1. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Yasushi et al. (6,485,418). 2. Claims 4-6, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mault (US 2002101 73728) in view of Jones, Jr. et al. (US 5,076,093).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''34'''
|align = "center"|US 20080161701
|align = "center"|11/13/2008
|align = "center"|12/28/2006
|102 and 112 rejections
|N/A
|Claims 1-9 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Haller et al. (US 200210052539).
|N/A
|Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''35'''
|align = "center"|US 20080161668
|align = "center"|2/12/2009
|align = "center"|12/29/2006
|103 rejection
|N/A
|N/A
|1. Claims 1-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ben-Haim (US 20020087089) in view of Rosenberg et al. (US 20060275775). 2. Claims I, 2, and 6-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Ben-Haim (WO 97124981). 3. Claims 13-1 6, and 22-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir (US 6371 930) in view of Rosenberg et al. (US 200610276775). 4. Claims 17-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shafir in view of Ben-Haim and Further in view of Hilton et al. (US 3250012).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''36'''
|align = "center"|US 20080161653
|align = "center"|2/5/2009
|align = "center"|4/16/2007
|102 and 103 rejections
|N/A
|Claims 1-6 are rejected under 35 U.S.C. 102(b) as being anticipated by TW 357077. <nowiki>’</nowiki>707 discloses in the English translation, and by applicant<nowiki>’</nowiki>s admission in the disclosure, all of the limitations of the instant invention
|Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lubell.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''37'''
|align = "center"|US 20080154143
|align = "center"|2/5/2009
|align = "center"|1/11/2007
|102 and 103 rejections
|N/A
|Claims 1, 2, 4-7, 9, 10, 12-1 4 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Xue et al. U.S. Patent Publication No. 200510038352 Al. Xue et al. <nowiki>’</nowiki>352 anticipates:
|1. Claims 3 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Arnold et al. U.S. Patent No. 5,713,367. 2. Claims 8 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xue et al. <nowiki>’</nowiki>352 as applied to claims 1 and 9 above, and further in view of Xue et al. U.S. Patent No. 5,792,065.
|N/A
|-
|}

= =
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''38'''
|align = "center"|US 20080146956
|align = "center"|2/12/2009
|align = "center"|12/17/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1,4-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628. 2. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,171,8 1 1) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257. 3. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 I), in view of Ohara et al., Journal of Gastroenterology 2004: 39:62 1-628 and further in view of Aygen (U.S. Patent Application Publication 20060 17 1887). 4. Claims 6, 8- 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori. 5. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S.Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori, in view of Aygen (U.S. Patent Application Publication 20060 17 1887) 6. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vallejo (U.S. Patent 6,17 1,8 1 1) in view of Meretek<nowiki>’</nowiki>s proposed BREATHTEKTM Urea Breath Test package insert for Helicobacter pylori) in view of Ohara et al., Journal of Gastroenterology 2004: 39:621-628, and further in view of Wong et al., Ailment Pharmacol Ther 2003; 17: 253-257,
|Claim 1 is rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''39'''
|align = "center"|US 20080146905
|align = "center"|3/19/2009
|align = "center"|10/4/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 6-1 1, 19, 20, 26, 27, 28, 31, and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Weinberg (US 5,519,221).
|Claims 5, 12-1 8, 21 -25, and 29-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weinberg (US 5,519 221) in view of Nelson et al (US 7,291,841 B2).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''40'''
|align = "center"|US 20080146897
|align = "center"|3/13/2009
|align = "center"|12/7/2005
|103 rejection
|N/A
|N/A
|1. Claims 1-6, 8, 9, 11, 12, 14, 15, 21-23 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen et a1 (Two-dimensional near-infrared transillumination imaging of biomedical media with a chromium-doped forsterite laser. Applied Optics 37(22) p. 5327-5336. 1998), hereinafter Gayen (1998), of record, in view of Levenson et al (US Patent No. 6,750,964), hereinafter Levenson (<nowiki>’</nowiki>964). 2. Claims 7 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claim 1 above, and further in view of Alfano (US Patent No. , 5,371,368), hereinafter Alfano (<nowiki>’</nowiki>368), of record. 3. Claims 13, 16-19 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayen . (1998) and Levenson (<nowiki>’</nowiki>964) as applied to claims 2 and 15 above, and further in view of Wang et al (Ballistic 2-D Imaging Through Scattering Walls Using an Ultrafast Optical Kerr Gate. Science. 253:p. 769-771. 1991), hereinafter Wang (1991), of record.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''41'''
|align = "center"|US 20080139967
|align = "center"|2/4/2009
|align = "center"|10/18/2006
|102, 103 and 112 rejections
|N/A
|Claims 1, 5-10, and 14-17 are rejected under 35 U.S.C. 102(b) as being anticipated by United States Patent Publication 2002101 93670 (Garfield et al.).
|1. Claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over United States Patent Publication 2002101 93670 (Garfield et al.) as modified by United States Patent 6421558 (Huey et al.). 2. Claims 3, 4, 19 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 6663570 (Mott et al.). 3. Claims 7-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5301 680 (Rosenberg). 4. Claims 12 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-1 7, 20, 21 and 22 above, and further in view of United States Patent 4781 200 (Baker). 5. Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. and Mott et al. as applied to claims 3, 4, 19 and 23 above, and further in view of Baker. 6. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5442940 (Secker et al.). 6. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al. as modified by Huey et al. as applied to claims 1, 5, 6, 10, 11, 14-17, 20, 21 and 22 above, and further in view of United States Patent 5670749 (Hon). 7. Claims 2-4 and I I are rejected under 35 U.S.C. 103(a) as being unpatentable over Garfield et al.
|1. Claim 8 contains the trademarksltrade names Bluetooth, Wi-Fi, Zigbie, and wireless USB. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph.
|-
|align = "center" bgcolor = "#808080"|'''42'''
|align = "center"|US 20080139951
|align = "center"|11/26/2008
|align = "center"|12/8/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-9, 1 1-1 2, & 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Porat et al. (USP<nowiki> </nowiki> 6,277,078; hereinafter "Porat").
|1. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078). Porat describes trending the cardiac flow turbulence over a time period; however, the detection of complete occlusion of the blood vessel is not specified. 2. Claims 6 & 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Benedict et al.(USP<nowiki> </nowiki> 5,520,190; hereinafter "Benedict"). 3. Claims 13, 14, & 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Porat et al.(USP<nowiki> </nowiki> 6,277,078) in view of Kadhiresan(USP<nowiki> </nowiki> 5,935,081).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''43'''
|align = "center"|US 20080139898
|align = "center"|10/28/2008
|align = "center"|12/7/2006
|102 rejection
|N/A
|Claims 1-1 4, and 29-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Sunvit et al. US Patent Number 6,024,699.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''44'''
|align = "center"|US 20080132800
|align = "center"|1/30/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|1. Claims 1,3,4,5 are rejected under 35 U.S.C. 102(b) as being anticipated by Denker et al (6,592,518). 2. Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by Dimmer et al (2004101 38554).
|1. Claims 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Chinchoy (2004101 72079). 2. Claims 6-1 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chinchoy (2004101 72079) in view of Denker et al (6,592,518). 3. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898). 4. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Denker et al (6,592,518) in view of Ben-Heim (6,285,898), and further in view of Chinchoy (2004101 72079). 5. Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dimmer et al (2004101 38554) in view of Chinchoy (2004101 72079).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''45'''
|align = "center"|US 20080132799
|align = "center"|3/19/2009
|align = "center"|11/30/2006
|102 and 103 rejections
|N/A
|Claims 1-5, 7-8, 10-18, and 20 are rejected under 35 U.S. C. 102(b) as being anticipated by Brunner et a1 (US Patent Application Publication 2003/0004652).
|1. Claims 6 and 9 are rejected under 35 U.S. C. 103(a) as being unpatentable over Brunner et a1 in view of Karjalainen et a1 (Karjalainen, P. A,; Tarvainen, M. R.; Laitinen, T., "Principal Component Regression Approach for QT Variability Estimation, " Engineering in Medicine and Biology Society, 2005. IEEE-EMBS 2005. 27th Annual International Conference, vol., no., pp. 1145-1 147, 17-18 Jan. 2006) 2. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brunner et a1 in view of Berger (US Patent No. 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''46'''
|align = "center"|US 20080132797
|align = "center"|3/6/2009
|align = "center"|10/31/2007
|103 rejection
|N/A
|Claims 1-19 are rejected under 35 U.S.C. 102(e) as being anticiapated by U. S. Publication No. 200210172323 to Karellas et al.
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''47'''
|align = "center"|US 20080119724
|align = "center"|3/18/2009
|align = "center"|11/17/2006
|102 and 103 rejections
|N/A
|1. Claims 1, 10-1 1 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by DiGioia Ill et al. (US Patent No. 5,880,976). 2. Claims 1-4, 7-1 4 and 16-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Mire et al. (US Pub No. 2004101 71 924). 3. Claim 1, 6-7, 9-1 1, 15-1 6, 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Sahay et al. (US Patent No. 5,824,085).
|Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mire et al. as applied to claim 1 above, and further in view of Bisek et al. (US Patent No. 5,306,306)
|N/A
|-
|align = "center" bgcolor = "#808080"|'''48'''
|align = "center"|US 20080119708
|align = "center"|3/17/2009
|align = "center"|10/25/2006
|103 and 112 rejections
|N/A
|N/A
|Claims 21 -30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent Application Publication No. 200310050546 to Desai et al in view of US Patent Application Publication No. 2003101 3061 6 to Steil et al. Regarding claim 21, Desai discloses a method comprising monitoring a data stream associated with an analyte level, wherein a current signal is generated associated with the data stream.
|Claims 27 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''49'''
|align = "center"|US 20080119702
|align = "center"|3/23/2009
|align = "center"|10/31/2006
|102 and 103 rejections
|N/A
|Claims 1-9 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Saidara (US 200510038332).
|1. Claims 10 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Peterka (US 200610004603). 2. Claims 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Saidara in view of Morrison (US 200610293577).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''50'''
|align = "center"|US 20080108913
|align = "center"|11/7/2008
|align = "center"|11/6/2006
|102 and 103 rejections
|N/A
|Claims 1-8, 10-1 8 and 20-25 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Billing (applicant submitted Foreign Reference WO 200510371 03).
|Claims 9 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Billing as applied in claims 1 and 12 above, and further in view of Guan (US 200510046 1 39).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''51'''
|align = "center"|US 20080108910
|align = "center"|12/29/2008
|align = "center"|10/7/2007
|102 rejection
|N/A
|Claims 22-44 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Deck et al (US 200810082023).
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''52'''
|align = "center"|US 20080108906
|align = "center"|12/24/2008
|align = "center"|11/8/2006
|102, 103 and 112 rejections
|N/A
|Claims 1-6, 1 1-1 3, and 18-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Albrecht et al. (U.S. Patent No. 5,755,671).
|Claims 7-1 0 and 14-1 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Albrecht et al.
|Claims 1-1 9 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''53'''
|align = "center"|US 20080108884
|align = "center"|3/3/2009
|align = "center"|9/24/2007
|102, 103 and 112 rejections
|N/A
|Claims 1-5, 11, and 13-14 are rejected under 35 U.S.C. 102(e) as being anticipated by Smith (US Patent Number 6,980,419 B2).
|N/A
|Claims 1-5, 1 1, 13 and 14 are rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''54'''
|align = "center"|US 20080108883
|align = "center"|1/8/2009
|align = "center"|11/2/2007
|102 and 103 rejections
|N/A
|1. Claims 1-6, and 9-1 0 are rejected under 35 U.S.C. 102(b) as being anticipated by Kiselik (US 7066896). 2. Claims 11, and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Shenoy et al. (US 660901 7).
|1. Claims 1-2, 4-6, 9-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik (US 7066896) in view of Einav et al. (US 2006029361 7). 2. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kiselik modified by Einav as applied to claim 4 above, and further in view of Brown (US 6692449). 3. Claims 14-17, 19-20, and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scott (US 61 55993) in view of Brown (US 6692449). 4. Claims 18 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shenoy and Brown as applied to claims 14 and 15 above, and further in view of Scott (US 61 55993).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''55'''
|align = "center"|US 20080103416
|align = "center"|2/4/2009
|align = "center"|12/17/2007
|103 rejection
|N/A
|N/A
|Claims 1-4, 7-1 1, 14-17, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,916,179 to Sharrock ("Sharrock") in view of US Pat. No. 4,739,211 to Strachan ("Strachan").
|N/A
|-
|align = "center" bgcolor = "#808080"|'''56'''
|align = "center"|US 20080103402
|align = "center"|3/18/2009
|align = "center"|10/30/2006
|102 and 103 rejections
|N/A
|Claims 1-4, 7-1 6, 18-23, and 26 are rejected under 35 U.S.C. 102(b) as being anticipated by Morgan (US 461 0254).
|1. Claims 5, 6, 17, 24, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254). 2. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US 461 0254) in view of Tamura (US 200310080712).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''57'''
|align = "center"|US 20080166031
|align = "center"|8/21/2008
|align = "center"|3/14/2008
|101, 102 and 103 rejections
|Claims I , 2 and 23are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim claims I , 3 and 43 of copending Application No. 10/873,660 in view of Moriyama et a/. (U.S. Publication number 2004/0086163A1)
|Claims 1-5, 7-10, 12-15, 17-20, 22 and 23 are rejected under 35 U.S.C. 102(e) as being anticipated by Moriyama et a/., "Moriyama" (U.S. Publication number 2004/0086163A1)
|Claims 6, 11, 16 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Moriyama as applied to claim 1 above in view of (Nonlinear Dynamics Ltd., TotalLab Applications, image analysis software for ID, electrophoresis gels, blots and colonies, www.nonlinear.com website, published 9/21/2004 from IDS).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''58'''
|align = "center"|US 20080161698
|align = "center"|8/28/2008
|align = "center"|1/3/2007
|101, 102 and 103 rejections
|Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim language is drawn to method of "determining", "analyzing", and "locating" and have no tangible, useful, or concrete result, and are hence non-statutory.
|Claims 1-3, 5-13, 15-20, are rejected under 35 U.S.C. 102(b) as being anticipated by Tearney et al. (U.S. 2003/0028100 Al) hereinafter "Tearney".
|Claims 4 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tearney et al. (U.S. 200310028 100 Al) in view of Nordstrom et al. (U.S. 200210177777 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''59'''
|align = "center"|US 20080139899
|align = "center"|4/23/2008
|align = "center"|11/2/2007
|101, 102, 103 and 112 rejections
|Claims 1-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.
|Claims 1-9 and 12-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen).
|Claims 10-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobsen et al. US Patent Number 6,198,394 (hereinafter Jacobsen) as applied to claim 1 above.
|1. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 2. Claim 3 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 3. Claim 12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. 4. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''60'''
|align = "center"|US 20070244373
|align = "center"|4/30/2008
|align = "center"|5/2/2006
|101, 102 and 103 rejections
|1. Claims 1-25 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. 2. Claims 18 and 25 are rejected under 35 U.S.C. 101, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and to overcome the 101 rejection
|1. Claims 1, 4, 6, 8, 9, 12, and 19 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent Application Publication No. 200410050394 to Jin.
|1. Claims I, 10, I I, 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 6,442,413 to Silver in view of US Patent Application Publication No. 200310014742 to Lewkowicz et al. 2. Claims 7, 13, 14, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jin, as applied to claims 1-6, 8-1 0, 12, 16, 17, 19, and 20 above, and further in view of US Patent No. 6,477,406 to Turcott. 3. Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lewkowicz, as applied to Claims I, 4, 6, 8, 9, 12, and 19 above, and further in view of US Patent No. 6,689,056 to Kilcoyne et al.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''61'''
|align = "center"|US 20080097237
|align = "center"|4/8/2008
|align = "center"|9/29/2006
|103 and 112 rejections
|N/A
|N/A
|1. Claims 1-6, 8, 29, 30, and 32-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410243207 to Olson et al. ("Olson") in view of US Pat. No. 5,035,247 to Heimann ("Heimann"). 2. Claims I I, 15, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 200410198469 to Bridger et al. ("Bridger") in view of US Pat. No.5,594,638 to lliff ("Illiff<nowiki>’</nowiki>), Olson, and Heimann. 3. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bridger in view of Illiff, Olson, and Heimann as applied to claim 1 1 above, and further in view of US. Pat. No. 6,409,684 to Wilk ("Wilk").
|Claims 28 and 31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.
|-
|align = "center" bgcolor = "#808080"|'''62'''
|align = "center"|US 20080097196
|align = "center"|6/5/2008
|align = "center"|8/30/2006
|102, 103 and 112 rejections
|N/A
|1. Claims 7 and 14 are rejected under 35 U.S.C. 102(b) as being unpatentable over Kalender (US Patent No. 5,301,672). 2. Claim 20 is rejected under 35 U.S.C. 102(b) as being unpatentable over Chenevert et al. (US Patent No. 6,167,293).
|1. Claims 1-6, 10, I I, 13, 15, 16 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992). 2. Claims 8, 9, 12 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kalender (US Patent No. 5,301,672) in view of Gelman (US Patent No. 6,337,992) as applied to claims 7, 10 and 15 above, and further in view of Brown (US Patent No. 5,459,769). 3. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Heuscher (US Patent No. 5,262,946).
|Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''63'''
|align = "center"|US 20080097173
|align = "center"|6/12/2008
|align = "center"|5/30/2007
|102 and 103 rejections
|N/A
|Claims 1 - 3, 11, 16 - 19, 22, 23, 25 - 27, and 32 - 38 are rejected under 35 U.S.C. 102(b) as being anticipated by Tsuchiya.
|1. Claims 4 - 10, 12 - 15, 24, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya, as applied to claims 1, 3 and 38 above. 2. Claims 20 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 32 above, and further in view of Arakaki et al. 3. Claims 21, 41, and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya as applied to claims 1 and 34 above, and further in view of Pologe. 4. Claims 28 and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pologe in view of Takatani et al. 5. Claims 30 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuchiya for the reasons given in paragraphs 2 and 4 above.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''64'''
|align = "center"|US 20080091122
|align = "center"|6/30/2008
|align = "center"|11/13/2007
|102 and 103 rejections
|N/A
|1. Claims 50 - 52, 62, 64 66, 68,70,72 and 74 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,448,996 to Bellin et al. 2. Claims 47,49 - 52, 62, 64 - 68, 70, 72 and 74 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent No. 5,846,206 to Bader.
|Claims 48 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,846,206 to Bader.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''65'''
|align = "center"|US 20080086060
|align = "center"|8/21/2008
|align = "center"|12/3/2007
|112 rejection
|N/A
|N/A
|N/A
|1. Claims 1-7, 9-20 are rejected under 35 U.S.C. 11 2, first paragraph, because the specification, while being enabling for quaternary amines, does not reasonably provide enablement for "an ion-balance reagent". 2. Claims 1-20 are rejected under 35 U.S.C. 11 2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''66'''
|align = "center"|US 20080086044
|align = "center"|9/25/2008
|align = "center"|3/26/2007
|102 and 103 rejections
|N/A
|1. Claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 6,128,519 to Say. 2. Claims 1-3, 5-7, 13, 14, 22, and 25-27 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,335,658 to Bedingham.
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 6,123,827 to Wong et al. Say lacks allowing a temperature of the reference solution to equilibrate with a temperature of the host. 2. Claims 9, 10, 20, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Say, as applied to claims 1-3, 5, 6, 8, 13-1 5, 17, 22, and 24-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 3. Claims 9-1 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bedingham, as applied to claims 1-3, 5-7, 13, 14, 22, and 25-27 above, and further in view of US Patent No. 5,976,085 to Kimball et al. 4. Claims 28 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 5,976,085 to Kimball et al. in view of US Patent No. 6,123,827 to Wong et al. 5. Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent No. 4,119,406 to Clemens in view of US Patent No. 6,123,827 to Wong et al. and US Patent No. 5,976,085 to Kimball et al..
|N/A
|-
|align = "center" bgcolor = "#808080"|'''67'''
|align = "center"|US 20080082012
|align = "center"|8/26/2008
|align = "center"|9/28/2006
|102 rejection
|N/A
|Claims 1-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Zhou et al (2006101 16596)
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''68'''
|align = "center"|US 20080082011
|align = "center"|1/9/2008
|align = "center"|9/14/2006
|102 and 103 rejections
|N/A
|Claims 1,3 - 15, and 19 - 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Goodman U.S. Patent No. 6,616,613.
|Claims 2 and 16 - 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goodman U.S. Patent No. 6,616,613 in view of Ranta U.S. Patent No. 7,050,798.
|N/A
|-
|align = "center" bgcolor = "#808080"|'''69'''
|align = "center"|US 20080161708
|align = "center"|9/8/2008
|align = "center"|8/4/2006
|102 and 103 rejections
|N/A
|1.Claims 1-3, 5-7, 22-27, 30-32 and 35-37 are rejected under 35 U.S.C. 102(e) as being anticipated by Taha et al. (US patent 6,564,090). 2. Claims 7, 9, 25, 29, 30, 34, 35 and 39 are rejected under 35 U.S.C. 102(b) as being anticipated by Berger (US Patent 5,560,368). 3. Claims 10-1 3 and 16-1 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Starobin et al. (US Patent 6,361,503).
|1. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Morganroth (US Pub. 20030097077). 2. Claims 8, 28, 33 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Taha et al. (US patent 6,564,090) in view of Millar et al. (Correlation between refractory periods.. .). 3. Claims 14 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Millar et al. (Correlation between refractory periods.. .). 4. Claims 15 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Starobin et al. (US Patent 6,361,503) in view of Berger (US Patent 5,560,368).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''70'''
|align = "center"|US 20080154122
|align = "center"|1/10/2008
|align = "center"|12/21/2006
|102 and 103 rejections
|N/A
|Claims 1-2 and 7-1 0, 12, 16-1 7, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Slager (USPN 5,771,895).
|1. Claims 3, I I, and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Walczak et al. (Pub. No. 2006101 551 88). 2. Claims 4-5, 13-14, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim et al. (Pub. No. 2002101 36440) and Cohen-Solal (USPN 5,933,518). 3. Claims 6 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slager in view of Yim and Cohen-Solal as applied to claims 4 and 13 above, and further in view of Kohle (Pub. No. 200410096088).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''71'''
|align = "center"|US 20080154098
|align = "center"|5/19/2008
|align = "center"|12/20/2006
|102 and 112 rejections
|N/A
|Claims 1-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Suzuki et al. US Patent Number 6,569,094 B2.
|N/A
|Claims 7 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
|-
|align = "center" bgcolor = "#808080"|'''72'''
|align = "center"|US 20080132782
|align = "center"|8/20/2008
|align = "center"|1/27/2005
|103 rejection
|N/A
|N/A
|Claims 1 - 20 are rejected under 35 USC 103(a) as being obvious over Uzgris et al. (US 6470,204 Bl) in view of Greenleaf et al. (US 2001/0053384 Al).
|N/A
|-
|align = "center" bgcolor = "#808080"|'''73'''
|align = "center"|US 20080139891
|align = "center"|8/26/2008
|align = "center"|10/25/2006
|102 and 103 rejections
|N/A
|Claims 1-6, and 8-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Walker et al. US Patent Number 6,302,844 Bl.
|Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Walker et al. US Patent Number 6,302,844 Bl as applied to claim 1 above, and further in view of Lang 6,758,812 B2
|N/A
|-
|align = "center" bgcolor = "#808080"|'''74'''
|align = "center"|US 20080114269
|align = "center"|6/24/2008
|align = "center"|10/10/2007
|102 and 103 rejections
|N/A
|Claims 1-6 and 9-1 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brown et al. (US 6,331,893 Bl , hereinafter Brown).
|N/A
|-
|}

= =
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''75'''
|align = "center"|US 20080097249
|align = "center"|N/A
|align = "center"|4/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''76'''
|align = "center"|US 20080097235
|align = "center"|N/A
|align = "center"|8/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''77'''
|align = "center"|US 20080097234
|align = "center"|N/A
|align = "center"|9/28/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''78'''
|align = "center"|US 20080097230
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''79'''
|align = "center"|US 20080097194
|align = "center"|N/A
|align = "center"|10/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''80'''
|align = "center"|US 20080097183
|align = "center"|N/A
|align = "center"|9/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''81'''
|align = "center"|US 20080097174
|align = "center"|N/A
|align = "center"|12/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''82'''
|align = "center"|US 20080097170
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''83'''
|align = "center"|US 20080097168
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''84'''
|align = "center"|US 20080097166
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''85'''
|align = "center"|US 20080097165
|align = "center"|N/A
|align = "center"|10/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''86'''
|align = "center"|US 20080095421
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''87'''
|align = "center"|US 20080091472
|align = "center"|N/A
|align = "center"|10/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''88'''
|align = "center"|US 20080091118
|align = "center"|N/A
|align = "center"|7/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''89'''
|align = "center"|US 20080091115
|align = "center"|N/A
|align = "center"|8/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''90'''
|align = "center"|US 20080091110
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''91'''
|align = "center"|US 20080091099
|align = "center"|N/A
|align = "center"|3/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''92'''
|align = "center"|US 20080091098
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''93'''
|align = "center"|US 20080091093
|align = "center"|N/A
|align = "center"|10/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''94'''
|align = "center"|US 20080091091
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''95'''
|align = "center"|US 20080091088
|align = "center"|N/A
|align = "center"|5/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''96'''
|align = "center"|US 20080091087
|align = "center"|N/A
|align = "center"|7/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''97'''
|align = "center"|US 20080089846
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''98'''
|align = "center"|US 20080086037
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''99'''
|align = "center"|US 20080082023
|align = "center"|N/A
|align = "center"|9/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''100'''
|align = "center"|US 20080082018
|align = "center"|N/A
|align = "center"|8/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''101'''
|align = "center"|US 20080082013
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''102'''
|align = "center"|US 20080082009
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''103'''
|align = "center"|US 20080082004
|align = "center"|N/A
|align = "center"|9/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''104'''
|align = "center"|US 20080082003
|align = "center"|N/A
|align = "center"|12/1/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''105'''
|align = "center"|US 20080081991
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''106'''
|align = "center"|US 20080081980
|align = "center"|N/A
|align = "center"|9/18/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''107'''
|align = "center"|US 20080081977
|align = "center"|N/A
|align = "center"|10/2/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''108'''
|align = "center"|US 20080081974
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''109'''
|align = "center"|US 20080183101
|align = "center"|N/A
|align = "center"|8/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''110'''
|align = "center"|US 20080183097
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''111'''
|align = "center"|US 20080183096
|align = "center"|N/A
|align = "center"|1/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''112'''
|align = "center"|US 20080183095
|align = "center"|N/A
|align = "center"|1/29/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''113'''
|align = "center"|US 20080183093
|align = "center"|N/A
|align = "center"|8/20/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''114'''
|align = "center"|US 20080183090
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''115'''
|align = "center"|US 20080183087
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''116'''
|align = "center"|US 20080183086
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''117'''
|align = "center"|US 20080183085
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''118'''
|align = "center"|US 20080183083
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''119'''
|align = "center"|US 20080183082
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''120'''
|align = "center"|US 20080183074
|align = "center"|N/A
|align = "center"|1/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''121'''
|align = "center"|US 20080183072
|align = "center"|N/A
|align = "center"|3/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''122'''
|align = "center"|US 20080183071
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''123'''
|align = "center"|US 20080183064
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''124'''
|align = "center"|US 20080183062
|align = "center"|N/A
|align = "center"|12/5/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''125'''
|align = "center"|US 20080183061
|align = "center"|N/A
|align = "center"|4/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''126'''
|align = "center"|US 20080183060
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''127'''
|align = "center"|US 20080183058
|align = "center"|N/A
|align = "center"|3/31/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''128'''
|align = "center"|US 20080183053
|align = "center"|N/A
|align = "center"|11/21/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''129'''
|align = "center"|US 20080183050
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''130'''
|align = "center"|US 20080183049
|align = "center"|N/A
|align = "center"|1/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''131'''
|align = "center"|US 20080183047
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''132'''
|align = "center"|US 20080181470
|align = "center"|N/A
|align = "center"|1/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''133'''
|align = "center"|US 20080177341
|align = "center"|N/A
|align = "center"|10/29/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''134'''
|align = "center"|US 20080177197
|align = "center"|N/A
|align = "center"|1/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''135'''
|align = "center"|US 20080177196
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''136'''
|align = "center"|US 20080177194
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''137'''
|align = "center"|US 20080177193
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''138'''
|align = "center"|US 20080177191
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''139'''
|align = "center"|US 20080177188
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''140'''
|align = "center"|US 20080177178
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''141'''
|align = "center"|US 20080177177
|align = "center"|N/A
|align = "center"|3/25/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''142'''
|align = "center"|US 20080177176
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''143'''
|align = "center"|US 20080177174
|align = "center"|N/A
|align = "center"|10/11/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''144'''
|align = "center"|US 20080177170
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''145'''
|align = "center"|US 20080177164
|align = "center"|N/A
|align = "center"|11/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''146'''
|align = "center"|US 20080177163
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''147'''
|align = "center"|US 20080177162
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''148'''
|align = "center"|US 20080177160
|align = "center"|N/A
|align = "center"|2/28/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''149'''
|align = "center"|US 20080177159
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''150'''
|align = "center"|US 20080177157
|align = "center"|N/A
|align = "center"|4/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''151'''
|align = "center"|US 20080177156
|align = "center"|N/A
|align = "center"|1/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''152'''
|align = "center"|US 20080172253
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''153'''
|align = "center"|US 20080171950
|align = "center"|N/A
|align = "center"|12/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''154'''
|align = "center"|US 20080171948
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''155'''
|align = "center"|US 20080171946
|align = "center"|N/A
|align = "center"|12/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''156'''
|align = "center"|US 20080171943
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''157'''
|align = "center"|US 20080171941
|align = "center"|N/A
|align = "center"|1/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''158'''
|align = "center"|US 20080171934
|align = "center"|N/A
|align = "center"|1/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''159'''
|align = "center"|US 20080171933
|align = "center"|N/A
|align = "center"|1/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''160'''
|align = "center"|US 20080171932
|align = "center"|N/A
|align = "center"|1/8/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''161'''
|align = "center"|US 20080171925
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''162'''
|align = "center"|US 20080171923
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''163'''
|align = "center"|US 20080171916
|align = "center"|N/A
|align = "center"|3/13/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''164'''
|align = "center"|US 20080171913
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''165'''
|align = "center"|US 20080167583
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''166'''
|align = "center"|US 20080167578
|align = "center"|N/A
|align = "center"|9/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''167'''
|align = "center"|US 20080167575
|align = "center"|N/A
|align = "center"|10/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''168'''
|align = "center"|US 20080167574
|align = "center"|N/A
|align = "center"|12/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''169'''
|align = "center"|US 20080167571
|align = "center"|N/A
|align = "center"|12/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''170'''
|align = "center"|US 20080167569
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''171'''
|align = "center"|US 20080167567
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''172'''
|align = "center"|US 20080167566
|align = "center"|N/A
|align = "center"|1/4/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''173'''
|align = "center"|US 20080167564
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''174'''
|align = "center"|US 20080167552
|align = "center"|N/A
|align = "center"|1/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''175'''
|align = "center"|US 20080167549
|align = "center"|N/A
|align = "center"|12/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''176'''
|align = "center"|US 20080167545
|align = "center"|N/A
|align = "center"|1/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''177'''
|align = "center"|US 20080167544
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''178'''
|align = "center"|US 20080167543
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''179'''
|align = "center"|US 20080167540
|align = "center"|N/A
|align = "center"|3/20/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''180'''
|align = "center"|US 20080167532
|align = "center"|N/A
|align = "center"|10/15/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''181'''
|align = "center"|US 20080165017
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''182'''
|align = "center"|US 20080161729
|align = "center"|N/A
|align = "center"|10/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''183'''
|align = "center"|US 20080161714
|align = "center"|N/A
|align = "center"|1/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''184'''
|align = "center"|US 20080161713
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''185'''
|align = "center"|US 20080161712
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}

= =
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#808080"|'''186'''
|align = "center"|US 20080161707
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''187'''
|align = "center"|US 20080161706
|align = "center"|N/A
|align = "center"|2/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''188'''
|align = "center"|US 20080161705
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''189'''
|align = "center"|US 20080161703
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''190'''
|align = "center"|US 20080161681
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''191'''
|align = "center"|US 20080161674
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''192'''
|align = "center"|US 20080161666
|align = "center"|N/A
|align = "center"|12/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''193'''
|align = "center"|US 20080161665
|align = "center"|N/A
|align = "center"|2/21/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''194'''
|align = "center"|US 20080161662
|align = "center"|N/A
|align = "center"|8/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''195'''
|align = "center"|US 20080161661
|align = "center"|N/A
|align = "center"|1/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''196'''
|align = "center"|US 20080161660
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''197'''
|align = "center"|US 20080161657
|align = "center"|N/A
|align = "center"|12/28/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''198'''
|align = "center"|US 20080161652
|align = "center"|N/A
|align = "center"|3/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''199'''
|align = "center"|US 20080161651
|align = "center"|N/A
|align = "center"|12/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''200'''
|align = "center"|US 20080154154
|align = "center"|N/A
|align = "center"|2/27/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''201'''
|align = "center"|US 20080154149
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''202'''
|align = "center"|US 20080154144
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''203'''
|align = "center"|US 20080154128
|align = "center"|N/A
|align = "center"|10/18/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''204'''
|align = "center"|US 20080154125
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''205'''
|align = "center"|US 20080154123
|align = "center"|N/A
|align = "center"|12/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''206'''
|align = "center"|US 20080154121
|align = "center"|N/A
|align = "center"|10/24/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''207'''
|align = "center"|US 20080154107
|align = "center"|N/A
|align = "center"|12/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''208'''
|align = "center"|US 20080154106
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''209'''
|align = "center"|US 20080154101
|align = "center"|N/A
|align = "center"|9/27/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''210'''
|align = "center"|US 20080154099
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''211'''
|align = "center"|US 20080146960
|align = "center"|N/A
|align = "center"|2/19/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''212'''
|align = "center"|US 20080146958
|align = "center"|N/A
|align = "center"|7/9/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''213'''
|align = "center"|US 20080146914
|align = "center"|N/A
|align = "center"|12/19/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''214'''
|align = "center"|US 20080146911
|align = "center"|N/A
|align = "center"|4/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''215'''
|align = "center"|US 20080146906
|align = "center"|N/A
|align = "center"|9/29/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''216'''
|align = "center"|US 20080146901
|align = "center"|N/A
|align = "center"|12/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''217'''
|align = "center"|US 20080146899
|align = "center"|N/A
|align = "center"|2/7/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''218'''
|align = "center"|US 20080146896
|align = "center"|N/A
|align = "center"|7/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''219'''
|align = "center"|US 20080146892
|align = "center"|N/A
|align = "center"|8/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''220'''
|align = "center"|US 20080146891
|align = "center"|N/A
|align = "center"|6/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''221'''
|align = "center"|US 20080146889
|align = "center"|N/A
|align = "center"|12/13/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''222'''
|align = "center"|US 20080139966
|align = "center"|N/A
|align = "center"|12/7/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''223'''
|align = "center"|US 20080139963
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''224'''
|align = "center"|US 20080139956
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''225'''
|align = "center"|US 20080139952
|align = "center"|N/A
|align = "center"|12/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''226'''
|align = "center"|US 20080139948
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''227'''
|align = "center"|US 20080139927
|align = "center"|N/A
|align = "center"|11/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''228'''
|align = "center"|US 20080139926
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''229'''
|align = "center"|US 20080139925
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''230'''
|align = "center"|US 20080139921
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''231'''
|align = "center"|US 20080139920
|align = "center"|N/A
|align = "center"|10/17/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''232'''
|align = "center"|US 20080139917
|align = "center"|N/A
|align = "center"|12/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''233'''
|align = "center"|US 20080139910
|align = "center"|N/A
|align = "center"|12/6/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''234'''
|align = "center"|US 20080139906
|align = "center"|N/A
|align = "center"|11/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''235'''
|align = "center"|US 20080139901
|align = "center"|N/A
|align = "center"|2/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''236'''
|align = "center"|US 20080137929
|align = "center"|N/A
|align = "center"|7/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''237'''
|align = "center"|US 20080132808
|align = "center"|N/A
|align = "center"|1/22/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''238'''
|align = "center"|US 20080132802
|align = "center"|N/A
|align = "center"|2/11/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''239'''
|align = "center"|US 20080132801
|align = "center"|N/A
|align = "center"|6/11/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''240'''
|align = "center"|US 20080132784
|align = "center"|N/A
|align = "center"|11/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''241'''
|align = "center"|US 20080132783
|align = "center"|N/A
|align = "center"|12/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''242'''
|align = "center"|US 20080132781
|align = "center"|N/A
|align = "center"|11/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''243'''
|align = "center"|US 20080132775
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''244'''
|align = "center"|US 20080125678
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''245'''
|align = "center"|US 20080125666
|align = "center"|N/A
|align = "center"|6/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''246'''
|align = "center"|US 20080125663
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''247'''
|align = "center"|US 20080125646
|align = "center"|N/A
|align = "center"|8/21/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''248'''
|align = "center"|US 20080125644
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''249'''
|align = "center"|US 20080125641
|align = "center"|N/A
|align = "center"|8/8/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''250'''
|align = "center"|US 20080125636
|align = "center"|N/A
|align = "center"|3/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''251'''
|align = "center"|US 20080119760
|align = "center"|N/A
|align = "center"|6/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''252'''
|align = "center"|US 20080119755
|align = "center"|N/A
|align = "center"|12/4/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''253'''
|align = "center"|US 20080119753
|align = "center"|N/A
|align = "center"|11/16/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''254'''
|align = "center"|US 20080119749
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''255'''
|align = "center"|US 20080119748
|align = "center"|N/A
|align = "center"|11/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''256'''
|align = "center"|US 20080119747
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''257'''
|align = "center"|US 20080119746
|align = "center"|N/A
|align = "center"|11/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''258'''
|align = "center"|US 20080119743
|align = "center"|N/A
|align = "center"|10/23/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''259'''
|align = "center"|US 20080119741
|align = "center"|N/A
|align = "center"|11/22/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''260'''
|align = "center"|US 20080119726
|align = "center"|N/A
|align = "center"|10/16/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''261'''
|align = "center"|US 20080119717
|align = "center"|N/A
|align = "center"|9/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''262'''
|align = "center"|US 20080119716
|align = "center"|N/A
|align = "center"|5/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''263'''
|align = "center"|US 20080119706
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''264'''
|align = "center"|US 20080119704
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''265'''
|align = "center"|US 20080119703
|align = "center"|N/A
|align = "center"|10/4/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''266'''
|align = "center"|US 20080119701
|align = "center"|N/A
|align = "center"|11/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''267'''
|align = "center"|US 20080119699
|align = "center"|N/A
|align = "center"|1/23/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''268'''
|align = "center"|US 20080119698
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''269'''
|align = "center"|US 20080119697
|align = "center"|N/A
|align = "center"|11/20/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''270'''
|align = "center"|US 20080118135
|align = "center"|N/A
|align = "center"|11/13/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''271'''
|align = "center"|US 20080114614
|align = "center"|N/A
|align = "center"|11/15/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''272'''
|align = "center"|US 20080114261
|align = "center"|N/A
|align = "center"|1/14/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''273'''
|align = "center"|US 20080114260
|align = "center"|N/A
|align = "center"|5/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''274'''
|align = "center"|US 20080114256
|align = "center"|N/A
|align = "center"|11/14/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''275'''
|align = "center"|US 20080114231
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''276'''
|align = "center"|US 20080114229
|align = "center"|N/A
|align = "center"|10/25/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''277'''
|align = "center"|US 20080114228
|align = "center"|N/A
|align = "center"|7/19/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''278'''
|align = "center"|US 20080114225
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''279'''
|align = "center"|US 20080114224
|align = "center"|N/A
|align = "center"|9/6/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''280'''
|align = "center"|US 20080114223
|align = "center"|N/A
|align = "center"|10/31/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''281'''
|align = "center"|US 20080114219
|align = "center"|N/A
|align = "center"|10/31/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''282'''
|align = "center"|US 20080110461
|align = "center"|N/A
|align = "center"|4/5/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''283'''
|align = "center"|US 20080108909
|align = "center"|N/A
|align = "center"|10/1/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''284'''
|align = "center"|US 20080108907
|align = "center"|N/A
|align = "center"|1/10/2008
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''285'''
|align = "center"|US 20080108905
|align = "center"|N/A
|align = "center"|12/3/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''286'''
|align = "center"|US 20080108903
|align = "center"|N/A
|align = "center"|11/8/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''287'''
|align = "center"|US 20080108894
|align = "center"|N/A
|align = "center"|5/7/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''288'''
|align = "center"|US 20080108892
|align = "center"|N/A
|align = "center"|11/2/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''289'''
|align = "center"|US 20080103406
|align = "center"|N/A
|align = "center"|10/26/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''290'''
|align = "center"|US 20080103404
|align = "center"|N/A
|align = "center"|10/30/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''291'''
|align = "center"|US 20080103403
|align = "center"|N/A
|align = "center"|9/12/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''292'''
|align = "center"|US 20080103397
|align = "center"|N/A
|align = "center"|10/26/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''293'''
|align = "center"|US 20080103390
|align = "center"|N/A
|align = "center"|10/23/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''294'''
|align = "center"|US 20080103377
|align = "center"|N/A
|align = "center"|10/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''295'''
|align = "center"|US 20080103376
|align = "center"|N/A
|align = "center"|10/27/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''296'''
|align = "center"|US 20080103375
|align = "center"|N/A
|align = "center"|9/24/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''297'''
|align = "center"|US 20080103371
|align = "center"|N/A
|align = "center"|10/30/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''298'''
|align = "center"|US 20080103370
|align = "center"|N/A
|align = "center"|10/22/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''299'''
|align = "center"|US 20080103369
|align = "center"|N/A
|align = "center"|9/14/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''300'''
|align = "center"|US 20080103368
|align = "center"|N/A
|align = "center"|10/17/2006
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|align = "center" bgcolor = "#808080"|'''301'''
|align = "center"|US 20080101675
|align = "center"|N/A
|align = "center"|8/10/2007
|Examination information not available
|N/A
|N/A
|N/A
|N/A
|-
|}